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Abstract 
 
Communication between neuronal and glial cells is important for many brain 
functions. Astrocytes can modulate synaptic strength by releasing 
gliotransmitters. The mechanisms underlying release of gliotransmitters remain 
uncertain with exocytosis being the most intriguing and debated pathway. 
Furthermore, the contribution of gliotransmitter release to synaptic transmission 
and plasticity is also debated. Therefore, the purpose of this project was to 
investigate whether astrocytes can release gliotransmitters via vesicular 
exocytosis and to investigate the role of this release in synaptic transmission and 
plasticity in the somatosensory cortex. To investigate this, the transgenic mice 
line called dnSNARE, where vesicular exocytosis of gliotransmitters is impaired 
specifically in astrocytes, were used in combination with electrophysiological 
and pharmacological approaches.  
 
It was shown that cortical astrocytes can release ATP via calcium-dependent 
vesicular exocytosis. The released astrocytic ATP can bind to neuronal P2X 
receptors. This results in inhibition of GABAergic transmission. This in turn 
leads to increase in NMDAR activity during synaptic transmission and plasticity. 
It was shown that NMDAR-dependent LTP is modulated via vesicular 
exocytosis of ATP from astrocytes. 
 
It was also shown that astrocytes can release glutamate and D-serine via 
vesicular exocytosis. However, release of D-serine was not required for LTP 
induction in the somatosensory cortex. Release of glutamate from astrocytes 
activated GluN2B-containing NMDARs on cortical neurones. These GluN2B-
containing NMDARs contributed to LTP induction in the cortex. 
 
The role of endocannabinoid signalling in synaptic transmission and plasticity 
was also investigated. It was shown that application of anandamide could result 
in calcium elevation in astrocytes by acting on CB1 receptors on these cells. This 
lead to vesicular exocytosis of ATP from astrocytes onto P2X receptors on 
neurones. This vesicular release of ATP from astrocytes contributed to LTP 
induction in the somatosensory cortex. 
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Chapter 1: Introduction: First part 
 
Role of Astrocytes in Synaptic Transmission and 
Plasticity 
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1.1 An Introduction to astrocytes and tripartite synapse  
 
The Central Nervous System (CNS) consists of two types of nerve cells: 
Neurones and Glial cells. Astrocytes are the main type of glial cells in CNS grey 
matter. In the grey matter, stellate protoplasmic astrocytes are characterised by 
irregular cell bodies, branched processes that are up to 50 m long and very 
negative membrane potentials (Volterra and Meldolesi, 2005). They also have 
specific proteins for example Glial fibrillary acidic proteins (GFAP), which are 
intermediate filaments not present in neurones. Gap junctions couples 
neighbouring astrocytes to one another (Wallraff et al., 2004). Astrocyte 
functions include role in neurogenesis (Seri et al., 2001), providing a link 
between neurones and blood (Golgi, 1885, Andrienzen, 1893) and clearing the 
extracellular space of neuronal activity driven accumulation of K+ (Walz, 2000) 
and glutamate (Bergles and Jahr, 1998, Hertz and Zielke, 2004); but because, 
unlike neurones, astrocytes do not generate action potentials it was previously 
thought that they do not actively contribute to synaptic transmission.  
 
In 1990, it was shown that glutamate application resulted in oscillatory and 
propagating calcium waves in cultured astrocytes (Cornell-Bell et al., 1990). 
This report suggested that astrocytes are not passive bystanders during synaptic 
transmission but are instead capable of sensing synaptic transmission. 
Furthermore, observation of intercellular calcium waves suggested that 
astrocytes are functionally interconnected. A few years later it was shown that 
astrocytes not only receive information from synaptic transmission but also 
contribute to neuronal synaptic transmission by releasing transmitters (Parpura et 
 21 
al., 1994, Araque et al., 1998, Araque et al., 1999). Owing to these discoveries, 
astrocytes were considered active participants in information processing in the 
brain and for this reason the term “tripartite synapse” was coined in 1999 
(Araque et al., 1999). The idea behind the concept of tripartite synapse is the 
bidirectional communication between astrocytes and neurones involving pre-
synaptic terminals, post-synaptic spines and astrocyte processes enwrapping 
these terminals and spines. The theory behind this concept is that 
neurotransmitters released from pre-synaptic neurones can activate receptors on 
astrocytes, thereby leading to release of more transmitters from astrocytes. These 
additional transmitters can then effect synaptic transmission by acting upon pre- 
and post-synaptic neurones. The transmitters released by astrocyte were termed 
gliotransmitters. The three major gliotransmitters are glutamate, Adenosine 
triphosphate (ATP) and D-serine. A single hippocampal astrocyte is in close 
proximity of approximately 100 neurones (Agulhon et al., 2008) and can make 
contact with over 100,000 synapses (Bushong et al., 2002). It has been shown 
that in the cortex, a single astrocyte can enwrap 4-8 neuronal somata and make 
contact with an estimated 300-600 neuronal dendrites (Halassa et al., 2007). 
These reports suggest that gliotransmission from a single astrocyte can modulate 
the activity of groups of synapses confined within the boundaries of the 
astrocyte. The extent to which astrocytes contribute to synaptic transmission and 
their functional significance are still unknown despite the considerable progress 
in gliotransmission research over the last 10-15 years. 
 
Disorders of the nervous system rise due to changes in synaptic transmission. 
Therefore, gliotransmission contribution to synaptic transmission implicates 
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astrocytes as a cause or mediatory factor in neurological disorders. In contrast to 
this, astrocytes could also be envisaged to have a protective role in disorders, 
preventing further damage rather than amplifying deleterious effects.  Astrocytes 
have been implicated in Alzheimer’s disease (Hartlage-Rubsamen et al., 2003), 
Parkinson disease (Tsai and Coyle, 2002, Tuominen et al., 2005) and epilepsy 
(Tian et al., 2005), hence the reason for study of astrocytes.  
 
1.2 Synaptic Plasticity 
 
Acquiring and retrieving memory is part of the cognitive process of brain. 
Memory involves alterations in inhibitory and excitatory connections between 
neurones of brain structures such as cortex and hippocampus. It is believed that 
synaptic plasticity underlies memory formation (Martin et al., 2000). Synaptic 
plasticity allows neurones to store information in response to experience. The 
term “Synaptic plasticity” refers to short and long term activity dependent 
changes in the strength of synaptic transmission. These changes in synaptic 
strength could be either structural changes or changes involving molecular 
mechanisms. The latter involves changes in neurotransmitter release and/or 
changes involving receptors that bind these transmitters. These changes can 
occur at pre-synaptic and post-synaptic levels. Long-term potentiation (LTP) 
refers to lasting changes that result in strengthening of synaptic transmission 
whilst Long term depression (LTD) refers to lasting changes that lead to 
weakening of synaptic transmission. There are different forms of experimentally 
induced LTP and LTD, depending on brain region and transmitter receptors 
involved.      
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Both hippocampus and cortex are involved in memory formation (Eichenbaum, 
2000). Hippocampus is involved in formation of new memories, whilst the 
neocortex is involved in consolidation and long-term storage of memories. LTP 
and LTD have been induced in different regions of the hippocampus and cortex, 
including dentate gyrus (Bliss and Lomo, 1973), CA1 region (Dudek and Bear, 
1992), visual cortex (Kirkwood and Bear, 1994) and somatosensory cortex 
(Castro-Alamancos et al., 1995). However, most studies of gliotransmitter role in 
synaptic plasticity have concentrated on hippocampus with few studies in the 
cortex. For this reason, in my project, I investigated synaptic plasticity in the 
somatosensory cortex.  
 
1.3 Ionotropic receptors in Long Term Potentiation 
 
AMPAR Structure and Function: Two types of Ionotropic glutamate receptors 
are N-methyl-D-aspartate receptors (NMDARs) and -amino-3-hydroxy-5-
methyl-4-isoxazole propionic acid receptors (AMPARs). AMPARs are tetramers, 
which means that they are composed from four possible subunits (GluA1-4). 
Each subunit of AMPAR consists of four membrane domains (M1-4), an 
extracellular domain and a C-terminal intracellular domain (Mayer and 
Armstrong, 2004). The extracellular domain consists of an N-terminal domain 
(NTD) and an Agonist binding domain (ABD) (Stern-Bach et al., 1994, Ayalon 
and Stern-Bach, 2001). As its name suggests, ABD is the site for glutamate 
binding. They are permeable to monovalent cations such as Na+ and K+ but are 
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not permeable to Ca2+ as the GluA2 subunit prevents calcium permeability 
(Hollmann and Heinemann, 1994) . 
 
NMDAR Structure and Function: NMDARs are also tetrameric. They have 
three classes of subunit types: GluN1-3. There are eight different subunits for 
GluN1, four subunits for GluN2 (GluN2A-D) and two subunits for GluN3 
(GluN3A-B) (Dingledine et al., 1999). Co-expression of at least one GluN1 and 
one GluN2 are required for the channel to be functional (Dingledine et al., 1999). 
Similar to AMPARs, each subunit consists of four membrane domains (M1-4), 
an extracellular domain and a C-terminal intracellular domain. Three of the 
membrane domains are transmembrane domains (TM1, 3 and 4), whilst M2 is a 
re-entrant pore loop (Mayer, 2006). The extracellular domain consists of an NTD 
and an ABD. Glycine and D-serine bind to the ABD of GluN1 and GluN3 (Yao 
and Mayer, 2006), whilst glutamate binds to ABD of GluN2 (Furukawa et al., 
2005).  
 
NMDA receptors have slower kinetics than AMPA receptors. AMPARs have a 
rise time of 100-600 s and a decay time of 2-3 ms (Colquhoun et al., 1992), 
whilst NMDARs have a rise time of about 7ms and a decay time of 200 ms 
(Lester et al., 1990). Unlike AMPARs, Mg2+ blocks current through NMDARs at 
resting membrane potentials (Mayer et al., 1984). Furthermore, unlike majority 
of AMPARs, most NMDARs have high permeability to Ca2+ (Burnashev, 1996, 
Watanabe et al., 2002). The high Ca2+ permeability, the blockage by Mg2+ at 
resting membrane potentials, and the slower kinetics of NMDA receptors are the 
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main properties of NMDARs that form the basis of the role in inducing a form of 
LTP that is called NMDAR-dependent LTP.  
 
NMDAR-dependent LTP: Experimental stimulation of pre-synaptic neurones 
results in a transmembrane voltage response in the post-synaptic spine. This 
post-synaptic response is as a result of Na+ influx through AMPARs (Figure 1.1: 
steps1-4). This leads to a small depolarisation of the post-synaptic spine. There is 
no ion flux through NMDARs because they are blocked by Mg2+ ion (Figure 
1.1A). If the amplitude and frequency of pre-synaptic stimulation is constant 
(baseline stimulation), then the synaptic efficacy remains the same i.e. with each 
pre-synaptic stimulation, same size of AMPAR-mediated post-synaptic response 
is observed. However, there are experimental protocols that can have long-
lasting changes on synaptic efficacy. These protocols involve activation of 
presynaptic neurones at a high frequency and include i) 100 Hz High frequency 
stimulation (HFS) (Bliss and Lomo, 1973) and Theta burst stimulation (TBS; see 
section 1.4 for details on this protocol). The high frequency of pre-synaptic 
neurone stimulation during these protocols leads to increase in Na+ flux in post-
synaptic neurone, hence leading to further depolarisation of the post-synaptic 
spine (Figure 1.1: step5). With more depolarisation, Mg2+ blockage of NMDARs 
is lowered (Mayer et al., 1984). As NMDARs are permeable to divalent cations 
in addition to Na+, their opening leads to Ca2+ entry and accumulation in the 
post-synaptic spine (Figure 1.1: step 6) (Burnashev, 1996, Watanabe et al., 
2002). Calcium can act as a second messenger to activate specific intracellular 
mechanisms. This involves activation of Calcium Calmodulin (CaM), which in 
turn activates -calcium-Calmodulin-dependent protein kinase II (CaMK-II) 
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(Figure 1.1: step7) resulting in CaMK-II auto-phosphorylation on residue Thr286 
(Malenka et al., 1989, Silva et al., 1992, Lisman et al., 1997). This kinase 
phosphorylates post-synaptic AMPA receptors at the GluA1 subunit (Roche et 
al., 1996, Barria et al., 1997) and GluA2 subunit (Oh and Derkach, 2005) thus 
increasing AMPAR conductance (Figure 1.1: step8). It has also been shown that 
CaMKII could also be involved in trafficking of more AMPA receptors to the 
synaptic spine (Figure 1.1: step9) (Hayashi et al., 2000). Thus, subsequent to 
delivery of HFS or TBS, when the frequency of presynaptic stimulation is 
returned to pre-induction frequency (baseline stimulation), the AMPAR 
conductance is larger in comparison to prior to TBS/HFS delivery (see Figure 
1.1C). This means that after TBS/HFS delivery, synaptic efficacy increases. As 
this increase in synaptic efficacy is long-lasting, it is called Long term 
potentiation. Larger synaptic efficacy means that there is a higher probability of 
action potential generation in the post-synaptic neurone as a result of synaptic 
transmission. The induction of LTP occurs during the short period of HFS/TBS 
delivery, where NMDARs are open. As LTP induction requires activity of 
NMDARs, this LTP is called NMDAR-dependent LTP. During LTP induction, 
NMDARs act as coincident detectors, meaning that they are activated only when 
the pre-synaptic release of glutamate is coincident with post-synaptic 
depolarisation. It is their blockage by Mg2+ at resting potentials that allows them 
to be coincident detectors. Their other unique property, which is calcium 
permeability, results in LTP induction. The induction of NMDAR-dependent 
LTP during TBS/HFS leads to increase in AMPAR component on post-synaptic 
neurone, which is called the expression of NMDAR-dependent LTP.         
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Figure 1.1.  See next page for Figure legend. 
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Figure 1.1. Induction of NMDAR-dependent LTP. Stimulation of pre-synaptic 
neurone results in calcium entry into pre-synaptic terminals (1) through voltage-
gated calcium channels. This triggers the fusion of vesicles to the membrane (2) and 
the subsequent release of neurotransmitters like glutamate from the terminal (3). 
Glutamate binding to AMPARs on the post-synaptic spine leads to the influx of 
sodium through these channels (4), hence causing depolarisation. Activation of pre-
synaptic neurone at a higher frequency (B), leads to increase in sodium flux into 
post-synaptic spine (5). This leads to further depolarisation of the post-synaptic 
spine, which relieves the magnesium blockage of NMDARs, therefore allowing 
calcium entry through these receptors (6). Calcium elevation activates intracellular 
signalling involving CaMK-II (7). Activated CaMK-II then phosphorylates AMPARs. 
This means that following return of pre-synaptic stimulation to baseline (0.1 Hz) 
frequency (C), there is an increase in conductance of AMPARs (8) and/or increase in 
number of AMPARs present at posy-synaptic density (9). This results in a higher 
synaptic efficacy.  
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Induction thresholds for NMDAR-dependent LTD and LTP:  LTD can be 
induced in the same hippocampal and cortical synapses where NMDAR-
dependent LTP can be induced (Dudek and Bear, 1992, Kirkwood and Bear, 
1994). Interestingly, this depression is also NMDAR dependent. Both NMDAR-
dependent LTP and NMDAR-dependent LTD are as a result of Ca2+ entry 
through NMDA receptors. In both cases NMDAR opening leads to intracellular 
signalling. The difference between LTP and LTD induction lies in the magnitude 
and duration of Ca2+ entry, which in turn depends on the frequency of the 
stimulation protocol (Malenka and Bear, 2004). The magnitude of calcium entry 
determines the direction of plasticity. This means that there are thresholds for 
both LTP and LTD induction. These thresholds are dependent on calcium levels. 
However, calcium entry depends on opening of NMDARs. This means that these 
thresholds are also dependent on the degree of depolarisation. The thresholds for 
LTP and LTD can be represented by the Artola, Brocher and Singer (ABS) rule 
(Figure 1.2) (Artola and Singer, 1993), which is derived from the Bienenstock, 
Cooper and Munro (BCM) model (Bienenstock et al., 1982). LTP is induced by 
high frequency stimulation, whilst LTD is induced by “low” frequency 
stimulation (LFS). This “low” frequency refers to the much lower frequency in 
comparison to HFS or TBS protocol, but the frequency of LFS is still higher than 
the frequency of baseline stimulation. With low frequency stimulation a 
moderate level of post-synaptic depolarisation is reached. This in turn leads to a 
moderate level of calcium elevation. If this calcium elevation reaches the first 
threshold (D in Figure 1.2) then LTD is induced. During higher frequency of 
pre-synaptic stimulation, the magnitude of calcium elevation in post-synaptic 
neurone is higher in comparison to LTD induction. If this higher calcium 
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elevation crosses the second threshold (P in Figure 1.2), then LTP is induced. 
LTP involves phosphorylation by kinases such as CaMK-II, which leads to 
increase in post-synaptic AMPAR component. In contrast, LTD involves 
AMPAR dephosphorylation by phosphotases such as calcineurin (Lee et al., 
1998) and endocytosis of AMPARs from the spine (Lu et al., 2007).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2. Artola, Brocher and Singer (ABS) rule. ΘD is the LTD threshold and θP 
is the LTP threshold. 
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NMDA-dependent LTP and other forms of plasticity are phenomenon that are 
induced experimentally but the mechanism of their induction and expression are 
believed to have physiological basis and functional relevance (Martin et al., 
2000). In the next section I will give a brief history on experimental protocols 
used to successfully induce LTP in the cortex.   
   
1.4 History of LTP protocol in the hippocampus and cortex 
 
Theta rhythm is characterized by the approximately sinusoidal extracellular 
waves of 3-12Hz recorded from various brain regions using 
electroencephalography. Theta waves can be recorded during learning-related 
behaviours in animals such as when a rat is walking, running, exploring or 
sniffing (Macrides et al., 1982). Classically, waves recorded from the brain with 
frequency in the 4-7 Hz range were categorised as theta waves but extracellular 
waves recorded from rat Hippocampus that are 3-12 Hz are also referred to as 
theta waves. It is believed that theta waves are due to synchronous oscillations of 
post-synaptic membrane potentials (Andersen, 1980, Buzsaki, 1986) but the 
neurones involved in the generation of these almost sinusoidal variations are not 
known. It is known that the Medial septum has a role in the mechanism of theta 
generation in the hippocampus (Green and Arduini, 1954). However, 
hippocampus preparation in vitro has also been shown to generate spontaneous 
theta rhythms independent of Medial septum and entorhinal cortex (Goutagny et 
al., 2009). 
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Many researchers have tried to induce LTP in various brain regions including 
hippocampus by using different protocols for stimulation of afferent pathways, 
which may or may not mimic the natural bursting activity of neurones in 
physiological conditions. Tetanus stimulation (HFS) is the most popular protocol 
for LTP induction in the hippocampus. However, some researchers attempted to 
induce LTP using the theta wave frequency range (Theta burst stimulation), 
which they believed to be a more physiological LTP induction protocol. Work by 
Larson and co-workers (Larson et al., 1986) was one of the studies that showed 
that burst stimulation with inter-burst frequency of 5 Hz (within theta frequency 
range) resulted in higher chance of LTP induction in the CA1 region of 
hippocampus compared to inter-burst frequencies that were out of the theta 
range. Two years later, another group (Pavlides et al., 1988) showed that in 
Dentate Gyrus, tetanic burst stimulation applied coincidently at the peak of theta 
waves also induced LTP whilst stimulation at the trough or other phases of theta 
waves did not. All this indicated a link between theta wave and LTP. Stimulation 
at theta wave frequency was considered the optimal frequency for LTP induction 
in the hippocampus.  
 
The reason that 5 Hz is the optimal frequency is due to the role played by -
aminobutyric acid (GABA) receptors. As mentioned above, glutamate released 
from excitatory pre-synaptic terminals can depolarise post-synaptic pyramidal 
neurones. However, in addition to this effect, pre-synaptic glutamate release can 
also activate inhibitory interneurones. These neurones can in turn release GABA, 
which can bind to and activate post-synaptic GABAA receptors of pyramidal 
neurones. The influx of Cl- ions through these receptors leads to generation of 
 33 
inhibitory post-synaptic potentials (IPSPs) in the post-synaptic neurone. This 
decreases the degree of depolarisation in these cells, thus Mg2+ blockage of 
NMDARs is not relieved. However, interneurones contain GABAB 
autoreceptors, which means that they are receptors that can be activated by 
GABA released from their own cell. The activation of these GABAB receptors 
leads to the reduction of GABA released from interneurones (Davies et al., 
1990), hence decreasing inhibition of pyramidal cells. This effect was found to 
have a peak at 200 ms (Davies et al., 1991). This means that during LTP 
experiments, burst delivery 200 ms after the previous burst leads to generation of 
smaller IPSPs in the pyramidal cell. This would lead to a larger depolarisation of 
these cells. Therefore, there is a higher probability that during stimulation, Mg2+ 
blockage of NMDARs is relieved, which would increase the chance of LTP 
induction. 
 
LTP protocols have also been conducted in the neocortex. Studies from the late 
80s and early 90s attempted to find the optimal protocol for LTP induction in the 
neocortex but the results where not successful. For example, one of the first 
attempts involved delivery of TBS to layer 6 of cortex whilst recording from 
layer 3. However, unlike in hippocampus, TBS did not induce LTP in the cortex 
(Komatsu et al., 1988). The problem of LTP induction in the cortex was solved 
in 1993 by a group of researchers (Kirkwood et al., 1993). These researchers 
stimulated layer 4 of neocortex rather than layer 6. They suggested that when 
recording from layer 2/3 in the cortex, stimulation of layer 6 leads to 
polysynaptic transmission whilst layer 4 stimulation involves monosynaptic 
transmission. During LTP induction in the CA1 region of hippocampus, 
 34 
stimulation of Schaffer collaterals involves monosynaptic transmission; therefore 
stimulation of layer 4 of cortex should result in a higher chance of LTP induction 
in this brain region. Indeed, with layer 4 stimulation they found that TBS 
protocol could induce LTP in the visual cortex just as it did in the hippocampus. 
Two years later, when a different group applied the same protocol to a different 
region of the cortex, the somatosensory cortex, they also successfully induced 
LTP (Castro-Alamancos et al., 1995).  
 
1.5 Metabotropic glutamate receptors 
 
In addition to ionotropic NMDARs and AMPARs, glutamate can also bind to 
metabotropic glutamate receptors (mGluRs). These receptors are of the C family 
of G-protein coupled receptors (GPCRs). Each mGluR is a dimmer with each 
subunit consisting of an extracellular glutamate-binding domain, a heptahelical 
transmembrane domain and an intracellular C-terminal domain, which couples 
with the heterotrimeric G-proteins (Pin et al., 2003). 
 
There are eight mGluR genes (mGluR1-8). These are grouped in three classes: I-
III. Class I mGluRs (mGluR1 and mGluR5) are involved in increasing 
intracellular calcium concentration (Frenguelli et al., 1993). After activation by 
glutamate, these receptors exert their effect via their coupling to Gq/G11. This 
leads to Phospholipase C activation, which in turn results into inositol 1,4,5-
triphosphate (IP3) generation, leading to Ca
2+ release from endoplasmic 
reticulum (ER) (Yuzaki and Mikoshiba, 1992). 
 
 35 
High expression of class I mGluRs has been detected in various brain regions 
including hippocampus and cortex (Baude et al., 1993, Romano et al., 1995). 
These receptors are mainly localised to peri-synaptic regions of post-synaptic 
neurones. They are also present on astrocytes. 
 
1.6 Astrocyte activity during Glutamatergic Transmission 
 
Calcium elevation in astrocytes: In order for astrocytes to contribute to 
synaptic transmission by gliotransmitter release they first need to “sense” 
synaptic transmission. They can sense synaptic transmission through intracellular 
calcium elevation as a result of activation of their receptors. It has been shown 
that metabotropic glutamate receptors are one type of receptors that result in 
calcium elevation in astrocytes. The presence of mGluR5 has been shown in 
acutely isolated astrocytes from rat hippocampus (Cai et al., 2000). Furthermore, 
in brain slices from 2-3 weeks old rats, it has been shown that electrical 
stimulation of Schaffer collaterals fibres leads to Ca2+ elevation in microdomains 
of hippocampal astrocytes (Panatier et al., 2011). This increase in astrocytic 
calcium levels was blocked by mGluR5 antagonists. This result suggested that 
glutamate release from pre-synaptic neurones as a result of electrical stimulation 
can spillover from synaptic cleft into extracellular space, where astrocyte 
microdomains are situated (Figure 1.3: steps 1-3). Glutamate in extracellular 
space can then bind to mGluRs present on astrocyte microdomains (Figure 1.3: 
step 5). This in turn leads to calcium elevations in these microdomains (Figure 
1.3: step 7).  
 
 36 
It has been shown that mGluR-dependent Ca2+ elevations in astrocytes can lead 
to the release of glutamate from these cells (Fellin et al., 2004). This released 
glutamate activated NMDARs on neurones and resulted in appearance of 
atypically large NMDAR-mediated currents called Slow Inward Currents (SICs). 
It was shown that these SICs were due to activity of GluN2B-containing 
NMDARs. As GluN2B NMDARs are thought to be extra-synaptic (see a section 
below entitled “Role for Synaptic and extra-synaptic NMDAR receptors” for 
more detail on GluN2B NMDARs) it was postulated that glutamate from 
astrocytes can activate extra-synaptic NMDARs on post-synaptic pyramidal 
neurones (Figure 1.3: steps 8-10).  
 
Taken together, the above studies suggested that astrocytic mGluR5 receptors are 
the main way for astrocytes to “sense” synaptic transmission. Following their 
activation as a result of calcium elevation, astrocytes contribute to synaptic 
transmission by releasing gliotransmitters such as glutamate. 
 
The above reports support the general consensus that calcium elevation in 
astrocytes is as a result of activation of mGluR5 on these cells. However, a 
recent study in hippocampus and cortex showed that astrocytic mGluR5 is 
significantly expressed only in mice that are less than two weeks of age. Mice 
older than 2-weeks showed little mGluR5 expression in astrocytes (Sun et al., 
2013). Immunolabelling in adult mice showed that 70-80% immunoreactivity for 
mGluR5 was associated with neuronal post-synaptic spines and dendritic shafts, 
whilst only 5% immunoreactivity was associated with astrocytes. In vitro and in 
vivo application of mGluR5 agonists such as 3,5-dihydroxyphenylglycine 
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(DHPG), increased astrocytic calcium elevation in young (P12-P15) mice but 
failed to increase calcium elevation in adult mice. Interestingly, application of 
exogenous ATP in adult mice resulted in calcium elevation in astrocytes. Taken 
together, the authors suggested that mGluR-dependent calcium signalling in 
astrocytes is restricted to young mice. In adult mice, calcium signalling in 
astrocytes does not depend on mGluR5 and probably depends on other receptors 
such as ATP ionotropic and metabotropic receptors. 
 
The above-mentioned study excludes the possibility of mGluR5-dependent 
activation of astrocytes in adult mice but it does not necessarily exclude the 
activation of astrocytic calcium signalling via glutamate. Ionotropic glutamate 
receptors on astrocytes can lead to calcium signalling in these cells. 
Electrophysiological recordings from acutely isolated cortical astrocytes and 
astrocytes in cortical slice preparations revealed differences in properties of 
NMDARs on astrocytes in comparison to their counterparts in neurones (Lalo et 
al., 2006). Unlike neuronal NMDARs, Mg2+ does not block astrocytic NMDARs 
at resting membrane potentials (Figure 1.3: steps 2 and 6). It was suggested that 
as astrocytes are not as excitable as neurones (they depolarise only slightly) the 
Mg2+/voltage-independence property of astrocytic NMDARs allows these 
receptors to be activated at resting membrane potentials. Subsequent research in 
cortical slices of adult (three months old) mice showed that activation of these 
astrocytic NMDARs via pharmacological agonists lead to calcium elevations in 
these cells (Palygin et al., 2010). Furthermore, astrocytic calcium elevations as a 
result of electrical stimulation of neuronal afferents were also shown to be 
NMDAR-mediated. Taken together, these results suggested that NMDA 
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receptors provide another route for calcium entry into astrocytes (Figure 1.3: 
steps 6-7).  
 
Pharmacological activation of calcium elevations in astrocytes: As mentioned 
above, calcium elevation in astrocytes leads to glutamate release from these cells. 
Therefore, in order to investigate the role of astrocytic glutamate release in 
synaptic transmission, researchers need to experimentally induce calcium 
elevations specifically in astrocytes. Researchers utilise different experimental 
methods to induce calcium elevations specifically in astrocytes. These methods 
include: uncaging of caged Ca2+ or IP3 by photolysis (Araque et al., 1998), 
mechanical or electrical stimulation of astrocytes (Jourdain et al., 2007) and 
activation of metabotropic receptors on astrocytes. The latter method usually 
involves using DHPG to specifically activate class I metabotropic glutamate 
receptors (Fellin et al., 2004). However, as mentioned above, these receptors are 
also present on neurones, hence DHPG application might not specifically 
activate astrocytes over neurones. Furthermore, as also mentioned above, 
expression of mGluR5 in astrocytes declines in rodents of above 2 weeks of age. 
Therefore, agonists of metabotropic glutamate receptors cannot be used to 
activate astrocytes in older animals. However, there exists another type of 
metabotropic receptors that show higher expression in astrocytes than in 
neurones and therefore can be used for calcium elevation specifically in 
astrocytes. These receptors will be introduced in the following section.  
 
Protease Activated Receptor-1 mediated calcium elevations in astrocytes: 
Thrombin is a serine protease involved in blood coagulation and tissue repair. 
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Thrombin can also induce numerous cellular responses by acting as a signalling 
molecule (Wang and Reiser, 2003). It does this via proteolytic activation of 
certain G protein-coupled receptors called protease activated receptors (PARs) 
(Coughlin, 1994). These receptors have an extracellular N-terminal domain. 
Cleavage of this domain by serine proteases such as thrombin reveals a tethered 
ligand with a peptide sequence of SFLLRN. This ligand can then activate the 
receptor by binding to the second transmembrane loop of the receptor (Lerner et 
al., 1996). This in turn leads to intracellular signal transduction. Synthetic 
peptides that mimic the action of the tethered ligand can directly activate PARs 
in the absence of proteolytic cleavage (Hollenberg et al., 1997).  
 
Protease-activated receptors have four members: PAR1-PAR4. These receptors 
are expressed in many different brain regions including hippocampus and cortex 
(Striggow et al., 2001). It has been shown that in the human hippocampus and 
cortex, PAR1 localisation is predominant in astrocytes over neurones (Junge et 
al., 2004). Like some other GPCRs such as mGluRs, PAR1 receptors are also 
coupled to Gq/G11 and PLC, meaning that their activation can lead to calcium 
elevation (Wang and Reiser, 2003). A study in CA1 region of hippocampus of 
brain slices from 2-3 weeks old mice has shown that application of exogenous 
synthetic PAR1 agonist (TFLLR) activates calcium elevations in astrocytes but 
not neurones (Lee et al., 2007). This shows that TFLLR can be used to 
selectively activate astrocytes over neurones. Furthermore, the same study 
showed that PAR1 activation of cultured astrocytes resulted in a calcium 
dependent glutamate release from these cells. In contrast, TFLLR application to 
cultured neurones neither resulted in calcium elevations nor in glutamate release, 
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again suggesting the specificity of TFLLR/PAR1 for astrocytes. It was also 
shown that in hippocampal slices, application of PAR1 agonist could increase 
evoked NMDAR EPSCs but failed to increase the frequency and amplitude of 
miniature AMPAR EPSCs. 
 
Another report provided further support to the above findings by showing that 
PAR1 agonist application to the CA1 region of hippocampus of 2-3 weeks old 
mice leads to calcium elevations specifically in astrocytes (Shigetomi et al., 
2008). This in turn lead to glutamate release from these cells, which lead to the 
appearance of NMDAR-mediated SICs in pyramidal neurons. 
 
Taken together, these findings suggest that PAR-1 application can increase 
calcium elevations specifically in astrocytes, which in turn leads to glutamate 
from these cells. The released glutamate can enhance neuronal NMDARs but has 
no significant effect on neuronal AMPARs.  
 
The above-mentioned studies investigated specific PAR1 activation of astrocytes 
only in young animals. However, a recent study of the CA3 region of 
hippocampus from 2 month old rats showed the localisation of PAR1 specifically 
on astrocytes (Shavit et al., 2011). Interestingly, by using electron microscopy, it 
was also shown that the localisation of PAR1 receptors was mainly at astrocytic 
processes surrounding the synapse (Figure 1.3: step 11). This suggested that 
release of endogenous proteases during synaptic transmission could potentially 
activate PAR1 receptors on astrocytes. Even though proteases such as thrombin 
are, under physiological conditions, excluded from the brain by the blood brain 
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barrier, their expression has been shown in neurones and glial cells (Arai et al., 
2006) suggesting endogenous release of proteases in the brain. Taken together, 
the above results show that PAR1 agonists such as TFLLR can be used as a 
pharmacological tool to activate calcium elevations specifically in astrocytes and 
not neurones. This allows researchers to investigate the role of calcium mediated 
gliotransmitter release from astrocytes.   
 
Effect of activation of astrocytic PAR1 on LTP: Glutamate released as a result 
of PAR1 activation of astrocytes can increase neuronal NMDAR activity. As 
NMDARs are involved in LTP induction, this suggests that PAR1 activation of 
astrocytes could have a potential role in synaptic plasticity. A group of 
researchers have attempted to investigate the role of PAR agonists on synaptic 
plasticity (Maggio et al., 2008). They recorded fEPSPs from hippocampal slices 
(CA1 region) from 2 months old rats. They showed that in the absence of HFS 
delivery, 10 minutes application of thrombin, which is an agonist for PAR1, 
PAR3 and PAR4 receptors, resulted in an NMDAR dependent LTP. This 
thrombin induced LTP was blocked by specific PAR1 antagonist, suggesting that 
only PAR1 receptors (and not PAR3 or PAR4) are involved in LTP induction. 
As PAR1 are mainly localised on astrocytes, these results suggest that thrombin-
induced LTP is as a result of PAR1 activation of calcium-dependent 
gliotransmitter release from astrocytes.   
 
It was further shown that LTP could not be induced if only a small concentration 
of a specific PAR1 agonist (SFLLRN) was applied. HFS protocol can induce 
LTP because during the delivery of this protocol depolarisation of post-synaptic 
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neurone crosses the LTP threshold (Figure 1.2). An experimental protocol that 
fails to depolarise the post-synaptic neurone above the LTP threshold is referred 
to as the sub-threshold protocol. The sub-threshold cannot induce LTP. However, 
when small concentration of SFLLRN was applied before delivery of a sub-
threshold stimulation protocol, LTP was induced. The size of this LTP was 
similar to LTP induced by threshold HFS protocol. This result suggested that 
application of PAR1 agonist could enhance the sub-threshold LTP protocol to the 
threshold level for LTP induction. As PAR1 are mainly localised on astrocytes, 
this enhancement of sub-threshold to threshold level can be attributed to PAR1 
activation of gliotransmitter release from astrocytes. 
 
Glutamate uptake by astrocytes: As mentioned above, calcium elevation in 
astrocytes can lead to glutamate release form these cells. However, one of the 
main functions of astrocytes is the clearance of glutamate spillover. Excitatory 
Amino Acid Transporters (EAATs) remove glutamate from the extracellular 
space and into the neurones or astrocytes preventing excitotoxicity (Verkhratsky 
and Kirchhoff, 2007). Two types of EAATs, Glutamate/Aspartate transporter 
(GLAST/EAAT1) and Glutamate transporter-1 (GLT1, EAAT2), are almost 
exclusively expressed in astrocytes (Figure 1.3: step 4) (Verkhratsky and 
Kirchhoff, 2007), with GLT1 accounting for 80% of glutamate uptake in the 
brain (D'Antoni et al., 2008).  Glutamate uptake by astrocytes prevents the 
spillover of this transmitter unto other synapses, thereby allowing for a spatially 
precise synaptic transmission. An interesting question that arises here is that if 
astrocytes are involved in clearance of glutamate from extracellular space, then 
what could be the function of glutamate released from these cells? Antibody 
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labelling has shown approximately six fold lower glutamate concentration in 
astrocytes than in neurones (Bramham et al., 1990), suggesting that perhaps 
astrocytes do not contribute to glutamate release. For these reasons, contribution 
to synaptic transmission by glutamate released from astrocytes has been 
questioned (Nedergaard and Verkhratsky, 2012).  
 
In summary, most glutamate that spills over into extra-synaptic space is removed 
by astrocytic EAATs (Figure 1.3: steps 1-4). Some of the extra-synaptic 
glutamate can activate ionotropic and metabotropic receptors on astrocytes, 
leading to calcium elevation in these cells (Figure 1.3: steps 5-7). Calcium 
elevation in astrocytes can result into gliotransmitter release. Experimental 
activation of calcium elevation in astrocytes shows glutamate release from these 
cells (Figure 1.3: steps 7-11). Glutamate release by astrocytes has been shown to 
enhance NMDAR activity of hippocampal neurones. The functional significance 
of this NMDAR enhancement is yet to be determined.   
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Figure 1.3. Astrocyte activity during glutamatergic transmission. Glutamate released 
from neuronal terminals (1) result in synaptic transmission by binding to post-synaptic 
receptors (2). Glutamate released during synaptic transmission spills over into extra-
synaptic space (3). Most of the glutamate in the extra-synaptic space is removed by 
EAATs on astrocytes (4). Some of the spilled over glutamate activates metabotropic 
receptors (5) and ionotropic receptors (6) on astrocyte microdomains. Activation of 
these receptors is a means by which astrocytes “sense” synaptic transmission. This leads 
to elevation of astrocytic intracellular calcium concentration (7). Calcium elevation can 
result in release of glutamate from astrocytes (8). Astrocytic glutamate can enhance 
neuronal NMDAR activity by binding to extra-synaptic neuronal NMDARs. These extra-
synaptic NMDARs are localised just outside the active zones (9) and at more distal 
regions such as dendritic shafts and soma (10). Extra-synaptic NMDARs are usually 
GluN2B containing receptors. Calcium elevation in astrocytes can be induced 
pharmacologically. PAR1 are localised mainly on astrocytes and not neurones (11). PAR1 
activation with synthetic PAR1 agonists can lead to calcium elevations specifically in 
astrocyte. Note that astrocytic calcium elevation as a result of activation of metabotropic 
glutamate receptors only occurs in young animals that are less than three weeks old.  
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Glutamatergic transmission involves the binding of glutamate to AMPARs, 
NMDARs and mGluRs. However, NMDAR activity also requires the binding of 
co-agonists in addition to glutamate.  
 
1.7 Role for NMDAR co-agonists glycine and D-serine 
 
The opening of NMDA receptors requires the binding of two agonists. Sole 
binding of Glutamate to GluN2 subunits of NMDARs either fails to open the 
receptor or will only gate the channel to sub-conductance level (Banke and 
Traynelis, 2003). The GluN1 subunit of NMDAR provides a binding site for D-
serine or glycine. Binding of either of these NMDAR co-agonists, together with 
glutamate binding to GluN2 subunit, leads to a complete opening of the NMDAR 
channel (Banke and Traynelis, 2003). As NMDARs are pivotal for induction of 
synaptic plasticity, the role for these co-agonists could potentially be crucial in 
induction of NMDAR-dependent LTP.  
 
Glycine release and uptake: It has been shown that glycine is present in 
neuronal synaptic vesicles of rat cortex (Martineau et al., 2013) thereby 
suggesting that neurones are the source of glycine release in the cortex (Figure 
1.4: step 1). Glycine transporters (GlyT-1) are present on both neurones and 
astrocytes. These Na+ dependent transporters can rapidly transport glycine into 
neurones and astrocytes (Figure 1.4: steps 6-7) (Bergeron et al., 1998, Cubelos et 
al., 2005). It has been suggested that this rapid uptake of glycine by GlyT-1 
prevents saturation of NMDARs, and enables D-serine to act as the primary co-
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agonist for modulating NMDAR activity in cortex and hippocampus (Fossat et 
al., 2011, Henneberger et al., 2013).  
 
D-serine release: Staining experiments have shown that in rat hippocampus and 
cortex, D-serine is mainly localised to astrocytes (Schell et al., 1997, Fossat et 
al., 2011, Martineau et al., 2013). These staining experiments showed that 
pattern of distribution for D-serine was similar to pattern of distribution for 
NMDARs, suggesting that astrocytic D-serine was localised in close vicinity of 
NMDA receptors (Schell et al., 1997). This finding indicates that D-serine 
release from astrocytes can modulate NMDAR activity. Studies in astrocyte 
cultures have suggested that the release of D-serine from astrocytes is vesicular 
and calcium dependent (Figure 1.4: step 2) (Bezzi et al., 2004, Mothet et al., 
2005). 
 
Due to the predominant astrocytic localisation of D-serine, it was previously 
thought that D-serine was only released via astrocytes and not neurones. 
However, evidence has been provided for neuronal localisation of D-serine in the 
hippocampus (Ehmsen et al., 2013) and cortex (Kartvelishvily et al., 2006). In a 
study from 2006, immunostaining of rat cortical slices suggested that D-serine 
was mainly localised to neurones (Kartvelishvily et al., 2006). The same study 
provided evidence of D-serine release from cortical neuronal cultures. D-serine 
release remained unaffected, when mechanism of neurotransmitter uptake into 
synaptic vesicles was blocked. This suggested that release of D-serine from 
cultured neurones is through a non-vesicular pathway. In a later study, the same 
group corroborated their findings in cultured neurones by providing evidence for 
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calcium independent non-vesicular D-serine release from neurones in cortical 
slices of adult (2 months old) rats (Rosenberg et al., 2010). Recently, it has been 
shown that this neuronal non-vesicular D-serine release is carried out by 
transporters called alanine-serine-cysteine transporter-1 (Asc-1) (Figure 1.4: step 
3) (Rosenberg et al., 2013).  
 
The studies described above suggest that D-serine can be released by both 
neurones and astrocytes. However, D-serine production depends solely on 
astrocytes. The first step of D-serine synthesis involves production of L-serine 
from glucose. This first step takes place in astrocytes and not neurones. Serine 
Racemase (SR) converts L-serine to D-serine. Both astrocytes and neurones 
express SR (Miya et al., 2008, Martineau et al., 2013) thereby suggesting that 
both cells are capable of converting L-serine to D-serine. In a model proposed by 
Herman Wolosker (Wolosker, 2011), it was suggested that astrocytes release L-
serine into extracellular space where it is taken up by neurones through Asc-1 
transporters. Neurones can then convert L-serine to D-serine. Subsequently, 
neurones can use Asc-1 transporters to release D-serine into extracellular space. 
 
D-serine is considered to be the primary co-agonist that modulates NMDAR 
activity. This is important because the degree of NMDAR activity determines 
whether LTP or LTD is induced. Furthermore, D-serine has been implicated in 
neurological disorders with NMDAR hypo-activity or NMDAR-mediated 
excitotoxicity (Katsuki et al., 2004, Van Horn et al., 2013) again suggesting the 
importance of D-serine release in modulation of NMDAR activity. For these 
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reasons, researchers are investigating the role of D-serine on synaptic 
transmission and plasticity.  
 
As mentioned above, astrocytic calcium-dependent vesicular release is a main 
source of D-serine. Therefore, the contribution of astrocytic vesicular release of 
D-serine on NMDAR activity is of interest. If this contribution is found to be 
significant, then one can envision astrocytic D-serine release as a possible 
therapeutic target in neurological disorders. 
 
D-serine role in synaptic transmission and plasticity:  Some researchers have 
attempted to elucidate the role of D-serine in synaptic transmission and 
plasticity. One group, whom worked on the Schaffer collaterals of CA1 region of 
hippocampus (Henneberger et al., 2010), showed that chelating Ca2+ 
concentration in astrocytes (hence, theoretically, blocking calcium-dependent 
gliotransmitter release) significantly reduced the extent of LTP. This drop in 
potentiation was rescued when exogenous D-serine was applied to the brain 
slice. This finding suggested a major role in LTP induction for D-serine released 
by hippocampal astrocytes.  
 
A different study in the Supra-optic nucleus (SON) of the hypothalamus also 
showed the importance of D-serine in LTP induction (Panatier et al., 2006). In 
this study, a pairing protocol induced LTP in the SON of virgin rats. However, 
addition of   D-amino acid oxidase (DAAO), which breaks down D-serine but 
not glycine, induced LTD rather than the usual LTP. In lactating rats, where 
astrocyte coverage is drastically reduced during lactation, the pairing protocol 
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(without DAAO) induced LTD. However, when exogenous D-serine was applied 
to brain slices from lactating rats, the pairing protocol lead to LTP induction. 
From these outcomes the authors concluded that D-serine release from astrocytes 
has a major role in LTP induction. This work was an inspiration for the same 
group to investigate the effect of D-serine in a different area of brain: the 
prefrontal cortex (Fossat et al., 2011). They showed that exogenous D-serine 
increased the amplitude of evoked NMDAR mediated EPSC. Surprisingly, 
glycine did not increase the amplitude of NMDAR-mediated EPSC. They 
attributed the lack of enhancing effect of glycine on rapid glycine uptake via 
glycine transporters (see above). They used the outcome of their results to 
reinforce the argument on the major role of D-serine (rather than glycine) in 
synaptic transmission.  
 
In a recent study by the same group, it was shown that in the CA1 region of rat 
hippocampus, endogenous D-serine acts on synaptic NMDARs whilst 
endogenous glycine acts on extra-synaptic GluN2B-containing NMDARs 
(Figure 1.4: steps 4-5) (Papouin et al., 2012). It was also shown that application 
of exogenous DAAO significantly decreased the extent of LTP. Application of 
D-serine alongside DAAO restored the size of LTP. These results suggested that 
endogenously released D-serine not only enhances synaptic NMDAR 
transmission but that this enhancement contributes to the extent of LTP in the 
hippocampus. In contrast, it was shown that endogenous glycine and GluN2B 
containing NMDARs did not contribute to LTP induction and LTP extent. The 
authors did not investigate the source of D-serine (neuronal or astrocytic) in this 
study.  
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The above results implicate D-serine release in LTP induction. However, not all 
studies are in agreement about the requirement of D-serine in LTP induction. In 
one study on 3-4 weeks old rats (Kang et al., 2013) and another study in 2-3 
months old rats (Rosenberg et al., 2013), DAAO application failed to change 
LTP extent in the CA1 region of hippocampus. These results suggest that 
endogenous D-serine is not required for LTP induction. 
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Figure 1.4. Glycine and D-serine release in the tripartite synapse. Neurones can 
release glutamate and glycine through calcium dependent vesicular release (1). D-serine 
is released via calcium dependent vesicle release from astrocytes (2). D-serine can also 
be released by neurones via a non-vesicular pathway involving Asc-1 transporters (3). A 
study in the hippocampus has shown that D-serine mainly acts on synaptic NMDARs (4) 
whilst glycine mainly acts on extra-synaptic NMDARs (5). It has been suggested that 
synaptic NMDAR modulation mainly depends on D-serine release because extracellular 
glycine is rapidly transported into astrocytes and neurones via GlyT-1 (6 and 7).  
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Decline in memory and cognitive function is generally linked to impaired 
synaptic plasticity. For example, aged rats show impaired LTP and learning 
(Clayton et al., 2002). Implication of NMDARs in LTP means that these 
receptors could be possible therapeutic targets for cognitive impairment. Broad 
NMDAR agonists and antagonists are not used for neurological disorders 
because of the adverse side effects of these pharmacological agents. Therefore, 
therapeutic targeting of specific NMDARs according to their subunit 
composition and localisation would be a better strategy. For this reason it is 
important to investigate the function, properties and localisation of different 
NMDAR subtypes. One of the studies mentioned above showed that LTP 
induction did not depend on extra-synaptic NMDA receptors (Papouin et al., 
2012). However, the scientific literature on the contribution of synaptic GluN2A-
containing NMDARs and extra-synaptic GluN2B-containing NMDARs in 
synaptic plasticity is controversial due to seemingly contradictory results from 
different labs.  
 
1.8 Role for Synaptic and extra-synaptic NMDA receptors 
 
For most NMDARs, there exists at least one GluN1 subunit and one GluN2 
subunit. Usually two of each of these subunits exists and the NMDAR is called 
the di-heterometic GluN1/GluN2 containing receptor. It has been shown that at 
start of development (up to one to two weeks of age) in the hippocampus and 
cortex, the GluN2B subtype is abundant whilst GluN2A is relatively rare. As 
development progresses towards maturity (post one to two weeks postnatal), the 
number of GluN2A subunits increases whilst number of GluN2B subunits 
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decreases (Sans et al., 2000, Erisir and Harris, 2003, Liu et al., 2004). In mature 
hippocampus and cortex, GluN2A subunit is the predominant GluN2 subunit 
whilst GluN2B subunit is the second most abundant GluN2 subunit (Monyer et 
al., 1994), suggesting that both subunits have important roles in NMDAR-
dependent transmission and plasticity.   
  
Synaptic NMDARs refer to receptors at the active zone of the synapse. Extra-
synaptic zone refers to parts of the neurone that does not contain active zones. 
The term Peri-synaptic zone usually refers to the extra-synaptic area about 100 
nm around the synapse (Petralia, 2012). The extra-synaptic area (excluding the 
peri-synaptic area) includes the soma and dendritic shaft. Extra-synaptic sites are 
mainly in contact with adjacent non-synaptic processes of glial cells and 
axons/dendrites of neighbouring neurones (Petralia et al., 2010). It is believed 
that in mature neurones, synaptic NMDARs mainly consist of GluN2A subunits 
whilst extra-synaptic NMDARs mainly consist of GluN2B subunits (Tovar and 
Westbrook, 1999, Valtschanoff et al., 1999, Groc et al., 2004, Groc et al., 2006, 
Petralia et al., 2010, Papouin et al., 2012).   
 
GluN2B-containing NMDA receptors have lower peak currents and slower rise 
and decay times compared to GluN2A containing NMDA receptors (Monyer et 
al., 1994, Erreger et al., 2005). A study in the granule cells of dentate gyrus 
showed that miniature NMDAR EPSCs had faster kinetics than evoked (by 
afferent stimulation) EPSCs (Dalby and Mody, 2003). This suggested that 
miniature NMDAR EPSCs consist of fast synaptic GluN2A containing NMDAR 
activity, whilst evoked EPSCs consist of a combination of fast synaptic NMDAR 
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activity and slower extra-synaptic GluN2B-containing NMDAR activity. This 
also suggests that when afferent fibres are not active (no action potentials) 
spontaneous release of glutamate only activates synaptic NMDARs. Release as a 
result of spontaneous activity is not sufficient enough for glutamate spillover to 
extra-synaptic regions (Figure 1.5A). Therefore, extra-synaptic NMDARs are not 
activated during spontaneous glutamate release. However, during evoked 
recordings, where afferent fibres are stimulated, extra-synaptic NMDARs are 
activated along with synaptic NMDARs (Figure 1.5B). This activation of extra-
synaptic receptors could be due to glutamate spillover as a result of more 
synaptic glutamate release (Figure 1.5B: step 6) (Rusakov and Kullmann, 1998). 
Alternatively, as mentioned in an earlier section, extra-synaptic GluN2B 
containing receptors can be activated by glutamate release from astrocytes 
(Figure 1.5B: steps 7-10) (Fellin et al., 2004).  
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Figure 1.5.  See next page for Figure legend. 
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Figure 1.5. Synaptic and extra-synaptic NMDAR mediated transmission. (A) When 
afferent fibres are not stimulated there is spontaneous vesicular release of glutamate from 
nerve terminals (1). This spontaneous glutamate release activates synaptic NMDARs on post-
synaptic neurones (2). There is no glutamate spillover. Therefore, extra-synaptic GluN2B 
containing NMDARs are not activated. (B) Afferent fibre stimulation leads to opening of 
voltage gated calcium channels at nerve terminals. This leads to calcium elevations at nerve 
terminals (3), which in turn results in increase in vesicular release of glutamate (4). Due to 
this increase in glutamate release, some of the glutamate spillover into extra-synaptic space 
(5). Spilled over glutamate can activate extra-synaptic GluN2B containing receptors directly 
(6). Alternatively, spilled over glutamate can activate calcium elevations in astrocytes by 
binding to astrocytic NMDARs (7) and mGluRs (8). This in turn leads to glutamate release 
from astrocytes (9), which can activate extra-synaptic GluN2B containing NMDARs (10). 
AMPARs are not shown in this schematic representation because during NMDAR EPSC 
recordings they are blocked by AMPAR antagonists. During these recordings, NMDARs are 
not blocked by magnesium because NMDAR EPSC are usually recorded at depolarised 
potentials or in the absence of extracellular Mg2+. Note that for simplicity, glycine and D-
serine release are not shown on this schematic representation. 
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Contribution of synaptic and extra-synaptic NMDA receptors to synaptic 
plasticity: As the number of GluN2B containing NMDARs decrease and the 
number of GluN2A containing NMDARs increase with development, one would 
expect that synaptic GluN2A containing NMDARs to be the main subtype 
needed for LTP induction. Indeed, many studies implicate the importance of 
GluN2A containing NMDA receptors in LTP induction. In a study in CA1 region 
of hippocampus in 9-10 weeks old mice, GluN2A KO resulted in a significant 
reduction in HFS-induced LTP, suggesting the importance of GluN2A subtype in 
LTP induction (Sakimura et al., 1995). In another study in CA1 region of 
hippocampus, from 4 week old mice, application of GluN2B antagonist 
Ifenprodil failed to block HFS-induced LTP whilst application of GluN2A 
antagonist NVP-AAM077 managed to block LTP (Liu et al., 2004). 
Furthermore, a more recent study showed that application of GluN2B antagonist 
did not have an effect on HFS induced LTP in the CA1 region of hippocampus of 
2-3 months old rats (Papouin et al., 2012). 
 
In contrast, there are other studies that show that NMDAR-induced LTP also 
depends upon the activation of extra-synaptic GluN2B-containing NMDA 
receptors. A study showed that over-expression of GluN2B receptors lead to 
enhancement of HFS-induced LTP in the CA1 region of hippocampus of 2-3 
months old rats, suggesting that GluN2B receptors are involved in modulating 
the extent of LTP (Wang et al., 2009). A study in the prefrontal cortex of 6-to-8 
weeks old mice showed that both GluN2A and GluN2B containing NMDA 
receptors were required for TBS-induced LTP induction (Zhao et al., 2005). 
Another study in the CA1 region of hippocampus of 2 months old rats showed 
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that Ifenprodil application significantly reduced the extent of HFS-induced LTP 
(Maggio et al., 2008). 
 
Taken together, it is likely that both GluN2B and GluN2A containing NMDARs 
contribute to LTP induction in the hippocampus and prefrontal cortex.  
 
Glutamatergic transmission is not the only form of synaptic transmission. 
Synaptic transmission also involves GABAergic and purinergic transmission. 
Both GABAergic and purinergic transmission can modulate glutamatergic 
transmission. Therefore, in the following sections I will introduce GABAergic 
and purinergic transmission. 
 
1.9 GABAergic transmission 
 
GABAA receptor structure: GABA is an inhibitory neurotransmitter released 
by interneurones via vesicular exocytosis. The ionotropic receptors for GABA 
are the pentameric GABAA receptors (GABAARs). Each GABAA subunit 
consists of an extracellular N-terminal domain, followed by four transmembrane 
domains and ending with an extracellular C-terminal domain (Sigel and 
Steinmann, 2012). There exist 8 different GABAA subunit classes (, , , , , 
, , ) and a total of 19 different GABAA subunits (Sigel and Steinmann, 2012). 
As a result of the large number of GABAA subunits, there exist a large number of 
GABAAR subtypes. The most abundant GABAAR in the brain consists of 1, 2, 
2 subunits (Sieghart and Sperk, 2002). 
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Phasic and tonic Inhibition: Post-synaptic GABAARs are exposed to a transient 
but high concentration of GABA following the release of this transmitter from 
pre-synaptic interneurones (Figure 1.6: step 1). Binding of GABA to GABAARs 
opens these receptors, allowing Cl- influx into the post-synaptic neurone (Figure 
1.6: step 2). This anion conductance is called an Inhibitory Post-Synaptic Current 
(IPSC) and leads to hyper-polarisation of the post-synaptic neurone (Figure 1.6: 
step 3) (Edwards et al., 1990). IPSCs are rapid and short-term events and 
underlie what is known as “phasic inhibition”.   
 
Phasic inhibition is due to fast synaptic release of GABA onto GABAARs that 
mainly have synaptic localisation. However, GABAARs also exist on extra-
synaptic sites. These extra-synaptic GABAARs are present on soma and axons of 
neurones. Low ambient concentrations of GABA in extra-cellular space can open 
these receptors leading to a temporally longer period of inhibition in comparison 
to phasic inhibition. This persistent inhibitory action of GABAergic transmission 
is called “tonic inhibition”. Phasic transmission is temporally specific as it occurs 
only during firing of interneurones. It is also spatially specific because it takes 
place only at specific inhibitory synapses where GABA is released.  In contrast, 
tonic inhibition is due to a persistent inhibition by ambient GABA 
concentrations; therefore it is not temporally specific. Furthermore, tonic 
inhibition does not involve activation of specific GABAergic synapses, but 
involves activation of extra-synaptic GABAARs of many neighbouring neurones. 
Therefore, tonic inhibition has lower spatial specificity compared to phasic 
inhibition. The existence of tonic inhibition has been shown in different regions 
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of the brain including hippocampus and cortex (Bai et al., 2001, Yamada et al., 
2007).   
 
The overall conductance (charge transfer) during tonic inhibition is higher than 
in phasic inhibition. This is because tonic inhibition involves a continuous and 
persistent activation of extra-synaptic GABAARs. Furthermore, as tonic 
inhibition involves the activity of GABAARs on many neighbouring neurones, 
there is a larger number of GABAARs recruited during tonic inhibition than in 
phasic inhibition. During phasic inhibition, only a small number of GABAARs 
are open. These GABAARs are mainly localised to synaptic/active sites. As these 
receptors are situated very close to GABA release terminals (Figure 1.6: step 2), 
their opening leads to appearance of IPSCs during voltage-clamp recordings. 
However, extra-synaptic GABAARs can also be recruited during synaptic 
transmission. This happens for extra-synaptic GABAARs that are close to site of 
synaptic release, where they can be activated by spillover of GABA from 
synaptic cleft during fast synaptic transmission (Figure 1.6: steps 4-5). This 
activation of extra-synaptic GABAARs also leads to appearance of IPSCs during 
patch clamp recordings. However, during tonic inhibition, extra-cellular ambient 
GABA is, temporally and spatially, far away from their release sites (Figure 1.6: 
step 6). Hence, their binding to extra-synaptic GABAARs does not lead to 
appearance of IPSCs. Instead, in a voltage clamp recording, this tonic inhibition 
of extra-synaptic receptors are associated with the holding current that is required 
to clamp the neurones at a given membrane potential. The larger the tonic 
GABAAR activity, the larger the size of the holding current. 
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As a result of its high temporal and spatial specificity, phasic inhibition is 
involved in the generation of rhythmic activities in neuronal networks by 
synchronising the activity of a large number of pyramidal neurones (Cobb et al., 
1995). Furthermore, phasic inhibition also has a role in TBS-induced LTP (see 
section 1.4). Tonic inhibition on the other hand puts a persistent threshold on 
excitation of neurones (Figure 1.6: step 7). 
 
Tonic inhibition could also have a role in modulating the threshold of synaptic 
plasticity. Studies in hippocampus have shown that some subtypes of GABAARs 
are predominantly present on extra-synaptic sites.  These include  and 5 
containing GABAARs (Brunig et al., 2002, Wei et al., 2003). It has been shown 
that these receptors are involved in tonic inhibition (Stell et al., 2003, Caraiscos 
et al., 2004) suggesting that tonic inhibition mainly involves extra-synaptic 
receptors. Another study has shown that these extra-synaptic GABAARs could 
also be involved in synaptic plasticity, learning and memory (Dawson et al., 
2006). They showed that in the CA1 region of hippocampus of 6-9 months old 
mice antagonism of 5 containing extra-synaptic GABAARs not only decreased 
tonic inhibition but also increased the extent of HFS-induced LTP in comparison 
to control conditions. Furthermore, in vivo investigation showed that antagonism 
of 5 containing extra-synaptic GABAARs lead to improvement in learning and 
memory tasks. These results implied that modulation of tonic inhibition by 
extrasynaptic GABAARs could have a role in modulating NMDAR-dependent 
LTP. These results suggest that in the investigation of excitatory synaptic 
plasticity such as NMDAR-dependent LTP of glutamatergic synapses, one must 
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keep in mind the potential modulating roles played by GABAARs and inhibitory 
transmission.  
 
Extracellular GABA concentration does not solely depend on release of GABA. 
It is also regulated by GABA transporters (GATs) (Chen et al., 2004). These 
transporters actively remove GABA from the extracellular space. The three types 
of GATs are numbered GAT1-3. GAT1 is localised to neurones (Guastella et al., 
1990) whilst GAT3 is mainly localised to glial cells (Figure 1.6: steps 7-8) 
(Borden et al., 1992). By maintaining extracellular GABA concentrations, GATs 
indirectly control tonic inhibition. This control of tonic inhibition has been 
shown for both GAT1 and GAT3 (Overstreet et al., 2000, Shigetomi et al., 
2012).  
 
In summary, phasic and tonic inhibition depend on release of GABA, uptake of 
GABA and localisation of post-synaptic GABAARs. The control of inhibition 
through these factors could have a modulatory role in glutamatergic synaptic 
plasticity. 
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Figure 1.6. Phasic and tonic inhibition. (A) During phasic inhibition there is a transient 
release of high amount of GABA into the synaptic cleft (1). Activation of synaptic GABAARs by 
GABA leads to Cl- entry into the post-synaptic neurone (2). This rapid and short-term GABAAR 
transmission is called IPSC (thick blue arrows), which leads to temporally and spatially 
specific hyper-polarisation (3). During fast phasic transmission there will be spillover of 
GABA onto extra-synaptic space (4). Binding of spilled over GABA to extra-synaptic GABAARs 
also leads to generation of fast GABAergic currents (5). (B) During tonic inhibition there is no 
synaptic release of GABA. However, low ambient concentrations of GABA are present in the 
extracellular space. Ambient GABA molecules continuously activate extra-synaptic GABAARs, 
leading to tonic inhibition (6). This tonic inhibition is persistent and slow (dashed blue lines) 
because GABA molecules are temporally and spatially far away from their release sites. Tonic 
inhibition is involved in maintaining a persistent threshold on post-synaptic excitation (7). 
Tonic inhibition also involves extra-synaptic GABAARs on neighbouring neurones, which are 
not shown on this diagram. Neuronal GAT1 (8) and astrocytic GAT3 (9) are involved in 
actively removing GABA from the extra-cellular space.   
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1.10 Purinergic transmission  
 
Structure and localisation of P2X receptors: It was first in 1972 that Geoffrey 
Burnstock introduced the concept of ATP as a neurotransmitter (Burnstock, 
1972). Both neurones and astrocytes can release ATP. Neuronal and astrocytic 
ATP release is either via exocytosis (Pankratov et al., 2006) or down a 
concentration gradient through plasmalemmal channels (Cotrina et al., 1998). 
ATP can be released at the same hippocampal and cortical nerve terminals where 
glutamate is released (Figure 1.7: part 1) (Pankratov et al., 2006, Pankratov et 
al., 2007). Subsequent to release, ATP binds ATP receptors on neurones and 
astrocytes. Ionotropic ATP receptors are called P2X receptors whilst 
metabotropic ATP receptors are called P2Y receptors. There exists seven subunit 
isoforms for P2X receptors: P2X1-7 (Khakh et al., 2001). P2X receptors 
(P2XRs) can exist either as homomeric or heteromeric assembly of P2X 
subunits. Heteromeric assemblies include P2X1/P2X2, P2X1/P2X4, P2X1/P2X5, 
P2X2/P2X3, P2X2/P2X6 and P2X4/P2X6 receptors (North, 2002). Homomeric 
P2X2 receptors, homomeric P2X4 receptors and P2X4/P2X6 heteromeric 
receptors are the most abundant P2XR subtype in the CNS system (Illes and 
Alexandre Ribeiro, 2004). High expression of P2X2 and P2X4 receptors has 
been shown in the hippocampus and cortex of adult rats (Le et al., 1998, Xiang et 
al., 1998). Most subtypes of P2X receptors are activated by low micromolar 
concentrations. Ionotropic P2X receptors are different in structure to NMDARs 
and AMPARs. NMDARs and AMPARs are tetrameric receptors but P2X 
receptors are trimeric (they are made up of three P2X subunits) (Erb et al., 2006). 
Each P2X subunit has an intracellular N-terminal domain, an extracellular ATP 
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binding domain and an intracellular C-terminal domain (Khakh et al., 2001). 
This means that each subunit has two transmembrane domains. Therefore, each 
P2X receptor contains six transmembrane domains. These transmembrane 
domains contribute to the function of the receptor pore (Egan et al., 2006). P2X 
receptors are permeable to both monovalent and divalent cations. For most P2X 
receptor subtypes calcium permeability is higher than monovalent cation 
permeability (Egan et al., 2006). Their calcium conductance is not as high as 
NMDARs but they are not blocked by magnesium at membrane potentials below 
-40mV (Pankratov et al., 2009). In fact, P2XR Ca2+ influx is higher at less 
depolarised membrane potentials (Pankratov et al., 1999).  
 
It has been shown that P2X receptors are expressed at low levels on neurones 
and that they are mainly present on peri- and extra-synaptic regions (Figure 1.7: 
part 5) (Le et al., 1998). Support for this finding comes from electrophysiological 
recordings where neuronal P2X receptors only contribute 5-15% to the amplitude 
of cortical evoked EPSC currents (Pankratov et al., 2003). Furthermore, electron 
microscopy has shown that P2X2 and P2X4 containing P2XRs are mainly 
situated at peri-synaptic sites in the CA1 region of rat hippocampus (Rubio and 
Soto, 2001). Due to the relative paucity of P2XRs on post-synaptic neurones in 
comparison to glutamatergic ionotropic receptors, it has been suggested that ion 
entry through P2X receptors does not contribute to depolarisation of the post-
synaptic neurone. However, P2XRs can contribute to synaptic transmission and 
plasticity by activation of downstream intracellular signalling as a result of 
calcium entry (Khakh and North, 2012). 
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In a study in the cortex, it was shown that acutely isolated astrocytes express 
functional P2X1/P2X5 heteromeric receptors in adult mice but not other P2X 
subunits (Lalo et al., 2008). The P2X1/P2X5 heteromeric receptors are unique in 
comparison to other P2X receptors because they are activated by nanomolar ATP 
concentrations. This high sensitivity of P2X1/P2X5 heteromeric receptors 
suggests that astrocytic P2XRs can detect extremely low levels of extra-cellular 
ATP.  It has been shown that application of exogenous P2X receptor agonist to 
isolated cortical astrocytes can lead to fast calcium elevation in these cells 
(Palygin et al., 2010). Furthermore, calcium elevation as a result of cortical 
neuronal afferent stimulation was partially blocked by P2X receptor antagonist. 
This suggested that ionotropic P2X receptors are also involved in astrocytic 
calcium elevation in addition to mGluRs and NMDARs (Figure 1.7: part 2). 
Taken together, these studies show the presence of P2X receptors on cortical 
astrocytes and their possible role in contributing to fast calcium rise in astrocytes.  
 
The role of purinergic signalling in synaptic transmission and plasticity: 
Application of exogenous ATP to brain slices can induce LTP. It has been shown 
that 10 minutes application of 10 M exogenous ATP to hippocampal slices 
from guinea pigs (Fujii, 2004) and rats (Ievglevskyi et al., 2012) can induce LTP. 
This LTP is induced without any TBS or HFS protocol and is solely as a result of 
ATP application. Interestingly, during ATP application there is a depression of 
evoked potentials and LTP is only expressed subsequent to ATP washout. This 
potentiation is called ATP-induced LTP to distinguish it from NMDAR 
dependent LTP, which is induced via high frequency stimulation protocols. 
However, ATP-induced LTP is also NMDAR dependent as application of 
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NMDAR antagonists blocks LTP induction (Fujii, 2004). It was shown that 
ATP-induced LTP does not depend on P2X or P2Y receptors but is dependent on 
plasma membrane associated ecto-protein kinases (Fujii, 2004). As a result, it 
was suggested that extracellular ATP could act as a phosphate donor for 
phosphorylation of NMDARs via these ecto-protein kinases (Figure 1.7: part 4). 
This phosphorylation can theoretically result into large Ca2+ influx into the 
NMDARs, thereby leading to LTP.   
 
It is believed that ATP binding to P2X receptors can contribute to NMDAR-
dependent LTP. In brain slices from 19-21 days old rats, high frequency 
stimulation of hippocampal Schaffer collaterals for 1 second induces LTP, 
whereas stimulation for 0.2 sec (a sub-threshold protocol) induces short-term 
potentiation. Inhibition of P2X receptors by the broad antagonist 
Pyridoxalphosphate-6-azophenyl-2’,4’-disulfonic acid (PPADS) during sub-
threshold protocol led to LTP induction (Pankratov et al., 2002). This suggested 
that antagonising P2X receptors reduces the LTP threshold. The same study also 
showed that in hippocampal pyramidal neurones, activation of P2X receptors by 
exogenous and endogenous ATP resulted in a reduction in the NMDAR response 
(Pankratov et al., 2002). Therefore, the authors suggested that activation of P2X 
receptors by ATP results in inhibition of NMDAR activity (Figure 1.7: part 6), 
which in turn increases the threshold for LTP induction.  
 
In contrast to the above report, a study using P2X4 KO mice showed that in the 
CA1 region of hippocampus from 3-4 weeks old mice, extent of LTP was 
significantly lower compared to WT mice (Baxter et al., 2011). Furthermore, in 
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P2X4 KO mice, facilitation of NMDAR EPSC via pharmacological NMDA 
application was lower in comparison to WT mice. These data suggested that 
P2X4 receptors significantly contribute to the size of LTP by increasing 
NMDAR activity. This finding suggests that P2X receptor activity can enhance 
NMDAR activity and so it seems to be contradicting the above-mentioned report 
where blocking P2XRs via PPADS application lead to LTP induction during the 
sub-threshold (0.2 Hz) protocol. These contradictory results suggest that role of 
P2XRs in modulating NMDAR activity and LTP is rather complex. However, it 
must be noted that PPADS does not block P2X4 receptors. Therefore, these 
seemingly contradictory results might be due to the specific roles played by 
different P2XR subtypes. 
 
Another group also showed the involvement of activation of P2XRs on 
enhancing glutamatergic synaptic efficacy. In this study in the hypothalamus, 
activation of P2X receptors by astrocytic ATP led to insertion of AMPARs on 
post-synaptic neurones (Figure 1.7: parts 7-9) (Gordon et al., 2005). This report 
also points to another important finding about purinergic transmission: the source 
of ATP that is involved in modulation of synaptic transmission is astrocytic.  
 
Interestingly, the same researchers who showed that ATP activation of P2X 
receptors led to attenuation of NMDAR activity have also shown that ATP 
activation of P2X receptors can lead to attenuation of GABAA receptor activity. 
They showed that calcium elevation in astrocytes via application of PAR-1 
agonist results in ATP release from these cells (Figure 1.7: parts 10-11). The 
released ATP then activates neuronal P2XRs and leads to intracellular signalling 
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(Figure 1.7: part 12). This P2XR-mediated intracellular signalling in turn leads to 
decrease in amplitude of GABAAR-mediated currents on cortical neurones 
(Figure 1.7: part 13) (Lalo et al., 2009). 
 
A further complexity in the role of purinergic transmission is the rapid (~200 ms) 
hydrolysis of ATP to Adenosine (Dunwiddie et al., 1997). Adenosine role has 
been attributed to the regulation of sleep (Schmitt et al., 2012). Extracellular 
ATP is broken down via dephosphorylation by ecto-nucleotidases to 5’-
Adenosine Monophosphate (5’-AMP) and subsequently to adenosine via 5’-
nucleotidase (Zimmermann and Braun, 1999). Alternatively, Adenosine can be 
released into the extracellular space directly from neurones via facilitated 
diffusion (Wall and Dale, 2013). There exists four different types of receptors for 
adenosine (Olah and Stiles, 1995). All these receptors are G-protein coupled 
metabotropic receptors with seven transmembrane domains and are called A1, 
A2a, A2b and A3 receptors. The A1 receptors are the most abundant adenosine 
receptors and are distributed throughout the brain with particularly high density 
in hippocampus and cortex (Fastbom et al., 1987). Binding of adenosine to A1 
receptors results in inhibition of neurotransmitter release (Proctor and 
Dunwiddie, 1987). This tonic suppression of neurotransmitter release by A1 
receptors is prominent for excitatory glutamatergic transmission (Dunwiddie and 
Hoffer, 1980). 
 
A study has shown that astrocytic vesicular release contributes to adenosine-
mediated tonic suppression. They showed this by developing the transgenic 
mouse line called dominant negative soluble N-ethylmaleimide-sensitive factor 
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attachment protein receptors (dnSNAREs) mouse (Pascual et al., 2005). In this 
transgenic mouse, the cytosolic portion of the SNARE domain of synaptobrevin 
2 is expressed selectively in astrocytes. This selectively prevents vesicular 
release from astrocytes but not neurones (see Chapter 2 for more details). In the 
CA1 region of the hippocampus of dnSNARE mice, baseline evoked fEPSPs 
were larger in comparison to baseline evoked fEPSP from WT mice (Pascual et 
al., 2005). Application of A1 receptor agonist to dnSNARE slices resulted in a 
decrease in the baseline fEPSP. These results suggested that in dnSNARE mice, 
impairment of astrocytic vesicular release results in less ATP release and hence 
less extracellular adenosine availability. This means that in hippocampal slices of 
dnSNARE mice, there is less tonic suppression of glutamatergic transmission via 
A1 receptors, hence resulting in a larger baseline fEPSP. Application of PPADS 
did not alter baseline fEPSP in WT and dnSNARE mice, thereby indicating that 
P2XRs do not contribute to baseline glutamatergic activity. The same study also 
showed that the size of HFS-induced LTP was less in dnSNARE mice compared 
to WT mice. The authors attributed the decrease in LTP size in dnSNARE mice 
to the larger baseline fEPSP in these mice. They suggested that as a result of 
larger baseline fEPSP, there is less extent for fEPSP size to increase by during 
LTP induction. Taken together, the authors concluded that the release of ATP 
from astrocytes and its subsequent rapid breakdown to adenosine persistently 
suppresses tonic excitatory synaptic transmission (Figure 1.7: steps 14-16). This 
suppression provides control over extent of LTP magnitude and threshold. Even 
before this study, it was already known that A1 receptors tonically inhibit 
glutamatergic transmission, thereby modulating LTP threshold. The originality 
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of this report resides in the fact that a major source of this extracellular adenosine 
is shown to be as a result of vesicular release from astrocytes. 
 
 
   
Figure 1.7. Different roles for purinergic signalling in synaptic transmission. ATP can be 
released from the same nerve terminals where glutamate is release (1). This ATP release can 
activate ionotropic P2X receptors (2) and metabotropic P2Y (3) receptors on astrocytes, 
thereby leading to calcium elevation in these cells. Extracellular ATP can enhance NMDAR 
activity by acting as a phosphate donor for phosphorylation by ecto-protein kinases (4). 
Neuronal P2X receptors are mainly localised to extra-synaptic regions (5). Activation of these 
extra-synaptic P2XRs by endogenously released ATP can inhibit NMDAR activity via P2XR 
triggered intracellular signalling involving phosphotases (6). ATP can also be released from 
astrocytes (7). This astrocytic ATP release can activate neuronal P2XRs (8). This in turn leads 
to AMPAR insertion on post-synaptic neurone (9). Astrocytic ATP release can also indirectly 
inhibit GABAARs. Activation of PAR1 receptors on astrocytes (10) leads to calcium elevation 
in these cells (11). This in turn leads to ATP release from astrocytes. The released ATP can 
then bind to extra-synaptic neuronal P2X receptors (12). This triggers activation of protein 
kinase C, which results in inhibition of neuronal GABAARs (13). Extracellular ATP released by 
neurones and astrocytes can be rapidly broken down to adenosine (14). Adenosine can then 
bind to A1 receptors on pre-synaptic neurones (15) leading to a persistent tonic suppression 
of calcium dependent neurotransmitter release (16).     
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1.11 Mechanisms of gliotransmitter release from astrocytes 
 
Astrocytes can release gliotransmitters such as Glutamate, ATP and D-serine. 
The contribution of these gliotransmitters to synaptic transmission and plasticity 
has been discussed above. Another area of tripartite research involves the 
investigation of mechanisms by which gliotransmitters are released from 
astrocytes. This area of research is rather controversial because different studies 
have suggested different mechanisms of gliotransmitter release. The release 
mechanism that is mostly under investigation, and for that reason is mostly 
debated, is calcium dependent vesicular exocytosis.  
 
Evidence in support of calcium dependent exocytosis of gliotransmitter release 
from astrocytes comes in four different forms:  
 
(1) Evidence for presence of vesicles in astrocytes: The presence of Synaptic-
like micro-vesicles (SLMVs) has been shown in astrocytes of brain slice 
preparations (Bezzi et al., 2004, Jourdain et al., 2007, Bergersen et al., 2012). 
These vesicles are about 30-40 nm in diameter, which is similar to the size of 
synaptic vesicles (Bergersen et al., 2012, Martineau et al., 2013). In addition to 
SLMVs, presence of larger vesicles of approximately 300 nm has been shown in 
cultured and acutely isolated astrocytes (Chen et al., 2005). 
 
Unlike neurones, astrocytes lack active zones. However, many studies have 
shown that astrocytic Ca2+ oscillations that occur either spontaneously or in 
response to neuronal stimulation are usually restricted to certain regions of 
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astrocytes (Aguado et al., 2002, Nett et al., 2002, Hirase et al., 2004, Panatier et 
al., 2011). These regions, which are called astrocyte microdomains, are believed 
to surround the synaptic cleft. These extra-synaptic microdomains contain small 
SLMV groups just beneath the astrocytic cell membrane (Bezzi et al., 2004). 
Imaging via electron microscopy has shown that these SLMV containing 
microdomains are opposite neuronal terminals and dendrites, thereby suggesting 
that these microdomains are exocytotic domains that can respond and modulate 
synaptic transmission (Bezzi et al., 2004).  
 
Taken together, evidence for presence of vesicles in astrocytes suggests that 
these cells can utilise vesicles for exocytosis. However, in situ studies have 
shown that astrocyte SLMVs to be seven to nine fold less dense compared to 
their synaptic counterparts (Bezzi et al., 2004, Jourdain et al., 2007, Martineau et 
al., 2013). Due to the paucity of SLMVs compared to neuronal vesicles, the level 
of contribution of exocytotic mechanism to gliotransmitter release has been 
debated.  
 
(2) Evidence for presence of proteins involved in exocytosis in astrocytes: 
Neuronal vesicular exocytosis involves the presence of certain proteins involved 
in the exocytosis mechanism. Neurotransmitter transporters such as the Vesicular 
glutamate transporters (VGLUTs) and Vesicular ATP transporter (VNUT) are 
involved in transporting neurotransmitters into vesicles ready for exocytosis. 
Vesicular exocytosis requires the formation of a functional complex between 
vesicular and membrane proteins called SNAREs. Vesicle associated membrane 
protein 2 (VAMP2), which is also called synaptobrevin 2, is, as the name 
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suggests, a vesicular SNARE. VAMP2 binds to two SNAREs on the plasma 
membrane. These are the syntaxins and SNAP25 (synaptosomoal-associated 
protein 25 kDa) (Jahn and Scheller, 2006). This binding is crucial for exocytosis. 
Synaptotagmin is another vesicular SNARE. Binding of Ca2+ to synaptotagmin 
catalyses exocytosis (Ushkaryov et al., 1992). 
 
The presence of some (but not all) of these analogous proteins has been found in 
astrocyte cultures. These include VGLUTs, VNUT, VAMP2, VAMP3 
(cellubrevin), syntaxin, SNAP23, synaptotagmin 4 and synaptotagmin 11 
(Parpura et al., 1995, Maienschein et al., 1999, Zhang et al., 2004, Cahoy et al., 
2008, Oya et al., 2013). However, some have argued that these findings could be 
due to artefacts of cell cultures (Fiacco et al., 2009, Hamilton and Attwell, 2010). 
Therefore, there have also been attempts to demonstrate the presence of these 
proteins in brain slices. The presence of VGLUT1/2 and VAMP3 has been 
shown in astrocytic SLMVs in slices of rat hippocampus (Bezzi et al., 2004). 
Furthermore, astrocytic VAMP2 expression has also been shown in rat cortical 
slices (Martineau et al., 2013). In contrast, there are reports that have failed to 
confirm the presence of some of these proteins. For example, Immunostaining 
and western blotting failed to demonstrate astrocytic VGLUT1/2 expression in 
both culture preparations and hippocampal/cortical slices from mice (Li et al., 
2013). Therefore, the presence of vesicular exocytosis in astrocytes remains 
controversial.  
 
(3) Evidence for localisation of gliotransmitters in astrocytic vesicles:  
Evidence for localisation of glutamate and D-serine in astrocytic vesicles of 
 76 
cortical slices from 1-month-old rats has also been provided (Bergersen et al., 
2012, Martineau et al., 2013). Evidence suggesting presence of ATP in astrocytic 
vesicles has been provided for astrocyte cultures (Pangrsic et al., 2007). In this 
study, fusion of astrocytic vesicles resulted in the release of ATP suggesting that 
astrocytes are capable of exocytotic ATP release. 
 
(4) Evidence for exocytosis of gliotransmitters as a result of calcium 
elevation:  Tetanus toxin can cleave VAMP2, thereby preventing fusion of 
vesicles and exocytosis. Pharmacological agonists like DHPG and NMDA can 
elevate calcium levels in astrocytes, thereby leading to gliotransmitter release. 
Use of these agonists with and without tetanus toxin has allowed researchers to 
investigate whether calcium dependent gliotransmitter release occurs through 
exocytosis. Researchers utilised this pharmacological approach and showed that 
calcium-dependent release of glutamate (Araque et al., 2000, Bezzi et al., 2004) 
and D-serine (Bezzi et al., 2004, Mothet et al., 2005) occurs via exocytosis in 
astrocyte cultures.  
 
Calcium-dependent exocytosis of ATP has also been shown in astrocyte cultures 
(Coco et al., 2003). However, this study showed that ATP release from astrocyte 
culture was only partially blocked by tetanus toxin. This result suggested that 
release of ATP through VAMP2-dependent exocytosis only partially contributes 
to ATP release from astrocytes. It was shown that ATP is mainly stored in 
secretory granules, which are VAMP-independent. The authors suggested that 
calcium dependent ATP release from astrocytes could occur via both vesicles 
and secretory granules.  
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The evidences for presence of exocytosis in astrocytes are all from studies in 
culture preparations. However, there have also been attempts by some studies to 
provide evidence for exocytosis of gliotransmitters in slice preparations. For 
example, in a recent study in the CA1 region of hippocampus (Kang et al., 
2013), clamping astrocytic Ca2+ at a high concentration of 100-150nM resulted in 
an increase in neuronal NMDAR fEPSP. However, when DAAO and a SR 
inhibitor where added to the patch clamp pipette, NMDAR fEPSP did not 
increase. This result suggested that astrocytes could enhance neuronal NMDAR 
activity by releasing D-serine via a calcium dependent mechanism. Furthermore, 
addition of a tetanus toxin to the patch pipette blocked the increase NMDAR 
fEPSP. This suggested that the calcium dependent release of D-serine from 
astrocytes was via a vesicular mechanism.  
 
As mentioned in a previous section, evidence for glutamate release as a result of 
astrocytic calcium elevation has been provided in brain slice preparations (Fellin 
et al., 2004). However, it is yet to be determined whether this calcium dependent 
glutamate release from astrocytes in slice preparation is via an exocytosis 
mechanism.  
 
An indirect evidence for exocytosis of ATP from astrocytes in brain slice 
preparations has been provided (Pascual et al., 2005). This evidence comes from 
the previously mentioned study that used the transgenic mice line called 
dnSNARE (see section ‘The role of purinergic signalling in synaptic 
transmission and plasticity’). It was shown in this study that in dnSNARE mice, 
there is a lower level of adenosine-mediated tonic suppression of 
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neurotransmitter release. It was suggested that this is as a result of less 
extracellular adenosine concentrations in dnSNARE mice compared to WT mice. 
As adenosine concentration depends on release and breakdown of ATP, the 
authors suggested that impairment of VAMP-dependent exocytosis of ATP in 
dnSNARE mice is the reason for lower level of adenosine-mediated tonic 
suppression in these mice. Therefore, this study provides indirect evidence for 
ATP release via exocytotic mechanism from astrocytes. A more direct evidence 
for calcium-dependent exocytosis of ATP from astrocytes remains to be 
affirmed.  
 
Gliotransmitter release via other mechanisms: As mentioned above, the 
density of astrocytic SLMVs is much less than synaptic vesicles. Therefore, it 
has been suggested that other mechanisms of gliotransmitter release could be 
involved in astrocytes. Studies in cultured hippocampal astrocytes have shown 
evidence for release of gliotransmitters via Ca2+ dependent exocytosis from 
lysosomes (Li et al., 2008, Liu et al., 2011). It was shown that lysosomes and 
SLMVs co-exist in cultured astrocytes (Liu et al., 2011). Non-exocytotic 
mechanisms have also been suggested. One such mechanism is via P2X7 
receptors. The P2X7 receptor is unusual compared to other P2X receptors 
because of formation of a large pore after its activation. It has been proposed that 
ATP and glutamate might be released from astrocytes in this manner (Suadicani 
et al., 2006, Hamilton et al., 2008). However, release through P2X7 receptors 
takes place only in pathological conditions and not physiological conditions. 
Another mechanism proposed is the release of ATP and glutamate through 
connexin hemichannels (Contreras et al., 2002, Stout et al., 2002, Ye et al., 
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2003). A possible mechanism is via Volume regulated anion channels (VRACs). 
This has been shown to occur during pathological conditions such as ischemia 
(Phillis et al., 1997) and involves the release of amino acids such as glutamate 
from astrocytes in response to their swelling as a result of ion and water entry. 
However, it has been suggested that this mechanism could also occur under 
physiological conditions as a result of mild swelling induced by glutamate and 
K+ uptake by astrocytes (Crepel et al., 1998, Amzica and Neckelmann, 1999, 
Kimelberg, 2004). A recent study has shown that calcium elevations in cultured 
astrocytes as a result of TFLLR application results in glutamate release not by 
vesicular exocytosis but via bestrophin-1 channels (Woo et al., 2012). Therefore, 
calcium-dependent gliotransmitter release does not necessarily mean that the 
release mechanism is exocytotic. Furthermore, not every astrocytic calcium 
elevation leads to gliotransmitter release.  
 
There exists an important study (Agulhon et al., 2010) where Ca2+ levels were 
specifically increased in hippocampal astrocytes (and not neurones) by using an 
RF (Arg-Phe) amide in slices of transgenic mouse line that expressed MAS-
related G protein-coupled receptor member A1 (MRGA1) specifically in 
astrocytes. Subsequent to this astrocyte-specific calcium elevation, no changes 
on short or long term plasticity where seen. Furthermore, in the same study, 
prevention of astrocytic Ca2+ oscillations via IP3 receptor type 2 (IP3R2) 
knockout mice (IP3R2 is specific to astrocytes) did not alter short or long term 
potentiation. The authors concluded that either calcium dependent gliotransmitter 
release is not involved in synaptic plasticity or that Ca2+ elevations are not the 
sole trigger for gliotransmitter release. The conclusion from this report was 
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important because it indicated that in addition to calcium elevation, other 
intracellular signalling pathways might also be required for vesicular and non-
vesicular release of gliotransmitters. An example supporting this idea is the 
generation of SICs via activation of astrocytes using PAR1 agonist but not by 
activation of astrocytic P2Y1 receptors (Shigetomi et al., 2008). Activation of 
both PAR-1 and P2Y1 receptors results in calcium elevation in astrocytes but 
only PAR1 activation leads to generation of SICs.  
 
In summary, astrocytic gliotransmitter release can involve a multitude of possible 
mechanisms, some of which might or might not have physiological relevance. 
Most of these mechanisms are dependent on elevations of astrocytic calcium 
levels. However, not every calcium elevation will have the same outcome. 
Furthermore, it is likely that different mechanisms of gliotransmitter release will 
have different effects on synaptic transmission. Therefore, in the investigation of 
role for gliotransmitter release in synaptic transmission and plasticity, one must 
take into account the mechanisms by which gliotransmitters are released.  
 
1.12 Project Objectives and hypothesis 
 
The purpose of this project was to investigate the role of gliotransmitter release 
in synaptic plasticity during LTP induction. Given that the cortex is involved in 
memory and cognition, my aim in this project was to investigate gliotransmitter 
role in synaptic plasticity in the cortex. Furthermore, given that calcium-
dependent exocytosis of gliotransmitters is the mechanism of release that has 
been mostly debated my aim was to investigate the role for gliotransmitter 
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release mediated via calcium-dependent vesicular exocytosis. For this purpose, I 
used the pharmacological agent PAR1 agonist and the transgenic dnSNARE 
mice. I will separate this general aim into different specific objectives: 
 
Role for astrocytic D-serine: Role for astrocytic D-serine release in LTP 
induction has been shown in hippocampus and hypothalamus (Panatier et al., 
2006, Henneberger et al., 2010) but not in the cortex. In this project, I have 
attempted to investigate whether vesicular release of D-serine from astrocytes is 
also important in LTP induction in the somatosensory cortex. 
 
Role for astrocytic glutamate: Evidence for glutamate release as a result of 
astrocytic calcium elevation has been shown in brain slices (Fellin et al., 2004). 
However, there is still no evidence from brain slices showing whether this 
astrocytic glutamate release is via vesicular exocytosis. Furthermore, the 
functional significance of this astrocytic glutamate release in synaptic 
transmission and plasticity has not been shown. It has been shown that glutamate 
release from astrocytes can activate neuronal extra-synaptic GluN2B-containing 
NMDARs (Fellin et al., 2004) but whether these receptors are involved in LTP 
induction is controversial (see section 1.8). Therefore, one of my aims was to 
investigate whether glutamate is released from astrocytes unto neurones via 
calcium-dependent vesicular exocytosis. My other aim was to investigate 
whether extra-synaptic GluN2B-containing NMDA receptors are involved in 
LTP induction in the somatosensory cortex. 
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Role for ATP release: It has been shown that tonic extracellular adenosine 
levels depend on vesicular exocytosis from astrocytes (Pascual et al., 2005). As 
adenosine levels depend on ATP breakdown, this suggests that astrocytes release 
ATP via vesicular exocytosis. However, as yet, there is no direct evidence for 
calcium-dependent exocytosis of ATP from astrocytes. As mentioned above, it 
has been shown that ATP is involved in modulation of synaptic transmission by 
modulating the activity of other receptors such as NMDARs and GABAARs 
(Lalo et al., 2009, Baxter et al., 2011). Therefore, my aim was to provide 
evidence for calcium dependent exocytosis of ATP from astrocytes and to 
investigate the role of this astrocytic ATP release in modulation of synaptic 
transmission and plasticity.  
 
My first hypothesis was that astrocytes release gliotransmitters via calcium-
dependent vesicular exocytosis. My second hypothesis was that calcium-
dependent exocytosis of ATP, glutamate and D-serine from astrocytes can 
positively modulate synaptic transmission and LTP induction in the 
somatosensorycortex. 
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Chapter 2: Materials and Methods 
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2.1 Animals 
 
Experiments were performed in somatosensory cortex of dnSNARE transgenic 
mice (Zhang et al., 2004), their WT littermates and transgenic mice expressing 
enhanced green fluorescent protein (EGFP) under the control of the glial 
fibrillary acidic protein (GFAP) promoter (Nolte et al., 2001). Mice were 1 to 3 
months old.  
 
Generation of transgenic dnSNARE mice as a tool for investigating 
vesicular exocytosis by astrocytes: As was mentioned in the introduction, there 
is mounting evidence that astrocytes can release gliotransmitters via SNARE 
protein dependent mechanisms. One of the proteins involved in this exocytosis 
mechanism is VAMP2. Astrocytic expression of VAMP2 and cellubrevin has 
been shown in brain slices (Bezzi et al., 2004, Wilhelm et al., 2004, Martineau et 
al., 2013). In 2005, dnSNARE mice were generated by a group of researchers 
(Pascual et al., 2005). Here, I will give a brief explanation on how these 
researchers generated this transgenic mice line. It has been shown that expression 
of an exogenous SNARE domain prevents the formation of endogenous SNARE 
complex (Hua and Scheller, 2001); hence preventing vesicular-mediated 
exocytosis. For this purpose, the cytosolic portion of VAMP2 (amino acids 1 to 
96) was selectively expressed in astrocytes in order to block gliotransmission 
(Pascual et al., 2005). Two lines of transgenic mice were developed. The first 
transgenic line (GFAP-tTA mouse) contained the 2kB human GFAP promoter 
followed by tTA (tetracycline transactivator) gene. GFAP is an intermediate 
filament expressed specifically by astrocytes and not neurons. In GFAP-positive 
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astrocytes of GFAP-tTA mice, GFAP promoter derives the expression of tTA. 
The second transgenic mice line was the tet-operator (tetO) transgenic mice line, 
which contained three constructs. Each construct contained the tetO responsive 
element promoter. For the first construct, lacZ sequence was downstream of tetO 
whilst the second construct contained EGFP domain and the third construct 
contained the dnSNARE domain. The three constructs were co-injected into 
C57/CH3 hybrid zygotes. The tetO transgenic mice were mated with GFAP-tTA 
transgenic mice. This crossing yielded mice lines that express SNARE, LacZ and 
EGFP in GFAP-positive astrocytes and not in neurones. The LacZ and EGFP are 
the reporters of the dnSNARE expression. LacZ was only expressed in astrocytes 
suggesting that dnSNARE domain is selectively expressed in astrocytes. 
Astrocytes that show EGFP expression are highly likely to express the SNARE 
domain of VAMP2, which blocks gliotransmission. Expression of the SNARE 
domain of VAMP2 during development might have detrimental effects. To 
prevent this, doxycycline (Dox) is supplied to mice drinking water (25g/ml) 
until 3 weeks of age. Doxycycline is then removed from drinking water. 4 weeks 
subsequent to the removal of Dox, electrophysiological experiments are 
performed. Doxycyline binding to tTA prevents the binding of tTA to tetO, 
hence suppressing expression of transgenes. The crossed transgenic mice line 
was called dnSNARE mice.  
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2.2 Drugs 
Tables 2.1a, 2.1b and 2.1c show the list of pharmacological agents used in this 
project 
Name Abbreviation Function Company
Thr-Phe-Leu-Leu-Arg-NH2 TFLLR-NH2 PAR-1 selective agonist Tocris Bioscience 
(Bristol, UK)
Anandamide AEA Endogenous cannabinoid 
receptor agonist
Tocris Bioscience 
(Bristol, UK)
N-(piperidin-1-yl)-5-(4-
iodophenyl)-1-(2,4-
dichlorophenyl)-4-methyl-1H-
pyrazole-3-carboxamide
AM251 CB1 receptor antagonist Tocris Bioscience 
(Bristol, UK)
Adenosine-5’-(γ-thio)-
triphosphate tetralithium salt
ATPγS Non-hydrolysable P2 receptor 
agonist
Tocris Bioscience 
(Bristol, UK)
6,7-dinitroquinoxaline-2,3-dione DNQX Selective AMPA antagonist Tocris Bioscience 
(Bristol, UK)
threo Ifenprodil hemitartate Ifenprodil GluN2B subunit- selective 
NMDAR antagonist 
Tocris Bioscience 
(Bristol, UK)
D-serine D-serine Glycine agonist at the 
NMDAR
Tocris Bioscience 
(Bristol, UK)
5-(3-bromophenyl)-1,3-dihydro-
2H-benzofuro[3,2-e]-1,4-
diazepin-2-one
5-BDBD P2X4 receptor antagonist Tocris Bioscience 
(Bristol, UK)
2-amino-5-phosphonovaleric 
acid (D-AP-5)
D-AP5 Competitive NMDAR 
glutamate site antagonist
Abcam biochemicals 
(Bristol UK)
DL-2-Amino-5-
phosphonopentanoic acid
DL-AP5 Competitive NMDAR 
glutamate site antagonist
Abcam biochemicals 
(Bristol UK)
4-[[4-Formyl-5-hydroxy-6-
methyl-3-
[(phosphonooxy)methyl]-2-
pyridinyl]azo]-1,3-
benzenedisulfonic acid 
tetrasodium salt
PPADS P2 receptor antagonist Abcam biochemicals 
(Bristol UK)
2-(3-Carboxypropyl)-3-amino-6-
(4 methoxyphenyl) pyridazinium 
bromide
Gabazine Competitive selective 
GABAA receptor antagonist
Abcam biochemicals 
(Bristol UK)
Tetrodotoxin TTX Selective inhibitor of Na+
channel conductance
Tocris Bioscience 
(Bristol, UK)
Sodium Fluoroacetate FAC Disrupts the Krebs cycle Sigma-Aldrich 
biochemicals 
(Dorset, UK)
Table 2.1a 
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Sigma-Aldrich 
biochemicals
(Dorset, UK)
Highly selective mGluR5 
metabotropic glutamate 
receptor antagonist 
MPEP6-Methyl-2-
(phenylethynyl)pyridine 
hydrochloride  
Abcam biochemicals
(Bristol UK)
GluN2C/GluN2D subunit 
selective NMDAR antagonist
UBP1412R*,3S*)-1-(Phenanthrenyl-3-
carbonyl)piperazine-2,3-
dicarboxylic acid
Sigma-Aldrich 
biochemicals
(Dorset, UK)
GABA transporter inhibitor, 
showing selectivity for GAT2 
and GAT3
(S)-
SNAP5114
(S)-1-[2-[Tris(4-
methoxyphenyl)methoxy]ethyl]-
3-piperidinecarboxylic acid 
Sigma-Aldrich 
biochemicals
(Dorset, UK)
Competitive AMPA/kainate
glutamate receptor antagonist
CNQX6-Cyano-7-nitroquinoxaline-2,3-
dione, FG-9065
Sigma-Aldrich 
biochemicals
(Dorset, UK)
Agonist for different 
glutamate receptors
GlutamateL-Glutamic acid
Tocris Bioscience 
(Bristol, UK)
P2X1-3 receptor antagonistNF2798,8'-[Carbonylbis(imino-4,1-
phenylenecarbonylimino-4,1-
phenylenecarbonylimino)]bis-
1,3,5-naphthalenetrisulfonic acid 
hexasodium salt
Tocris Bioscience 
(Bristol, UK)
GABAA antagonistBicucullineR-(R*,S*)]-6-(5,6,7,8-
Tetrahydro-6-methyl-1,3-
dioxolo[4,5-g]isoquinolin-5-
yl)furo[3,4-e]-1,3-benzodioxol-
8(6H)-one
Sigma-Aldrich 
biochemicals
(Dorset, UK)
GABAA receptor antagonistPTXPicrotoxin
CompanyFunctionAbbreviationName
Table 2.1b 
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Name Abbreviation Function Company
Magnesium chloride
Calcium chloride
Sodium chloride
Potassium chloride
Sodium bicarbonate
Casium Chloride
Sodium dihydrogen
monophosphate
Glucose
Guanosine triphosphate 
Magnesium Adenosine 
triphosphate 
Ethylene glycol-bis(β-
aminoethyl ether)-N,N,N′,N′-
tetraacetic acid tetrasodium salt 
4-(2-Hydroxyethyl)piperazine-
1-ethanesulfonic acid, N-(2-
Hydroxyethyl)piperazine-N′-(2-
ethanesulfonic acid)
MgCl2
CaCl2
NaCl
KCl
NaHCO3
CsCl
NaH2PO4 
C6H12O6
GTP
MgATP
EGTA
HEPES
Salts for Krebs and 
intracellular solution
Sigma-Aldrich 
biochemicals 
(Dorset, UK)
Bis[2-(acetyloxymethoxy)-2-
oxoethyl]-[2-[2-[2-[bis[2-
(acetyloxymethoxy)-2-
oxoethyl]amino]-5-
methylphenoxy]ethoxy]-4-[3,6-
bis(dimethylamino)xanthen-9-
ylidene]cyclohexa-2,5-dien-1-
ylidene]azanium bromide
Rhod-2 AM Cell permeable fluorescent 
Ca2+ indicator
Abcam biochemicals
(Bristol UK)
Glycine, N-[4-[6-
[(acetyloxy)methoxy]-2,7-
difluoro-3-oxo-3H-xanthen-9-
yl]-2-[2-[2-[bis[2-
[(acetyloxy)methoxy]-2-
oxoethyl]amino]-5-
methylphenoxy]ethoxy]phenyl]-
N-[2-[(acetyloxy)methoxy]-2-
oxoethyl]-,(acetyloxy)methyl 
ester
Fluo-4 AM Fluorescent calcium indicator Sigma-Aldrich 
biochemicals
(Dorset, UK)
Fura 2 acetoxymethyl ester Fura-2 AM Fluorescent calcium indicator Abcam biochemicals
(Bristol UK)
Table 2.1c 
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2.3 Cortical Slice Preparation 
 
Cervical dislocation was carried out on mice prior to decapitation in accordance 
with United Kingdom legislation. After decapitation, brains were rapidly 
dissected on ice-cold physiological saline cutting solution containing (in mM): 
130 NaCl, 2.7 KCl, 3 MgCl2, 0.5 CaCl2, 18 NaHCO3, 1 NaH2PO4, 15 glucose 
and pH 7.4 gassed with 95% O2 to 5% CO2. Dissected brain was glued to a 
vibratome chamber containing the cutting solution. Coronal cortical slices (300 
m thick) were cut using a vibrating slicer (Manual advance vibroslice, World 
Precision Instrument, USA) at 4C. Cortical slices were then incubated in a 
chamber containing the incubating solution at room temperature for 2-6 hours 
prior to field EPSP or whole cell voltage clamp recording. The incubating 
solution was same as the cutting solution except that the incubating solution 
contained (in mM) 1 MgCl2 and 2.5 CaCl2.  
 
2.4 Electrophysiological recordings 
 
Whole-cell voltage-clamp recordings: Whole-cell voltage-clamp recordings 
from layer 2/3 pyramidal neurones were made with patch pipettes (5-10 M) 
filled with intracellular solution (in mM):  5 NaCl, 5 MgCl2, 10 HEPES, 0.5 
GTP, 5 MgATP, 10 EGTA, 1 CaCl2, 110 CsCl with a pH of 7.33. Slices were 
perfused with physiological saline at a rate of 1.5-2.5 ml/min. The physiological 
saline used for perfusion was the same as the incubating solution. The patch 
pipettes were thin walled glass microelectrode (World Precision Instruments, 
USA). Evoked and spontaneous currents were recorded using an AxoPatch200B 
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patch-clamp amplifier (Axon Instruments, USA) filtered at 2 kHz and digitized 
at 5 kHz. Experiments were controlled by PCI-6229 data acquisition board 
(National Instruments, USA) and WinFluor software (Strathclyde 
Electrophysiology Software, UK). Series resistances were 5-12 M and input 
resistances were 500-1100 M; both varied by less than 20% in the cells 
accepted for analysis.  
 
For activation of synaptic inputs and fEPSPs, layer 4 of cortex was stimulated 
using a concentric bipolar microelectrode with 127 m thick core diameter and 4 
m thick tip diameter (World Precision Instruments, USA). A constant current 
stimulator isolator (A.M.P.I ISO-Flex, IBIS Instrumentation Canada Inc) was 
used for evoking synaptic currents. Stimulus duration was 300 s. 
  
During spontaneous EPSC recordings, in order to trigger synaptically driven 
astroglial Ca2+ transients, High Frequency Stimulation (HFS) consisting of 5 
pulses at 100 Hz was delivered to EPSC recordings. This HFS was repeated 
twice with an interval of 200 ms.  
 
Field EPSP recordings: Slices were perfused with physiological saline as 
above. Thin walled glass microelectrode (World Precision Instruments, USA) 
was placed at layer II/III of the cortex. The pipette was filled with the same 
physiological saline used for perfusion of brain slices. Pipette resistances were 1-
2 M.  
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For induction of synaptic plasticity, HFS was repeated 10 times with 200 ms 
interval. This 10× repetition of HFS was called Theta Burst stimulation (TBS). 
Each HFS consists of 5 pulses; therefore each sequence of TBS consists of total 
of 50 pulses. One, two, three or five sequences of TBS were delivered in an 
attempt to induce synaptic plasticity. Each sequence was delivered once every 
ten seconds. Prior to TBS protocol or drug application, at least 10 minutes of 
steady baseline field EPSP (fEPSPs) were recorded. Baseline fEPSP were 
obtained at 0.1 Hz (every 10 sec) using a stimulation intensity that produced 
approximately 30-50% of maximal response.  
 
Input-output protocol: Input refers to stimulating amplitude in mAs. Output 
refers to the size of the recorded fEPSP. Stimulus amplitude was increased from 
0 mA to 1.4 mA in steps of 0.1 mA whilst recording fEPSPs.  
 
Paired pulse protocol: Two simulating pulses were delivered with time 
intervals of either 50 ms or 200 ms, whilst recording fEPSPs. For each 
experiment, each paired pulse protocol was repeated 10 times. Paired pulse ratio 
(PPR) was calculated each time by dividing the fEPSP slope of the second pulse 
by the fEPSP slope of the first pulse. The average of the 10 PPRs was then taken 
as the PPR value for that paired pulse protocol in that experiment e.g. PPR 
during baseline (control) in WT mice.  
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2.5 Fluorescent calcium imaging in astrocytes 
 
To monitor the cytoplasmic-free Ca2+concentraton [Ca2+]i, cortical astrocytes 
were loaded by 40 min incubation with Fura-2AM. For fura-2 excitation, cells 
were alternately illuminated at wavelengths of 340±5 nm and 380±5 nm using 
the OptoScan monochromator (Cairn, Faversham, UK). Fluorescent images were 
recorded using Olympus BX51 microscope equipped with UMPLFL20x/NA0.95 
objective and 2× intermediate magnification and Andor iXon885 EMCCD 
camera; exposure time was 35 ms at 2×2 binning; experiments were controlled 
by WinFluor software. The [Ca2+]i levels were expressed as F340/F380 ratio 
averaged over the whole-cell image. 
 
To investigate the Ca2+ signaling activated by PAR-1 receptor agonist, cortical 
neurons and astrocytes of WT and dnSNARE mice were loaded with 50 µM 
Fluo-4. Whole-cell voltage-clamp recordings were used to confirm the 
identification of neurons and astrocytes and verify the lack of changes in the 
basic electrophysiological properties of the dnSNARE astrocytes. The Fluo-4 
fluorescence signal was excited at 488±10 nm and measured at 530±20 nm; the 
fluorescent images were recorded and analyzed as described above. 
 
Astrocytes were identified by their morphology under DIC observation and 
EGFP fluorescence (astrocytes from dn-SNARE and GFAP-EGFP mice).  
 
To investigate astrocytic Ca2+ signalling during application of AEA and AM251 
to cortical slices, multi-photon fluorescent Ca2+-imaging was used. Astrocytes of 
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neocortical slices were loaded by 30 min incubation with 1 μM of Rhod-2AM at 
33˚C. Multi-photon imaging of neurones and astrocytes was performed using 
Zeiss LSM-7MP multi-photon microscope coupled with the SpectraPhysics 
MaiTai pulsing laser; experiments were controlled by ZEN LSM software (Carl 
Zeiss, Germany). Images were further analyzed offline using ZEN LSM (Carl 
Zeiss) and ImageJ (NIH) software. The [Ca2+] levels were expressed as ΔF/F 
ratio averaged over region of interest (ROI). For analysis of spontaneous Ca2+ 
transients in astrocytes, three ROIs located at branches and one ROI located at 
soma were chosen. Overall Ca2+ response to agonists of eCB agonist or synaptic 
stimulation was quantified using ROI covering the whole cell image. 
 
2.6 Vibro-dissociation technique to acutely isolate neurons and 
astrocytes 
 
Neurones and astrocytes were acutely isolated using the modified “vibrating 
ball” technique (Vorobjev, 1991, Lalo et al., 2006). The glass ball (200 µm 
diameter) was moved slowly some 10–50 µm above the slice surface, while 
vibrating at 100 Hz (lateral displacements 20–30 µm). This technique preserves 
the function of membrane proteins and therefore is devoid of many artifacts of 
enzymatic cell isolation and culturing procedures. The composition of external 
solution for all isolated cell experiments was (mM) 135 NaCl, 2.7 KCl, 2.5 
CaCl2, 1 MgCl2, 10 HEPES, 1 NaH2PO4, 15 glucose, pH adjusted with NaOH to 
7.3.  
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2.7 Data Analysis 
 
Field EPSP slope: Extracellular field recordings consisted of an artefact, a pre-
synaptic component and fEPSP (Figure 2.1). Please refer to section 3.2 on how 
these components were distinguished from one another. The slope of the fEPSP 
was taken for analysis (Figure 2.1).  
 
 
                                
0.5 mV
20 ms
artefact
Pre-synaptic
component
fEPSP  
 
 
 
 
 
Forty to sixty minutes post TBS can be taken as a measure of early LTP/LTD 
phase. For each recording, an average fEPSP slope was taken from fEPSPs 
recorded from 40-60 minutes post TBS delivery. This average fEPSP slope was 
calculated for all the recordings in each experimental protocol e.g. for TBSx5 
delivery to WT mice where n=15, 15 average fEPSP slopes were obtained. Then 
Figure 2.1. Example of an extracellular field recording. The artefact, pre-synaptic 
component and fEPSP have been highlighted. The red line shows where the slope of 
fEPSP was taken. This fEPSP slope was taken for analysis. 
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the average of these 15 average fEPSPs was taken as the measure of the size of 
synaptic plasticity for that protocol. This average was calculated for all protocols. 
These pooled values were then represented as bar-charts (e.g. see Figure 3.3). 
Average time-courses were also created for fEPSP slopes for each protocol. 
These are shown alongside their corresponding bar-charts.   
 
Evoked EPSCs: Due to the background noise in the recordings, it is not possible 
to know the precise value of EPSC amplitude. To be able to obtain consistent 
values for EPSC amplitudes across the whole recording, each EPSC in the 
recording had to be fitted with a model curve. Each EPSC was fitted with a 
model curve with a single exponential rise and decay phases. This was done 
using a software designed by Yuriy Pankratov (Pankratov and Krishtal, 2003). 
The offset, rise time and decay time for the model were estimated from the noisy 
EPSC. These estimates were used to fit a model curve to the EPSC. The 
parameters of each model curve were reasonably restricted by the range of 1-3 of 
the initial values. The software used minimal-square root procedure to determine 
the amplitude of the model curve. The rise time, decay time and offset were 
optimised by the gradient method to minimise the mean-square error (Pankratov 
and Krishtal, 2003). The mean square error of the fit was usually 5-20% of the 
EPSC amplitude. The rise time, decay time and amplitude of the fitted curve 
were taken for each EPSC.   
 
Spontaneous EPSCs: The software designed by Yuriy Pankratov was used for 
automatically detecting spontaneous events from the recordings (Pankratov and 
Krishtal, 2003). The software automatically detected spontaneous EPSCs with 
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amplitude higher than 2xSD of baseline noise. Subsequent to this initial 
detection, every single spontaneous event was analysed within the 140 ms time 
window (40 ms before and 100 ms after peak). This analysis involved the same 
model fitting procedure as used for evoked EPSC explained above. If the mean 
square error of the fit exceeded 20%, then that spontaneous current was removed 
from the analysis. 
 
Quantal Analysis: The software designed by Yuriy Pankratov was used for the 
following analysis (Pankratov and Krishtal, 2003). The Probability Density 
Function (PDF) was obtained from the EPSC amplitude distribution of the 
recording. This was done by convolving each peak measurement (

x i) with a 
normal distribution 

G(0,). The PDF of the peak EPSC was obtained from:   
                                               

P(x) 
1
N
G(xi,)
i1
N
  
Where N is the sample size. The optimal width of Gaussian Kernel

 was chosen 
as 0.2-0.3 SDnoise. The SDnoise was the standard deviation of the baseline noise 
amplitude. Such a value is not too small and therefore avoids false peaks. It is 
also not too large as to obscure the quantal features of PDF. 
 
Discrete peaks in the PDF suggest the presence of quantal release of transmitters. 
In an ideal situation, if there is no noise to the recording and there is no quantal 
variance, then the distance between successive peaks would be uniform and 
would represent the quantal amplitude. Due to the high quantal variance at 
central synapses, the peaks of the PDF are not resolved uniformly. Therefore, 
quantal binomial model of release must be fitted to the data to be able to 
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determine whether the peaks in the amplitude distribution correspond to quantal 
peaks. For this purpose, two models were fitted to the amplitude distribution. The 
null hypothesis (H0) model was a non-quantal unimodal model. The unimodal 
model means that either 1) the peaks of the amplitude distribution are not quantal 
peaks (that they are peaks that appear randomly) and so the model is a 
continuous model or 2) that the amplitude distribution has quantal peaks but the 
quantal variance (SDq
2) and/or the SDnoise is too large as to obscure the peaks. 
The unimodal model was a normal distribution with mean () and standard 
deviation (SDEPSC) of the amplitude distribution. The quantal binomial model 
was also fitted to the amplitude distribution. This was the alternative hypothesis 
(H1). The PDF obtained above was used to estimate the parameters of this model. 
The distance between the peaks was taken as the preliminary estimate for quantal 
amplitude (q). The number of apparent peaks was taken as preliminary estimate 
for the maximal number of quanta/number of release sites (n). The mean quantal 
content (m) was estimated as either 

 q  or as 

1 CV 2 . CV is Coefficient of 
Variation and equals 

SDEPSC . The probability of release (p), which was 
assumed to be uniform for all release sites, was estimated as 

m n . 
 
The quantal binomial model had the following equation (Redman, 1990): 


S(x)  
j  0
n F j
2((SDnoise)
2  j(SDq )
2 )
exp[( jx)2 / 2((SDnoise)
2  j(SDq )
2)
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where x is the current amplitude and (j) is the number of quantal releases e.g. j=0 
means there was no quantal release (response failure). 

F j  is the probability of 
release for (j) quantal releases. It is represented by 
                                              

F j 
j
n




p
j (1  p)n  j   
 
Both models were optimally fitted to the data using likelihood maximization 
technique of Expectation maximisation (EM) (Stricker and Redman, 1994), 
which adjusted the values of the estimated parameters to maximise the log-
likelihoods for the best fit to the data. This gave log-likelihood estimates, L0 and 
L1, for each model. L0 is the log-likelihood of the optimal fit to the unimodal 
model (H0) and L1 is the log-likelihood of the optimal fit to the binomial model 
(H1). To compare the fit of the two models (to see whether log likelihood of L1 is 
significantly higher than L0), Wilks statistics 

(W ) was performed 
                                                    

W  2 L0  L1  
The distribution of 

W  was assumed to be asymptotically distributed as a 2 
random variable. The Wilks statistics for the fit of the two models was located on 
the 2 distribution. The binomial model was accepted if the unimodal model 
could be rejected at significance level 0.05.     
 
All data are presented as mean±SD unless stated otherwise. 
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Chapter 3: Results 1 
 
Role for calcium dependent gliotransmitter release in 
synaptic transmission and plasticity. 
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3.1. Introduction 
 
Previous studies investigating gliotransmitter role in synaptic transmission and 
plasticity have been carried out in the hippocampus (Pascual et al., 2005, 
Henneberger et al., 2010) with no report on gliotransmitter role during LTP 
induction in the cortex. Gliotransmitters can be released via different 
mechanisms. Calcium-dependent vesicular exocytosis is one possible mechanism 
of gliotrasnmitter release. Therefore, in this chapter my aim was to investigate 
the role of calcium dependent exocytosis of different gliotransmitters (glutamate, 
ATP and D-serine) during synaptic transmission and plasticity in the cortex. 
 
To investigate the role of vesicular gliotransmitters in synaptic transmission and 
plasticity, the transgenic mice line dnSNARE were used. In dnSNARE mice 
vesicular release is specifically impaired in astrocytes and not neurones. 
Researchers who engineered these transgenic mice showed that in the CA1 
region of the hippocampus the size of LTP is significantly reduced in these mice 
compared with recordings from wild-type (WT) mice (Pascual et al., 2005). 
They attributed this attenuation of LTP to reduced tonic extracellular adenosine 
levels in dnSNARE mice. They suggested that as vesicular ATP release from 
astrocytes is impaired in dnSNARE mice, there is less extracellular ATP 
available to be broken down to adenosine. Therefore, tonic adenosine levels are 
reduced, resulting in a decrease in tonic suppression of glutamatergic 
transmission. This leads to a higher baseline glutamatergic transmission. The 
authors suggested that higher baseline glutamatergic transmission means that 
during LTP induction there is less extent for potentiation of glutamatergic 
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transmission, hence resulting in a lower LTP size in dnSNARE mice. Taken 
together, these results suggested that vesicular release of ATP from astrocytes is 
involved in LTP modulation in the hippocampus. However, astrocytic vesicular 
release also involves the release of glutamate and D-serine. Theoretically, release 
of these gliotransmitters is also impaired in dnSNARE mice. Despite the 
availability of these mice for 9 years there has not been any investigation in the 
role of astrocytic glutamate and D-serine (glutamatergic) release using these 
mice. Therefore, in this project, dnSNARE mice were used to investigate the role 
of astrocytic release of both purinergic and glutamatergic gliotransmitters during 
synaptic transmission and plasticity in the somatosensory cortex. 
 
Some of the results in this chapter are based on the previous findings by my 
colleagues. For this reason, I will introduce these previous findings prior to 
proceeding to presenting the results obtained in my project. 
 
Evidence for exocytosis of ATP from astrocytes has been provided in culture 
preparations by previous studies (Coco et al., 2003, Pangrsic et al., 2007). In 
slice preparations, only indirect evidence has been provided for vesicular 
exocytosis of ATP from hippocampal astrocytes (Pascual et al., 2005). This 
indirect evidence was provided by researchers who engineered the dnSNARE 
mice. As mentioned above, these researchers showed that adenosine-mediated 
tonic suppression of neurotransmitter release depends on vesicular exocytosis 
from astrocytes. As adenosine levels depend on ATP breakdown, it was 
suggested that astrocytes release ATP via vesicular exocytosis. There is yet to be 
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a report showing direct evidence for calcium-dependent exocytosis of ATP from 
astrocytes in slice preparations. 
 
To investigate whether astrocytes vesicularly release ATP, one must be able to 
specifically activate release from astrocytes in cortical slices. This would ensure 
that the evidence for ATP release in the cortex is specifically attributed to an 
astrocyte release. It has been shown that in hippocampal slices, PAR-1 agonist 
application can result in G-protein coupled calcium elevations specifically in 
astrocytes and not neurones (Lee et al., 2007, Shigetomi et al., 2008). It has also 
been shown that this specific calcium elevation in astrocytes results in glutamate 
release from these cells. Therefore, PAR-1 agonists can be used for specific 
activation of gliotransmitter release from astrocytes. My colleagues performed 
calcium imaging to investigate whether similar to hippocampal astrocytes, 
astrocytes in the somatosensory cortex also show specific calcium elevations in 
response to PAR-1 agonist application. For this purpose, pyramidal neurones and 
astrocytes in layer 2/3 of somatosensory cortex were patch clamped. Calcium 
indicator Fluo-4 (50 µM) was loaded in the patch pipette to allow for calcium 
imaging. The membrane holding voltage was set at -40 mV for patched 
pyramidal neurones and -80 mV for patched astrocytes. Figure 3.1A shows a 
gradient contrast image of a cortical pyramidal neurone of dnSNARE mice. The 
electrophysiological characterisation (using different holding voltages) of this 
neurone is shown below the image. As can be seen, there is a fast voltage-gated 
Na+ current, which indicates that the patched cell was a neurone and not an 
astrocyte. As shown on Figure 3.1B-D, application of L-glutamate (100 µM) 
resulted in calcium elevation in the neurones. In contrast, there was no neuronal 
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calcium elevation with application of TFLLR (30 µM). This was the case for 
both WT and dnSNARE mice (Figure 3.1D). My colleagues repeated the same 
procedure was for patch-clamped astrocytes. Figure 3.1E represents a gradient 
contrast image and an Enhanced Green Fluorescence Protein (EGFP) fluorescent 
image of a cortical astrocyte from dnSNARE mice. Its electrophysiological 
characterisation is shown below the images. The large K+ current and lack of Na+ 
current shows that the patched cell is an astrocyte and not a neurone. As shown 
on Figure 3.1F-H, application of TFLLR resulted in calcium elevation in 
astrocytes from both WT and dnSNARE mice. This result showed that in the 
somatosensory cortex, PAR-1 agonist application specifically activates calcium 
elevations in astrocytes and not neurones. Therefore, PAR-1 agonist can be used 
as a pharmacological agent for the specific activation of astrocytes.   
    
To investigate whether astrocytes vesicularly release ATP in the cortex, neurones 
in layer 2/3 of cortex were voltage clamped at membrane potential of -80 mV. 
P2XR- mediated miniature currents were recorded under tetrodotoxin (1 µM 
TTX) and antagonists of NMDARs (30 µM D-APV), AMPARs (50 µM CNQX) 
and GABAARs (100 µM picrotoxin) (Figure 3.2). Theoretically, calcium 
elevation should result in vesicular release from astrocytes. To specifically 
activate calcium elevation in astrocytes, PAR-1 agonist TFLLR (10 µM) was 
exogenously applied to cortical slices following 10 minutes of baseline P2XR-
mediated miniature EPSC (mEPSC) recordings. As shown on Figures 3.2A and 
3.2D, application of TFLLR resulted in a significant increase in P2XR-mediated 
mEPSCs (increase of 72±21%, n=17).  This result suggests that activation of 
calcium elevation in astrocytes can lead to release of ATP from these cells.  
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Intracellular calcium elevation can result into vesicular release of transmitters. 
To show that the release is indeed vesicular, the above-mentioned protocol was 
repeated in dnSNARE mice. In dnSNARE mice, vesicular release from 
astrocytes is impaired. Therefore, if astrocytic ATP release is via vesicular 
exocytosis, then in dnSNARE mice there should be no increase in the frequency 
of P2XR-mediated mEPSCs. As shown on Figures 3.2B and 3.2E, application of 
TFLLR failed to increase the frequency of P2XR-mediated mEPSCs. This result 
provided the first direct evidence that ATP release from cortical astrocytes in 
slice preparation is via vesicular exocytosis.  
 
As shown on Figure 3.2A, application of PPADS (10 µM), which is a P2XR 
antagonist, decreased the frequency of P2XR-mediated mEPSCs. With PPADS 
application, the average decrease in P2XR-mediated mEPSCs frequency was 
45±16% (n=7). This provides evidence that the mEPSCs recorded were indeed 
P2XR-mediated. The reason that not all P2XR-mediated mEPSCs were 
abolished following application of PPADS is probably because PPADS does not 
block P2X4 containing receptors. However, P2X4 containing receptors could 
potentially contribute to purinergic signalling in the cortex (Baxter et al., 2011). 
Therefore, my colleagues repeated the above protocol with TFLLR in previously 
characterised P2X4 KO mice (Sim et al., 2006). As shown on Figures 3.2C and 
3.2F, application of TFLLR also increased the frequency of P2XR-mediated 
mEPSCs in P2X4 KO mice but this increase was only 28±15% (n=12), which 
was significantly lower than in WT mice (p<0.005). This result suggests that 
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P2X4 containing receptors are also activated following release of ATP from 
astrocytes. 
 
Further analysis of P2XR-mediated mEPSCs revealed that in WT mice, mEPSCs 
showed bimodal amplitude distributions (Figure 3.2G). The amplitude 
distributions had peak times at 3.1±0.9 pA and 5.7±1.6 pA whilst the decay time 
distributions had peaks at 9.1±0.9 ms and 15.3±1.8 ms (n=14). The mEPSCs 
with slower amplitudes had longer decay times whilst the mEPSCs with larger 
amplitude had faster decay times (see Figure 3.2A for some example mEPSCs). 
Application of TFLLR selectively increased the probability of detection of 
smaller and slower mEPSCs in all 14 neurones tested. In contrast, P2XR-
mediated mEPSCs recorded from dnSNARE mice did not show two peaks in the 
distributions of amplitude or decay times (Figure 3.2H). The P2XR-mediated 
mEPSCs showed only a unimodal distribution, with peak corresponding to large 
and fast mEPSCs. Application of TFLLR failed to change the amplitude and 
decay times of these mEPSCs. 
  
Taken together, these results showed that P2XR-mediated mEPSCs have two 
distinct populations, which differ by their amplitudes and decay times. The larger 
and faster mEPSCs are present in both WT and dnSNARE mice. This suggested 
that these larger and faster mEPSCs have neuronal origin. In contrast, the 
population of mEPSCs that show slower decay times and smaller amplitudes, are 
only present in WT mice. Furthermore, the increase in frequency of P2XR-
mediated mEPSCs as a result of TFLLR application is due to increase in the 
frequency of these smaller and slower mEPSCs in WT mice. This suggested that 
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the smaller and slower mEPSCs are due to vesicular exocytosis of ATP from 
astrocytes.  
 
The results obtained by my colleagues (Figures 3.1 and 3.2) have been published 
(Lalo et al., 2014). In the same paper further proof for ATP release from 
astrocytes was provided by using ATP biosensors. It was shown that application 
of TFLLR onto WT cortical slices resulted in a significant increase in 
extracellular ATP concentration. This increase was impaired in cortical slices 
from dnSNARE mice, again suggesting that ATP can be released specifically by 
astrocytes via vesicular exocytosis following TFLLR application. Please see 
Figure S10 in the paper for more details.                      
 
 
 
 
 
 
 
 
 107 
 
 
 
 
 
 
 
 
Figure 3.1.  Differential action of PAR-1 agonist in the pyramidal neurones and 
astrocytes of somatosensory cortex. Pyramidal neurones (A-C) and astrocytes (E-G) of 
layer2/3 of somatosensory cortex of WT and dnSNARE mice were loaded with Ca2+ 
indicator Fluo-4 via patch pipette. Calcium signals were evoked in neurones and 
astrocytes by a 30-s long rapid application of 30 µM TFLLR and 100 µM L-glutamate to 
slices. The membrane holding voltage was -40 mV for neurones and -80 mV for 
astrocytes. A represents gradient contrast image and electrophysiological 
characterisation of neurones of dnSNARE mice. B shows Ca2+ transients evoked in a 
neurone of dnSNARE mouse by application of TFLLR and L-glutamate. C shows 
representative pseudo-colour fluorescent images recorded at rest and at the peak of 
calcium elevation. D shows the pooled data of peak calcium elevation. The difference 
between TFLLR and glutamate was statistically significant (p=0.004, one-way ANOVA). E 
represents gradient contrast image, EGFP fluorescent image and electrophysiological 
characterisation of astrocytes of dnSNARE mice. F shows Ca2+ transients evoked in an 
astrocyte of dnSNARE mouse by application of TFLLR and L-glutamate. G shows 
representative pseudo-colour fluorescent images recorded at rest and at the peak of 
calcium elevation. H shows the pooled data of peak calcium elevation.        
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mEPSCs:
 
 
 
 
 
 
 
 
 
Figure 3.2.  Quantal release of ATP from astrocytes in slice preparations. P2XR-
mediated mEPSCs were recorded in the presence of TTX (1 µM), CNQX (50 µM) and D-
APV (30 µM) and picrotoxin (100 µM) at -80 mV holding voltage. A-C show 
representative transmembrane currents in different experimental conditions. Orange 
dots represent currents with larger amplitude and kinetics whilst green dots represent 
currents with smaller amplitude and kinetics.  D-F show time-courses for change in 
frequency during application of TFLLR. Each dot represents the frequency calculated for 
a 1 minute window. For Wt mice n=14, for dnSNARE mice n=18 and for P2X KO mice 
n=12. G-H show the amplitude and decay time distributions for P2XR-mediated mEPSCs 
before after TFLLR application. Shaded area show the amplitude distribution of 
background noise. B also shows and EGFP fluorescence image from dnSNARE mice. Scale 
bar is 20 µm.   
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3.2. Distinguishing the fEPSP from the artefact and pre-synaptic 
component of the cortical field recording   
 
On way to investigate synaptic transmission and plasticity is to record fEPSPs. 
To record fEPSPs in the somatosensory cortex, the field-recording pipette was 
placed in layer 2/3 of cortex whilst layer 4 of cortex was stimulated using a 
bipolar electrode. These recordings were carried out at a frequency of 0.1 Hz. As 
can be seen from Figure 3.1, the recorded signal has a complex shape with 
different components. Experiments were carried out to distinguish between the 
artefact, pre-synaptic component and fEPSP. Tetrodotoxin (TTX) blocks voltage 
gated Sodium channels, hence preventing synaptic transmission. Therefore, 
application of TTX should remove both the pre-synaptic volley and the fEPSP, 
enabling one to distinguish the stimulus artefact from the rest of the recorded 
signal. Figure 3.1A shows the effect of TTX (1 µM) application on the recorded 
signal. As can be seen from this figure, TTX application removed all the 
components of the recorded signal with the exception of the artefact, which has 
been highlighted in the figure.  
 
After distinguishing the stimulus artefact, the aim was to distinguish the fEPSP 
from the rest of the recorded signal. fEPSP is a post-synaptic component. Three 
experiments were carried out to distinguish the fEPSP from the pre-synaptic 
component of the signal. One experiment involved application of AMPA 
receptor antagonist DNQX. fEPSP is as a result of glutamatergic transmission. 
As glutamatergic transmission involves the opening of AMPA receptors, the 
post-synaptic component of the recorded signal should be blocked by AMPA 
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receptor antagonists leaving the pre-synaptic component unchanged. Figure 3.1B 
shows the effect of DNQX (30 µM) application on the recorded signal. The part 
of the signal that has disappeared after DNQX application is the AMPAR 
component of the signal. This is the fEPSP of the signal and has been highlighted 
as the post-synaptic component on the figure. DNQX application did not block 
the other components of the recorded signal. This has been highlighted as the 
pre-synaptic component of the signal.    
 
The other two experiments involved the decrease in pre-synaptic release. 
Lowering of calcium levels can lead to decrease in pre-synaptic release. Increase 
in Magnesium concentration can also result in decrease in pre-synaptic release by 
blocking Calcium channels (Lansman et al., 1986). Therefore, concentrations of 
Mg2+ and Ca2+ of the Krebs solution were altered to see the effect on pre-
synaptic component and fEPSP. Under control conditions, Krebs contains 1 mM 
Mg2+ and 2.5 mM Ca2+. Change of calcium concentration from 2.5 to 0 mM 
resulted in decrease in pre-synaptic component and disappearance of the post-
synaptic component (Figure 3.3C). Increase of Magnesium concentration from 1 
mM to 4 mM also decreased both the pre-synaptic and post-synaptic components 
(Figure 3.3D). 
 
Taken together, these results distinguish the fEPSP from the artefact and pre-
synaptic component of the recorded signal. For subsequent field recordings, the 
fEPSP component distinguished here is used for investigating synaptic 
transmission and plasticity.     
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Figure 3.3. Separation of artefact, pre-synaptic component and post-synaptic component of 
fEPSP. A. 10 minutes application of TTX (1 µM) to fEPSP recording. B.. 15 min application of 
DNQX (30 µM) to fEPSP recording C. 10 minute application of 0 mM Ca2+ to fEPSP recording. 
D.. 20 minute application of 4 mM Mg2+ to fEPSP recording. Control fEPSPs (black) were 
recorded in 1 mM Mg2+ and 2.5 mM Ca2+. Following ten minute baseline recording, the condition 
was changed (Red). WT mice were used for all the above recordings. 
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3.3. Stronger stimulation amplitude is required to reach 50% of 
maximum fEPSP response in cortical slices of dnSNARE mice 
compared to cortical slices of WT mice  
  
Researchers who developed the dnSNARE mice have shown that in CA1 region 
of hippocampus, baseline glutamatergic transmission is higher in dnSNARE 
slices in comparison with control slices (Pascual et al., 2005). They attributed 
this to lower tonic adenosine levels in dnSNARE mice. The authors suggested 
that due to impairment of vesicular release from astrocytes in dnSNARE mice, 
there is a decrease in extracellular ATP. As adenosine levels depend on ATP 
breakdown, tonic adenosine levels are also reduced, resulting in decrease in tonic 
suppression of glutamatergic transmission. This leads to a higher baseline 
glutamatergic transmission. They showed this by recording fEPEPs from CA1 
region of hippocampus and changing the stimulus strength at regular intervals. 
This protocol is called the input-output protocol, where input refers to stimulus 
strength and output refers to fEPSP size. They showed that fEPSP was larger in 
dnSNARE mice than in WT mice for the same stimulus strength. To see whether 
this is the case in the somatosensory cortex, I also performed the input-output 
protocol in both WT and dnSNARE mice.  
 
For input-output protocol, different stimulus amplitudes were delivered whilst 
recording fEPSPs at a frequency of 0.1 Hz (Figure 3.4). For stimulus strengths 
between 0.45 mA to 1.0 mA, fEPSP was significantly larger in WT mice 
compared to dnSNARE mice (p<0.01; two sample independent t-test; n=15 for 
dnSNARE mice and n=21 for WT mice). The stimulation strength required to 
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reach 50% of maximum fEPSP response in cortical slices of WT mice is 0.5 pA 
whilst the stimulation strength required to reach 50% of fEPSP max in 
dnSNARE mice is 0.7 pA. These results suggest that in dnSNARE mice, larger 
stimulus strength is required to reach the same level of synaptic transmission as 
in WT mice. This means that baseline synaptic transmission is larger in cortex of 
WT mice compared to dnSNARE mice. This result is in contrast to the above-
mentioned study in the CA1 region of hippocampus, where baseline synaptic 
transmission was higher in dnSNARE mice than in WT mice. These results from 
cortical slices suggest that impairment of vesicular gliotransmitter release from 
astrocytes results in decrease in baseline glutamatergic transmission in the 
somatosensory cortex.   
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Figure 3.4. Input-output dependence for WT and dnSNARE mice. For stimulus strengths 
between 0.45 mA to 1.0 mA, fEPSP was significantly larger in cortical slices of WT mice 
compared to dnSNARE mice (p<0.01; 2 sample independent t-test). For the remaining stimulus 
strengths, there was no statistically significant difference between WT and dnSNARE mice 
(p<0.05). Example fEPSPs from WT and dnSNARE mice are shown on the right of the figure. 
These examples are from stimulus strength 0.6 mA (dashed blue line). At 0.6 mA, fEPSP is larger 
for WT mouse than in dnSNARE mouse.   
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3.4. Vesicular release of gliotransmitters contributes to TBS-
induced LTP in the cortex 
 
It has been shown that in the CA1 region of the hippocampus, LTP size is lower 
in dnSNARE mice compared to WT mice (Pascual et al., 2005). My objective 
was to investigate whether this was the case in the somatosensory cortex. It has 
been shown previously that 4-6 trains of TBS application can induce LTP in the 
cortex (Kirkwood et al., 1993). I used TBSx5 protocol to induce LTP in the 
somatosensory cortex. As can be seen from Figure 3.5A, delivery of TBSx5 to 
the somatosensory cortex results in LTP induction. The average percentage 
change in fEPSP 40-60 minutes post TBS application was +58±7.54% (n=15, 
Figure 3.5B). TBSx5 was also delivered to cortical slices from dnSNARE mice. 
In agreement with the abovementioned study of LTP in hippocampus of 
dnSNARE mice (Pascual et al., 2005), my results showed a significant drop in 
LTP size in dnSNARE mice (+11±10.1%, n=14) compared to WT mice (p<0.01, 
two sample independent t-test; Figure 3.5A-B). These results show that vesicular 
gliotrasnmitter release contributes to LTP induction in the somatosensory cortex. 
 
I obtained the data on Figure 3.5 by a joint effort with Dr Oleg Palygin and Dr 
Jemma Andrew.   
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Figure 3.5. Vesicular release of gliotransmitters contributes to TBS induced LTP in the 
cortex. A shows the average time-courses for LTP recordings in WT and dnSNARE mice. Orange 
arrow shows position of TBS application. B represents the average % increase in fEPSP 40-60 
minutes post TBS delivery. Two sample independent t-test was performed between WT and 
dnSNARE data. Paired t-test was performed for average % change in fEPSP from baseline. p<0.05, 
*; p<0.01, **; p<0.001, ***.  C shows example fEPSPs before and after TBSx5 delivery.  
           
           
           
           
            
P<0.05, * ; p<0.01, **; p<0.001. 
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3.5. TBSx5-induced LTP in the cortex is an NMDAR dependent 
form of LTP 
 
It has been shown that TBS-induced LTP is NMDAR-dependent in the 
hippocampus (Malenka et al., 1989), visual cortex (Kirkwood et al., 1993) and 
somatosensory cortex (Castro-Alamancos et al., 1995). NMDARs are usually not 
open at resting membrane potentials as they are blocked by Mg2+. However, high 
frequency activity of pre-synaptic neurones during TBS delivery can result in 
depolarisation of post-synaptic neurones thereby leading to opening of post-
synaptic NMDARs. The opening of these NMDARs leads to calcium entry into 
the post-synaptic neurones thereby leading to LTP. To show that my LTP 
recordings in WT mice were also NMDAR-dependent, the TBSx5 protocol was 
carried out in the presence of DL-AP5, which is an antagonist of NMDA 
receptors. After 10 minutes of baseline recordings, DL-AP5 was applied onto the 
slice. DL-AP5 application did not decrease the size of fEPSP (Figure 3.6). This 
was as expected because it was shown above that fEPSP consisted of AMPA 
receptor activity (Figure 3.4B). Following 5 minutes of DL-AP5 application, 
TBSx5 protocol was applied. As can be seen from Figure 3.6, LTP induction was 
prevented with DL-AP5 application. This result confirms that TBS-induced LTP 
in the cortex is an NMDAR-dependent LTP. 
 
The flow-chart on Box 3.1 shows the summary of results that have been shown 
thus far. I have shown that astrocytic release of gliotransmitters via vesicular 
exocytosis is required for LTP induction. Gliotransmitters can be divided into 
two groups: purinergic and glutamatergic. In the following sections I will 
 117 
investigate the role of these gliotransmitters in synaptic transmission and 
plasticity.  
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Figure 3.6. TBSx5-induced LTP in the cortex is NMDAR dependent. A shows the 
average time-courses. These recordings were performed in WT mice. For the DL-AP5 
recordings, DL-AP5 was applied 5 minute prior to TBS and washed out 5 minutes post 
TBS. Orange arrow shows position of TBS application. B represents the average % 
increase in fEPSP 40-60 minutes post TBS delivery. Two sample independent t-test was 
performed between TBSx5 and TBSx5+DL-AP5 data. Paired t-test was performed for 
average % change in fEPSP from baseline. p<0.05, *; p<0.01, **; p<0.001, ***.  C shows 
example fEPSPs before and after TBSx5 delivery. 
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Box 3.1. 
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3.6. Exogenous ATP, but not exogenous D-serine, can rescue LTP 
during TBSx5 protocol in cortical slices from dnSNARE mice 
 
As was shown in section 3.4, vesicular release from astrocytes significantly 
contributes to LTP induction. This suggests that gliotransmitters released from 
astrocytes could have a role in synaptic plasticity in the cortex. But which one of 
the gliotransmitters is involved in LTP induction? D-serine has been implicated 
in modulation of LTP. In a study in the CA1 region of hippocampus, BAPTA 
was used to chelate Ca2+ levels in astrocytes; hence blocking calcium dependent 
gliotransmitter release (Henneberger et al., 2010). This resulted in a significant 
reduction in LTP size. This drop in potentiation was rescued when exogenous D-
serine was applied to the brain slice. This report suggested a major role in LTP 
induction for D-serine released by hippocampal astrocytes. 
 
To investigate whether D-serine is also involved in LTP induction in the 
somatosensory cortex, exogenous D-serine (10 µM) was applied during TBSx5 
protocol in dnSNARE cortical slices. Surprisingly, D-serine did not rescue LTP 
in dnSNARE mice (Figure 3.7). These results suggest that in the somatosensory 
cortex, vesicular release of D-serine from astrocytes does not contribute to LTP 
induction. 
  
If D-serine is not the gliotransmitter involved in LTP induction in the 
somatosensory cortex, then which gliotransmitter contributes to LTP induction? 
ATP is another gliotransmitter released by astrocytes. One of my aims in this 
project was to investigate the role of vesicular release of ATP from astrocytes. 
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ATP can modulate synaptic transmission by modulating the activity of other 
receptors such as NMDARs and GABAARs (Lalo, Andrew et al. 2009; Baxter, 
Choi et al. 2011). As TBS-induced LTP is NMDAR dependent, ATP release 
could potentially modulate synaptic plasticity. To investigate this, exogenous 
ATPγS was applied to dnSNARE cortical slices during TBSx5 protocol. ATPγS 
is a non-hydrolysable from of ATP, which means that it is not broken down to 
adenosine. Therefore, application of ATPγS ensures that only the effects of ATP, 
and not adenosine, are investigated. As shown on Figure 3.7, application of 
exogenous ATPS (20 µM) to dnSNARE slices significantly increased the extent 
of TBSx5-induced LTP compared to control recordings (p<0.001, two sample t-
test). With ATPS application, the average increase in fEPSP 40-60 minutes post 
TBSx5 was +40.54±9.66% (n=6).  
 
Taken together, these results suggest that ATP could be the gliotransmitter that 
contributes to LTP induction in the somatosensory cortex. Researchers who 
engineered the dnSNARE mice also showed that ATP release from astrocytes is 
involved in LTP induction in the hippocampus. However, they attributed this 
effect to breakdown of ATP to adenosine. Here, I have shown that ATP itself 
could have a potential role in LTP induction in the somatosensory cortex.      
 
I obtained the data shown on Figure 3.7 in collaboration with Dr Oleg Palygin 
and Dr Jemma Andrew.  
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Figure 3.7.  Exogenous ATP, but not exogenous D-serine, can rescue LTP during 
TBSx5 protocol in cortical slices from dnSNARE mice. These recordings were 
performed in dnSNARE mice. A shows the average time-courses. Orange arrow shows 
position of TBS application. 10 minutes of baseline fEPSP recordings were made before 
TBS application. Purple bar represents the time-span (5 minutes prior and 5 minutes 
post TBS) that exogenous ATPγS (20µM) or D-serine (10µM) was applied. B represents 
the average % increase in fEPSP 40-60 minutes post TBS delivery. The average % change 
in fEPSP for the dnSNARE recordings was +11±10.1%. The average % change in fEPSP for 
the D-serine recordings was -1.11±7.46%. The average % change in fEPSP for the ATPγS 
recordings was +40.54±9.66%. Paired t-test was performed for average % change in 
fEPSP from baseline. Two sample independent t-tests were performed between control 
and D-serine/ATPγS experiments. p<0.05, *; p<0.01, **; p<0.001, ***.  C shows example 
fEPSPs before and after TBSx5 delivery. 
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3.7. ATP-induced LTP is impaired in cortical slices from 
dnSNARE mice 
 
As was shown in the previous section, application of exogenous ATPγS can 
rescue LTP during TBSx5 in dnSNARE mice. This suggested that astrocytic 
ATP contributes to TBS-induced LTP in the somatosensory cortex. However, it 
is known that application of exogenous ATP alone, without delivery of HFS or 
TBS protocol, can induce LTP in WT hippocampal slices from guinea pigs 
(Fujii, 2004) and rats (Ievglevskyi et al., 2012). This is called ATP-induced LTP. 
This LTP is only expressed after ATP has been washed out of the slice. 
 
The above-mentioned reports showed ATP-induced LTP in WT slices. However, 
it is possible that ATP application alone can also induce LTP in dnSNARE 
cortical slices. If this is the case, it might mean that the LTP rescued via ATPγS 
application during TBSx5 in dnSNARE mice (shown on Figure 3.7) is not really 
a rescue of TBSx5-induced LTP but that it is solely dependent on exogenous 
ATP application i.e. it can be induced in both dnSNARE mice and WT mice in 
the absence of TBS protocol delivery. Therefore, to investigate whether this is 
the case in cortical slices, I decided to apply ATPγS in the absence of TBS 
protocol. As shown on Figure 3.8A, 10 minutes application of exogenous ATPγS 
(20µM) to WT cortical slices resulted in a significant LTP induction (p<0.001). 
In agreement with the above-mentioned reports in CA1 region of hippocampus, 
during ATPγS application there was a drop in fEPSP; LTP was only expressed 
following ATPγS washout. The average increase in fEPSP 40-60 minutes post 
ATPγS washout was +38±5.84% (n=14; Figure 3.8D). To my knowledge this is 
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the first time that evidence for ATP-induced LTP has been provided in the 
somatosensory cortex.   
 
Application of ATPγS to dnSNARE cortical slices resulted in a small non-
significant LTP (p<0.05; Figure 3.8). The average increase in fEPSP following 
ATPγS washout was +9.09±5.27% (n=6; Figure 3.8D). There was a significant 
difference in average change in fEPSP between ATPγS application in WT and 
dnSNARE mice (p<0.05; Figure 3.8D). These results suggest that ATP-induced 
LTP is impaired in dnSNARE cortical slices. This is in contrast to ATPγS 
application to dnSNARE cortical slices during TBSx5 delivery where there was a 
significant LTP. To highlight the difference between ATPS application in 
dnSNARE mice when TBSx5 is delivered and when TBSx5 is not delivered, the 
average time-courses of these two data are shown on Figure 3.7C. There was a 
significant difference in fEPSP change 40-60 minutes post ATPγS washout 
between data with TBSx5 and data without TBSx5 (Figure 3.8D). 
  
Taken together, these results suggest that in dnSNARE mice, both TBSx5 
induced LTP and ATP-induced LTP are impaired. In dnSNARE mice, LTP is 
induced only when both protocols are applied together. This is in contrast to WT 
cortical slices, where separate application of either TBSx5 or ATPγS, induces a 
large LTP. 
 
Even though in WT slices, ATP-induced LTP does not require HFS or TBS 
protocol, it is, however, an NMDAR-dependent form of LTP. The mechanism 
for ATP-induced LTP has been attributed to modulation of post-synaptic 
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NMDARs via ATP (Fujii, 2004). It has been suggested that ATP can act as a 
phosphate doner for phosphorylation of NMDARs via plasma membrane 
associated ecto-protein kinases. This means that ATP can indirectly modulate 
NMDAR activity thereby leading to Ca2+ influx and LTP. In contrast to the 
results from Fujii, another report suggested that ATP-induced LTP in rat 
hippoampus is dependent on both P2X and P2Y receptors (Ievglevskyi et al., 
2012). Both these reports used exogenous ATP to induce LTP. However, I used 
ATPγS to induce LTP. As ATPγS is a non-hydrolysable form of ATP, my results 
suggest that ATP can induce LTP without acting as a phosphate donor. 
Therefore, it is likely that ATP-induced LTP is mediated via action of P2X and 
P2Y receptors.     
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Figure 3.8.  ATP-induced LTP is impaired in cortical slices from dnSNARE mice. 10 
minutes of baseline fEPSP recordings were made before ATPγS (20µM) application.  A 
shows the average time-courses for ATPγS (20µM) application in WT and dnSNARE mice. 
No TBSx5 protocol was delivered in either case. Purple bar represents the time-span (10 
minutes) of exogenous ATPγS (20µM) application. B shows example fEPSPs before and 
after ATPγS application. C shows the average time-courses for ATPγS application in 
dnSNARE mice with and without TBSx5 delivery. Orange arrow shows position of TBSx5 
delivery. D represents the average % increase in fEPSP 40-60 minutes post ATPγS 
application. The average % change in fEPSP for ATPγS application in  dnSNARE mice with 
TBSx5 delivery was +40.54±9.66%. The average % change in fEPSP for ATPγS 
application without TBSx5 delivery in dnSNARE mice was +9.09±5.27%. The average % 
change in fEPSP for ATPγS application with TBSx5 delivery in WT mice was +38±5.84%. 
Paired t-test was performed for average % change in fEPSP from baseline. Two sample 
independent t-tests were performed between each two sets of data. p<0.05, *; p<0.01, **; 
p<0.001, ***.  
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Box 3.2. 
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3.8. Neuronal activity causes vesicular release of ATP from 
cortical astrocytes in slice preparations  
 
It was shown in section 3.6 that application of exogenous ATPγS can rescue 
TBSx5-induced LTP in the somatosensory cortex. As a result of this finding it 
was suggested that astrocytes contribute to LTP induction via release of ATP. 
Therefore, the next aim of this project was to investigate whether ATP release 
from astrocytes contributes to synaptic transmission and plasticity. To investigate 
this, first evidence for ATP release from cortical astrocytes must be provided 
(see Box 3.2). 
 
Evidence for vesicular release of ATP from astrocytes as a result of 
pharmacological activation of these cells via TFLLR was provided by my 
colleagues (see Section 3.1). In this section, the idea was to provide evidence for 
vesicular release of ATP from astrocytes as a result of activation of these cells 
via neuronal activity. It has been shown by several studies that neuronal activity 
can activate calcium elevations in astrocytes via activation of ionotropic and 
metabotropic receptors on these cells (Palygin et al., 2010, Panatier et al., 2011). 
As was shown in the previous section, calcium elevation in astrocytes via 
TFLLR application resulted in release of ATP from these cells. The objective in 
this section was to see whether calcium elevation in astrocytes as a result of 
neuronal activity could cause the vesicular release of ATP from these cells. For 
this purpose, neuronal P2XR-mediated currents were recorded in the presence of 
picrotoxin (100 µM) and CNQX (50 µM) at -80 mV holding voltage. Following 
5 minutes of baseline P2XR-mediated spontaneous EPSC (sEPSC) recordings, 
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an episode of HFS was delivered to the afferent neuronal fibres. The HFS 
consisted of 5 pulses of 100 Hz stimulation, repeated two times with 200 ms 
(theta frequency) interval. As shown on Figures 3.9A and 3.9C, delivery of HFS 
resulted in a 2-fold elevation in the frequency of P2XR-mediated sEPSCs in WT 
mice. This suggests that following HFS delivery to afferent fibres, there is an 
increase in ATP release. This ATP release could be as a result of neuronal and 
astrocytic release. To see whether astrocytic vesicular exocytosis contributes to 
HFS-induced increase in sEPSCs, the same protocol was repeated in cortical 
slices from dnSNARE mice. In contrast to WT mice, there was only a modest 
transient increase in the frequency of P2XR-mediated sEPSCs in dnSNARE 
mice (Figures 3.9B and 3.9D). 
  
Further analysis of P2XR-mediated sEPSCs was carried out. In WT mice, the 
average baseline sEPSC amplitude was 8.6±2.4 pA and the average sEPSC decay 
time was 9.9±2.5 ms (n=6). During the first 30 seconds after HFS delivery, the 
average amplitude increased to 12.4±4.2 pA and the decay time also increased to 
11.2±2.3 ms (Figures 3.9C and 3.9E). One to three minutes post HFS, the 
average frequency of sEPSCs remained larger than baseline frequency; however 
the average amplitude decreased below baseline values (Figure 3.9C). This is as 
a result of increase in population of sEPSCs with lower amplitudes (5.5±1.3 pA) 
and slower decay times (15.4±2.2 ms) 1-3 minutes post HFS delivery (Figures 
3.9E and 3.9G). As the number of these low amplitude sEPSCs increases, the 
overall average amplitude of sEPSCs (6.86±1.6 pA) drops below baseline. 
Therefore, as was the case with P2XR-mediated mEPSCs recorded by my 
colleagues (see Figure 3.2), there exist two distinct populations of purinergic 
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sEPSCs. One population (“slow” sEPSCs) has smaller amplitude and slower 
decay times whilst another population (“fast” sEPSCs) has larger amplitudes and 
faster decay times (Figures 3.9E and 3.9G). Thirty seconds post HFS delivery 
results in appearance of sEPSCs with large amplitudes (19.6±2.7 pA) and fast 
decay times (9.2±2.5 ms). The amplitude of these large currents corresponded to 
double of unitary amplitude of the “fast” purinergic sEPSCs. This suggests that 
there is an increase in the frequency of these “fast” sEPSCs 30 seconds post HFS 
delivery. However, 1-3 minutes post HFS delivery shows an increase in the 
frequency of “slow” sEPSCs.    
 
As was shown on Figure 3.2, TFLLR application resulted in increase in 
frequency of population of P2XR-mediated mEPSCs that had small amplitudes 
and slow decay times. It was shown that these mEPSCs were due to vesicular 
release from astrocytes. As HFS delivery in WT mice also results in increase in 
these “slow” sEPSCs, one can suggest that these “slow” sEPSCs are due to 
release of ATP from astrocytes subsequent to activation of these cells via HFS 
delivery to neuronal afferents. Indeed, as shown on Figure 3.9D, there was no 
significant increase in frequency of sEPSCs following 1-3 minutes post HFS 
delivery to neuronal afferents in dnSNARE mice. HFS delivery to dnSNARE 
mice only resulted in increase in frequency of “fast” sEPSCs 30 seconds post 
HFS (Figures 3.9D and 3.9F). In dnSNARE mice there was a selective loss of the 
population of “slow” sEPSCs (Figure 3.9H) again suggesting that these “slow” 
EPSCs are as a result of astrocytic release. 
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Taken together, these data suggest that “fast” P2XR-mediated EPSCs are as a 
result of neuronal release of ATP whilst “slow” P2XR-mediated EPSCs are as a 
result of   calcium dependent vesicular release of ATP from astrocytes. This ATP 
release from astrocytes can be triggered both pharmacologically (TFLLR 
application) and by activation of neuronal afferents. These data provide first ever 
direct evidence for vesicular release of ATP from astrocytes in cortical slices.      
 
The data presented in Figure 3.9 was obtained by a joint effort with Dr Yuriy 
Pankratov. 
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Figure 3.9.  Neuronal activity causes vesicular release of ATP from cortical 
astrocytes in slice preparations. A and B show calcium imaging of astrocytes of 
layer2/3 of somatosensory cortex of both WT and dnSNARE mice. Scale bar is 10 µm. A 
and B also show voltage-clamp recordings of membrane currents in pyramidal neurones 
in the presence of picrotoxin (100 µM) and CNQX (50 µM) at -80 mV holding voltage. The 
P2X antagonist NF279 (3 µM) inhibited the sEPSCs, thereby suggesting that sEPSCs were 
indeed P2XR-mediated. Inlays show the average waveform (20 events) of spontaneous 
sEPSCs recorded before (rest) and 1 min after HFS (stim). C and D show the time-courses 
for amplitude and frequency of sEPSCs before and after HFS delivery. Each dot shows the 
average amplitude and frequency of spontaneous currents recorded in a 1 minute time 
window in the pyramidal neurones of WT and dnSNARE mice. E and F show the 
amplitude and decay time distributions of sEPSCs recorded before, immediately after (0-
30 seconds), and 1-3 minutes after HFS (n=6). G and H represent the plot of decay time of 
sEPSCs against amplitude of sEPSCs. The corresponding waveforms (average of 20 
traces) are shown in the inlay.         
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Box 3.3. 
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3.9. Role for astroglial ATP release: modulation of post-synaptic 
GABAA receptors in neocortical neurones 
 
It was shown in section 3.8 that astrocytes are capable of calcium dependent 
vesicular release of ATP in the somatosensory cortex. The next objective was to 
investigate the role of astrocytic ATP release in synaptic transmission and 
plasticity (Box 3.3). As was shown in section 3.6, application of exogenous ATP 
can rescue TBSx5-induced LTP in dnSNARE mice, thereby indicating that 
astrocytic ATP release contributes to LTP induction. What is the mechanism 
whereby ATP release from astrocytes can contribute to LTP induction? As was 
discussed in section 3.7, the mechanisms for both TBS-induced LTP and ATP-
induced LTP are NMDAR dependent. Therefore, theoretically, if ATP is to have 
a role in LTP induction then release of ATP from astrocytes must somehow 
modulate NMDAR activity. As mentioned above, application of ATPγS, which 
is a non-hydrolysable analogue of ATP, lead to ATP-induced LTP, thereby 
suggesting that ATP can indirectly modulate NMDARs by acting via its 
ionotropic or metabotropic receptors.  
 
It has been shown previously by my colleagues that application of ATP 
analogues can decrease the amplitude of miniature IPSCs in cortical slices (Lalo, 
Andrew et al. 2009). Furthermore, it was also shown that in cortical slices, 
activation of astrocytes via TFLLR application results in increase in frequency of 
P2XR-mediated mEPSCs. This lead to P2XR-mediated intracellular signalling, 
which in turn resulted in decrease in amplitude of evoked and miniature GABAA 
receptor-mediated IPSCs. My colleagues have shown recently that the P2XR-
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mediated inhibition of GABAA receptor activity as a result of application of 
TFLLR is absent in dnSNARE mice (Lalo, U. Palygin. 2014) (Please refer to 
Figure 6 of this paper). These results show that activation of P2XRs via 
astrocytic ATP can indirectly inhibit post-synaptic GABAA receptors in cortical 
neurones. 
 
GABAA-mediated IPSCs are rapid and short-term events and underlie what is 
known as phasic inhibition. Phasic inhibition is due to fast synaptic release of 
GABA onto GABAARs that mainly have synaptic localisation. However, 
GABAARs also exist on extra-synaptic sites. Low ambient concentrations of 
GABA in extra-cellular space can open these receptors leading to a temporally 
longer period of inhibition in comparison to phasic inhibition. This persistent 
inhibitory action of GABAergic transmission is called “tonic” inhibition. Tonic 
inhibition does not result into appearance of IPSCs. Instead, in a voltage clamp 
recording, tonic inhibition is associated with the holding current that is required 
to clamp neurones at a given membrane potential. The larger the tonic GABAAR 
activity, the larger the size of the holding current. If ATP released from 
astrocytes can inhibit GABAergic phasic inhibition, then it is possible that it can 
also inhibit tonic inhibition. To investigate this, pyramidal neurones from layer 
2/3 of somatosensory cortex were voltage clamped at holding potential of -80 
mV under CNQX (50 µM) and D-APV (30 µM). Tonic inhibition was assessed 
by the change in the whole-cell holding current under action of GABAAR 
antagonist bicuculline (50 µM). 
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As shown on Figure 3.10A, application of bicuculline to WT mice showed a 
tonic current of 39.9±8.3 pA (n=20). Application of tonic current to dnSNARE 
cortical slices, showed a tonic current of 76.9±15.1 pA (n=10), which was almost 
two times higher than in WT mice (Figure 3.10B). There was a significant 
difference in the average amplitude of tonic current between WT and dnSNARE 
mice (p<0.01). This shows that in dnSNARE mice there is less inhibition of 
extra-synaptic GABAARs. This suggests that vesicular exocytosis from 
astrocytes is involved in the inhibition of tonic GABAergic activity. As was 
mentioned above, ATP release from astrocytes can inhibit phasic GABAergic 
activity. Therefore, it is possible that inhibition of tonic GABAergic activity is 
also as a result of ATP release from astrocytes. To investigate this, TFLLR was 
applied prior to bicuculline application to both WT and dnSNARE mice (Figure 
3.10A-B). Application of TFLLR to WT cortical slices resulted in a marked 
upward shift in the holding current; the rest of the holding current was efficiently 
diminished by bicuculline. The average amplitude of tonic current subsequent to 
TFLLR application was 12.6±6.8 pA (n=14), which showed a decrease of 
68±14% in amplitude in comparison to control/without TFLLR (Figure 3.10C). 
In contrast, application of TFLLR did not have a significant effect on tonic 
current in cortical slices from dnSNARE mice. In dnSNARE mice, the average 
amplitude of tonic current recorded under the action of TFLLR was 72.2±9.1 pA 
(n=7), which did not show a significant change in comparison to control (Figure 
3.10C). In WT mice, the down-regulation of tonic current following TFLLR 
application was considerably attenuated by application of PPADS (10 µM). As 
TFLLR results in gliotransmitter release specifically from astrocytes, these result 
again show that vesicular release from astrocytes can inhibit tonic GABAergic 
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activity. Furthermore, as PPADS prevents this TFLLR inhibition of tonic 
GABAergic activity, these results suggest that it is the vesicular release of ATP 
that is involved in inhibition of tonic GABAergic transmission.     
  
The above-mentioned results suggest that calcium-dependent vesicular release of 
ATP from astrocytes can inhibit both phasic and tonic GABAergic inhibition. 
However, in a recent study in the hippocampus, it has been shown that 
spontaneous calcium elevations in astrcoytes can modulate both phasic and tonic 
inhibition via GAT3 GABA transporters (Shigetomi et al., 2012). GABA 
transporters can control extracellular GABA concentrations, thus controlling 
GABAergic tonic inhibition. This report showed that chelation of astrocytic 
calcium, and thereby preventing calcium oscillation in astrocytes, resulted in 
decrease in activity of GAT3 transporters. This lead to increase in extracellular 
GABA concentrations, which resulted in increase in GABAergic tonic inhibition. 
Phasic inhibition however decreased (IPSC amplitude decreased). The authors 
attributed the decrease in phasic inhibition to GABAAR desensitisation as a result 
of the increase in extracellular GABA concentrations. In summary, this report 
provided evidence that astrocytic calcium elevation is required for GAT3 control 
of GABAergic transmission in the hippocampus. Therefore, it is possible that in 
my experiments (Figure 3.10B), the larger tonic inhibition in dnSNARE mice 
compared to WT mice can be attributed to decrease in GAT3 activity in 
dnSNARE mice. However, this is unlikely for two reasons: first, calcium 
elevation is not impaired in dnSNARE mice (Figure 3.1), therefore, GAT3 
activity should not be impaired; second, my results and those of my colleagues 
show decrease in both phasic and tonic inhibition.  
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To provide further support that GAT3 activity in astrocytes is not altered in 
dnSNARE mice, inhibitor of GAT3 (30 µM of (S)-SNAP5114) was applied to 
both WT and dnSNARE mice during IPSC recordings (Figure 3.11). Application 
of (S)-SNAP5114 to WT mice resulted in a significant increase in tonic 
inhibition and a significant decrease in the amplitude of phasic IPSCs. 
Application of (S)-SNAP5114 to dnSNARE mice also resulted in a significant 
increase in tonic inhibition and a significant decrease in the amplitude of phasic 
IPSCs. There was no significant difference in change in tonic and phasic 
inhibition between WT and dnSNARE mice (Figure 3.11, p<0.05, two sample t-
test). As the effect of inhibition of GAT3 is simi;ar between WT and dnSNARE 
mice, these data suggest that the increase in tonic inhibition in dnSNARE mice is 
not as a result of alteration in GAT3 activity in these mice but as a result of 
impairment of vesicular release of ATP.   
 
The results shown on Figures 3.9, 3.10 and 3.11 have been published (Lalo, U. 
Palygin O. et al. 2014).       
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Figure 3.10. Exocytosis of ATP from astrocytes down-regulates the tonic inhibitory 
synaptic signalling. A and B show example IPSC recordings at -80 mV under the 
presence of CNQX (50 µM) and D-APV (30 µM). Tonic GABAAR-mediated signalling was 
evaluated by upward shift in the whole-cell holding current (ΔIhold) caused by application 
of bicuculline (50 µM) to layer 2/3 pyramidal neurones in brain slices of WT and 
dnSNARE mice. C shows bar-charts representing the average amplitude of tonic GABAAR-
mediated current measured in different conditions. Two sample independent t-tests 
were performed between each two sets of data. p<0.05, *; p<0.01, **.   
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Figure 3.11. Inhibition of GABA GAT3 transporters decreased the GABAergic mIPSCs 
and increased the tonic current in neurones of WT and dnSNARE mice. A and B show 
GABAergic IPSC recordings in WT and dnSNARE mice under CNQX (50 µM), D-APV (30 µM) 
and PPADS (10 µM) at -80 mV holding voltage. Examples of mIPSCs, recorded at moments 
indicated, and average waveforms of phasic GABAergic current (average of 25 mIPSCs) are 
shown in the inlays below. C shows bar-charts that represent the average change for effect on 
phasic and tonic inhibition by (S)-SNAP5114 (30 µM).  Paired t-test was perfomed for each 
data. Two sample independent t-tests were performed between each two sets of data. p<0.05, 
*; p<0.01, **.   
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3.10. ATP-mediated inhibition of GABAergic transmission leads 
to increase in NMDAR activity, thereby contributing to LTP 
induction 
 
The findings in the previous section showed that astrocytic ATP can indirectly 
inhibit both phasic and tonic GABAergic transmission by acting on neuronal 
P2X receptors. Theoretically, inhibition of GABAergic transmission should 
increase excitability and result into higher chance of LTP induction. For 
example, it has been shown that in the CA1 region of hippocampus, inhibition of 
extra-synaptic GABAARs not only decrease tonic inhibition but also increase the 
extent of HFS-induced LTP in comparison to control conditions (Dawson et al., 
2006). Therefore, it is possible that ATP can contribute to LTP induction by 
increasing excitation through inhibition of GABAergic transmission. This 
increase in excitation could, theoretically, lead to increase in NMDAR activity. 
This could be the case for ATP-induced LTP, where ATP is applied 
exogenously, and TBS-induced LTP, where ATP is released by astrocytes.  
 
To investigate whether NMDAR activity increases as a result of inhibition of 
GABAergic transmission, the NMDAR component of fEPSP was investigated. 
As was shown on Figure 3.3B, application of DNQX completely abolished the 
fEPSP suggesting that fEPSP consists of AMPAR activity. If inhibition of 
GABAergic transmission results in NMDAR activity, then one would expect the 
appearance of an NMDAR component in the fEPSP following inhibition of 
GABAergic transmission. To investigate whether fEPSP consists of an NMDAR 
component, D-serine and D-AP5 were applied to fEPSP recordings. 
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Application of D-serine (10 µM) to fEPSP recordings resulted in a slight non-
significant increase of +3.79±3.01% in fEPSP with respect to baseline recording 
(p<0.05, paired t-test; n=5; see Figure 3.12A, E and F). Following D-serine 
application, D-AP5 was applied on top of D-serine (Figure 3.12A). Application 
of D-AP5 (30 µM) resulted in a slight non-significant decrease of -4.74±3.76% 
in fEPSP (this time the % decrease is with respect to D-serine application and not 
baseline; see Figure 3.12A, E and F). These results show that, as expected, 
fEPSPs do not have a significant NMDAR component and therefore mainly 
consist of AMPAR activity as was shown on Figure 3.3B.  
 
The above result shows that in control conditions, fEPSPs do not have a 
significant NMDAR component. To show that inhibition of GABAergic 
transmission results in appearance of NMDAR component in fEPSP recordings, 
the GABAA receptor antagonist, Gabazine (150 nM), was applied. Application of 
Gabazine resulted in an increase in fEPSP (Figure 3.12B and F). To see whether 
this increase is as a result of NMDAR activity, exogenous D-serine and D-AP5 
were applied on top of Gabazine application (Figure 3.12B). Application of D-
serine increased the fEPSP slope further (Figure 3.12B and F). The average 
increase in fEPSP with Gabazine and D-serine application was 34.01±9.76% 
with respect to baseline (n=4; see Figure 3.12E). This increase was statistically 
significant (p<0.01, paired t-test). Application of D-AP5 subsequent to D-serine 
resulted in significant drop of -48.58±13.94% in fEPSP (p<0.01, paired t-test; see 
Figure 3.12B, E and F). This result shows that blocking of GABAA receptors 
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leads to an increase in NMDAR component of fEPSP, thereby showing that 
inhibition of GABAergic transmission can increase NMDAR activity. 
 
To see whether ATP also results in appearance of an NMDAR component in the 
fEPSP, ATPγS (20 µM) was applied to fEPSP recordings prior to application of 
D-serine and D-AP5. However, as ATPγS application results in depression of 
fEPSP and as it is only after washout that LTP is expressed (see Figure3.8A), D-
serine and D-AP5 were applied 20 minutes after washout of ATPγS (Figure 
3.12C). As expected, washout of ATPγS resulted in an increase in fEPSP. 
Application of D-serine subsequent to ATPγS washout resulted in a further 
increase in fEPSP (Figure 3.12C and F). The average increase in fEPSP 
following ATPγS washout and D-serine application was +18.74±8.19% (n=7, 
Figure 3.12E). This increase was statistically significant (p<0.05, paired t-test). 
Subsequent application of D-AP5 resulted in a significant decrease in fEPSP of -
37.48±16.38% (p<0.01; see Figure 3.12C, E and F). These results suggest that 
ATP can increase the NMDAR component of fEPSP. As was mentioned in 
section 3.7, work by other researchers has shown that ATP can increase 
NMDAR activity by acting as a phosphate donor (Fujii, 2004). However, here I 
have shown that ATPγS, which is a non-hydrolysable form of ATP, can also lead 
to increase in NMDAR activity. This suggests that the increase in NMDAR 
activity following ATPγS application is via a mechanism other than phosphate 
donation. As ATP can result in inhibition of GABAergic transmission and as 
inhibition of GABAergic transmission via Gabazine application results in 
increase in NMDAR activity, I suggest that the possible mechanism for increase 
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in NMDAR activity following ATPγS application is through the ATP/P2XR-
mediated inhibition of GABAergic transmission.   
   
As was discussed in sections 3.8 and 3.9, PAR-1 agonist can result in calcium 
dependent vesicular release of ATP specifically from astrocytes. This ATP 
release can then activate P2XRs on neurones, which in turn can lead to inhibition 
of GABAergic phasic and tonic inhibition. In the current section I have provided 
evidence for appearance of NMDAR activity following application of Gabazine 
or ATPγS. As application of PAR-1 agonist can lead to both the release of ATP 
and the inhibition of GABAergic transmission then it is possible that PAR-1 
agonist application can also lead to the appearance of NMDAR activity. To 
investigate this, TFLLR (10 µM) was applied to cortical slices during fEPSP 
recordings. Application of TFLLR resulted in an increase in fEPSP (Figure 
3.12D-F). To see whether this increase was due to NMDAR activity, D-serine 
and D-AP5 were applied subsequent to TFLLR application (Figure 3.12D). D-
serine application increased fEPSP even further. The average increase in fEPSP 
as a result of TFLLR and D-serine application was +17.01±4.62% (n=7; see 
Figure 3.12E). Application of D-AP5 resulted in a significant decrease of -
28.34±7.70% in fEPSP (n=7, p<0.05, paired t-test; see Figure 3.12E). This result 
suggests that application of PAR-1 agonist can result in appearance of NMDAR 
activity. As PAR-1 agonist results in vesicular release of ATP specifically from 
astrocytes, these results suggest that ATP release from astrocytes can lead to a 
significant increase in NMDAR activity. 
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To investigate that the TFLLR mediated increase in NMDAR activity is indeed 
due to vesicular release from astrocytes, TFLLR was also applied to cortical 
slices from dnSNARE mice. In contrast to WT mice, TFLLR application to 
dnSNARE mice did not result in a significant increase in fEPSP (Figure 3.12D 
and F). Application of D-serine on top of TFLLR also failed to significantly 
increase fEPSP. The average increase in fEPSP following TFLLR and D-serine 
application was +2.65±2.81% (n=7). Application of D-AP5 resulted in a small 
non-significant drop in fEPSP of -3.58±3.32% (n=7, p<0.05, paired t-test, see 
Figure 3.12E). These results show that TFLLR mediated increase in NMDAR 
activity is dependent on vesicular release from astrocytes. As TFLLR application 
result in vesicular release of ATP from astrocytes (see Figure 3.2), this data 
suggest that TFLLR mediated vesicular release of ATP from astrocytes can lead 
to NMDAR activity.   
 
As was shown on Figure 3.7A, application of ATPγS during the delivery of 
TBSx5 can rescue LTP in dnSNARE mice. If, as suggested above, the 
mechanism of ATP mediated increase in NMDAR activity is via inhibition of 
GABAergic transmission, then the rescue of LTP via application of exogenous 
ATPγS in dnSNARE mice is also as a result of inhibition of GABAergic 
transmission. To investigate whether in dnSNARE mice, inhibition of 
GABAergic transmission can also rescue LTP, Gabazine was applied to 
dnSNARE cortical slices prior to delivery of TBSx5. Gabazine (150 nM) was 
applied to dnSNARE mice 10-20 minutes before start of baseline fEPSP 
recording. Delivery of TBSx5 to Gabazine treated slices from dnSNARE mice 
resulted in a significant increase in the extent of LTP compared to control 
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(p<0.01, two-sample t-test; see Figure 3.13). With Gabazine application, the 
average increase in fEPSP 40-60 minutes post TBSx5 was +35.47±9.23% 
(n=10). This result shows that inhibition of GABAA receptors can rescue LTP in 
dnSNARE mice. This suggests that the mechanism of rescue of LTP in 
dnSNARE mice via ATPγS application could involve the inhibition of 
GABAergic transmission.   
 
Taken together, the results in this section suggest that vesicular release of ATP 
from astrocytes can lead to increase in NMDAR activity during synaptic 
transmission. ATP results in this increase by decreasing GABAergic 
transmission. Therefore, it is possible that during TBS protocol, release of ATP 
from astrocytes can inhibit GABAergic transmission, hence leading to increase 
in NMDAR activity and LTP induction.  
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Figure 3.12.  Application of ATPγS, Gabazine and TFLLR can increase the NMDAR 
component of fEPSP. A-D show time-courses of fEPSP recordings during application of 
different pharmacological agents. Each time-course is from a single experiment. Each dot 
shows the average fEPSP slope of fEPSPs recorded in a 1 minute time window. Bar-charts 
(E) represent the average % change in fEPSP across several experiments. Paired t-test 
was performed for average % change in fEPSP from baseline. p<0.05, *; p<0.01, **. F 
shows example fEPSPs corresponding to time-courses and bar-charts shown in A-E. In A, 
exogenous D-serine (10 µM) was applied after 10 minutes of stable baseline recording. 
Subsequently, D-AP5 (30 µM) was applied after 10 minutes of D-serine application. In B,  
Gabazine (150 nM) was applied for 15 minutes. Subsequently, D-serine was applied for 
10 minutes followed by D-AP5. In C, ATPγS (20µM) was applied for 10 minutes. It was 
then washed out for 20 minutes, followed by application of D-serine and then D-AP. In D, 
which shows to time-courses (one for WT and one for dnSNARE mice), TFLLR (10 µM) 
was applied for 10 minutes. This was followed by 10 minutes application of D-serine and 
then D-AP5. 
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Figure 3.13.  Inhibition of GABAA receptors can rescue LTP during TBSx5 in 
dnSNARE mice. These recordings were performed in dnSNARE mice. A shows the 
average time-courses. Gabazine (150 nM) was applied 10-20 minutes prior to start of 
recording. Orange arrow shows position of TBS application. 10 minutes of baseline fEPSP 
recordings were made before TBS application. B represents the average % increase in 
fEPSP 40-60 minutes post TBSx5 delivery. The average % change in fEPSP for control 
dnSNARE recordings was +11±10.1%. The average % change in fEPSP for Gabazine-
treated dnSNARE slices was +35.47±9.23%. Paired t-test was performed for average % 
change in fEPSP from baseline. Two sample independent t-tests were performed between 
control and Gabazine-treated experiments. p<0.05, *; p<0.01, **; p<0.001, ***.  C shows 
example fEPSPs before and after TBSx5 delivery. 
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3.11. Activation of astrocytic vesicular release with TFLLR can 
contribute to TBS-induced LTP.    
 
A sub-threshold stimulation protocol is a stimulation protocol that usually fails to 
depolarise the post-synaptic neurone above the LTP threshold. A group of 
researchers have shown that application of small concentration of PAR-1 agonist 
to CA1 region of hippocampus of 2 months old mice can result in LTP induction 
with a sub-threshold HFS protocol (Maggio et al., 2008). Therefore, I decided to 
investigate whether in the somatosensory cortex, application of PAR-1 agonist 
can also induce LTP with a sub-threshold protocol. This will provide further 
evidence that vesicular release from astrocytes can contribute to LTP induction. 
For this purpose, I had to first find a suitable TBS sub-threshold protocol. 
 
As was shown on Figure 3.5, delivery of TBSx5 can result in the induction of 
LTP. It is known that four to six trains of TBS can induce LTP in the cortex 
(Kirkwood et al., 1993). Therefore, to find a suitable sub-threshold protocol, I 
decided to lower the number of trains of TBS to 1-3 trains. Delivery of TBSx1 
induced a non-significant increase of +6.17±3.64% in fEPSP 40-60 minutes post 
TBS (n=6, p<0.05, paired t-test; see Figure 3.14). Interestingly, delivery of 
TBSx2 induced a slight, though significant, decrease of -15±6.56% in fEPSP 40-
60 minutes post TBS (n=7, p<0.05, paired t-test; see Figure 3.14). In contrast to 
TBSx2, delivery of TBSx3 induced a significant potentiation of 19.83±8.84% 
40-60 minutes post TBS (n=12, p<0.05, paired t-test; see Figure 3.14).  
 
 149 
The above results can be explained using the Artola, Brocher and Singer (ABS) 
rule. The ABS rule suggests that with moderate level of post-synaptic 
depolarisation, a moderate level of calcium elevation is reached. If the level of 
depolarisation/calcium elevation reaches a first threshold, then LTD is induced. 
With higher stimulation, post-synaptic depolarisation is increased further. If post-
synaptic depolarisation reaches a second threshold, then LTP is induced. For a 
graphic representation of the ABS rule please refer to Figure 1. Using the ABS 
rule one can suggest that during TBSx1, post-synaptic depolarisation does not 
reach the first threshold, therefore there is no long term plasticity. During 
TBSx2, post-synaptic depolarisation crosses the first threshold leading to LTD. 
Addition of an extra train of TBS increases post-synaptic depolarisation above 
the second threshold, leading to LTP. Addition of more trains of TBS, as in 
TBSx5, results in a further increase in post-synaptic depolarisation, hence 
leading to a larger extent of LTP. This can be seen on Figure 3.14, where TBSx5 
shows a larger potentiation in comparison to TBSx3.  
 
Impairment of TBSx5-induced LTP in dnSNARE mice suggested that LTP 
induction with TBSx5 requires vesicular release from astrocytes. As LTP 
induction requires vesicular release from astrocytes, one can suggest that the 
reason that with sub-threshold TBS protocol LTP is not induced is because 
during this protocol astrocytes are activated to a lesser extent. This in turn would 
suggest that the degree of astrocytic vesicular release would positively contribute 
to post-synaptic depolarisation. Therefore, a sub-threshold protocol like TBSx2 
induces LTD and not LTP because it has less vesicular release from astrocytes in 
comparison to TBSx5. This means that if during TBSx2, astrocytes are further 
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activated by applying the PAR-1 agonist TFLLR, then the second threshold of 
the ABS rule might be reached and thereby LTP might be induced. To test this 
hypothesis, TFLLR (10 µM) was applied during TBSx2 delivery to cortical 
slices from WT mice. Application of TFLLR during TBSx2 reversed the 
direction of plasticity from LTD to LTP (Figure 3.15). Application of TFLLR 
during TBSx2 showed a small but significant LTP with an average fEPSP of 
+18.07±7.30% 40-50 minutes post TBS (n=14, p<0.05, paired t-test; see Figure 
3.15B). There was a statistically significant difference between TBSx2 under 
control conditions and TBSx2 under TFLLR (p<0.05, two sample independent t-
test; see Figure 3.15B). As PAR-1 agonist results in vesicular release specifically 
from astrocytes, the results from Figure 3.15 provide further evidence that 
vesicular release from astrocytes is required for LTP induction.  
 
Astrocytes can release D-serine, ATP and glutamate. As was shown on Figure 
3.7, exogenous ATP could rescue LTP in dnSNARE mice but exogenous D-
serine failed to do so. This suggested that it was the vesicular release of ATP 
from astrocytes that was required for LTP induction in the cortex and not the 
astrocytic release of D-serine. To provide further evidence that D-serine is not 
required for LTP induction, TBSx2 protocol was delivered during D-serine 
application. In contrast to TFLLR, application of D-serine (10 µM) during 
TBSx2 did not change the direction of synaptic plasticity from LTD to LTP. D-
serine application during TBSx2 induced an LTD comparable to that of TBSx2 
delivery under control conditions (Figure 3.15). With TBSx2 delivery during D-
serine application, a significant LTD was induced with an average % decrease in 
fEPSP of -16.5±5.72% 40-50 minutes post TBSx2 (n=7, p<0.05, paired t-test; 
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see Figure 3.15B). There was no statistically significant difference between 
TBSx2 under control and TBSx2 under D-serine (p<0.05, two sample 
independent t-test). In contrast, there was a significant difference between 
TBSx2 under D-serine and TBSx2 under PAR-1 agonist (p<0.01, two sample t-
test; see Figure 3.15B). These data provide further evidence that in the 
somatosensory cortex, D-serine does not contribute to LTP induction. 
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Figure 3.14. Sub-threshold protocols of LTP induction. These recordings were 
performed in WT mice. A shows the average time-courses for fEPSP recordings for 
different numbers of TBS delivery. Orange arrow shows position of TBS delivery. 10 
minutes of baseline fEPSP recordings were made before TBS delivery. B represents the 
average % change in fEPSP 40-60 minutes post TBS delivery. The average % increase in 
fEPSP 40-60 minutes post TBSx5 was +58±7.54%. The average % increase in fEPSP 40-
60 minutes post TBSx3 was +19.83±8.84%. The average % decrease in fEPSP 40-60 
minutes post TBSx2 was -15±6.56%. The average % increase in fEPSP 40-60 minutes 
post TBSx1 was +6.17±3.64%. Two sample independent t-test was performed, in turn, 
between TBSx5 and each of the sub-threshold protocols. Paired t-test was performed for 
average % change in fEPSP from baseline. p<0.05, *; p<0.01, **; p<0.001, ***. C shows 
example fEPSPs before and after TBSx2 delivery. 
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Figure 3.15. Application of PAR-1 agonist during TBSx2 reverses the direction of 
plasticity from LTD to LTP. These recordings were performed in WT mice. A shows the 
average time-courses for fEPSP recordings with TBSx2 protocol. Orange arrow shows 
position of TBSx2 delivery. 10 minutes of baseline fEPSP recordings were made before 
TBS delivery. Purple bar shows the time-span of D-serine (10 µM) or PAR1 agonist (10 
µM TFLLR) application (each was applied 5 minute prior to TBSx2 and washed out 5 
minutes post TBSx2). B represents the average % change in fEPSP 40-50 minutes post 
TBSx2 delivery. The average % decrease in fEPSP was -15±6.56% for TBSx2 protocol 
under control conditions. The average % decrease in fEPSP was -16.5±5.72% for TBSx2 
protocol under D-serine application. The average % increase in fEPSP was +18.07±7.30% 
for TBSx2 protocol under TFLLR application. Two sample independent t-test was 
performed between each two pairs of data. Paired t-test was performed for average % 
change in fEPSP from baseline. p<0.05, *; p<0.01, **. C shows example fEPSPs before and 
after TBSx2 delivery. 
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The above finding showed that D-serine release is not required for LTP 
induction. This suggests that the rescue of LTP with TFLLR application during 
TBSx2 is not dependent on vesicular release of D-serine from astrocytes. In 
contrast, it was suggested that ATP release from astrocytes could contribute to 
LTP induction in the somatosensory cortex. It was shown in the previous 
sections that TFLLR activation of astrocytes can result in release of ATP from 
these cells. The released ATP then acts on P2X receptors on post-synaptic 
neurones, leading to inhibition of GABAergic transmission and increase in 
NMDAR activity. These findings suggest that the rescue of LTP with TFLLR 
application during TBSx2 could be as a result of TFLLR-mediated activation of 
astrocytic ATP release onto neuronal P2XRs. To investigate whether this rescue 
of LTP is dependent on the TFLLR-mediated increase in P2XR activity, P2XR 
antagonists PPADS (10 M) and 5-BDBD (5 M) were applied along with 
TFLLR during delivery of TBSx2 protocol. Inhibition of P2X receptors during 
TBSx2 prevented the TFLLR-mediated induction of LTP. Instead a significant 
LTD was induced (p<0.05, paired t-test; see Figure 3.16). The size of this LTD 
40-50 minutes post TBS delivery was -28±10.56% (n=12). There was a 
statistically significant difference between the data for TBSx2 delivery under 
PPADS, 5-BDBD and TFLLR and the data for TBSx2 delivery under TFLLR 
but with no P2XR antagonists (p<0.01, two sample t-test; see Figure 3.16B). In 
contrast, the size of LTD with TBSx2 delivery under PPADS, 5-BDBD and 
TFLLR was similar to size of LTD when TBSx2 was applied under no 
pharmacological agent (control). There was no statistically significant difference 
between these two data (p<0.05, two sample t-test; see Figure 3.16B).   
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These results show that rescue of LTP with TFLLR during TBSx2 application is 
dependent on P2XRs. As TFLLR results in vesicular release of ATP from 
astrocytes, these findings suggest that astrocytic ATP can contribute to LTP 
induction by acting on neuronal P2XRs.  
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Figure 3.16. PAR-1 agonist rescue of LTP during TBSx2 is P2XR dependent. These 
recordings were performed in WT mice. A shows the average time-courses for fEPSP 
recordings with TBSx2 protocol. Orange arrow shows position of TBSx2 delivery. 10 
minutes of baseline fEPSP recordings were made before drug application. Purple bar 
shows the time-span of application of PAR1 agonist (10 µM TFLLR), PPADS (10 µM) and 
5-BDBD (5 µM). B represents the average % change in fEPSP 40-50 minutes post TBSx2 
delivery. The average % decrease in fEPSP was -15±6.56% for TBSx2 protocol under 
control conditions. The average % decrease in fEPSP was -28±10.56% for TBSx2 protocol 
under TFLLR, PPADS and 5-BDBDB. The average % increase in fEPSP was +18.07±7.30% 
for TBSx2 protocol under TFLLR application. Two sample independent t-test was 
performed between each two pairs of data. Paired t-test was performed for average % 
change in fEPSP from baseline. p<0.05, *; p<0.01, **. C shows example fEPSPs before and 
after TBSx2 delivery. 
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According to the ABS rule, increase in post-synaptic depolarisation results in 
increase in calcium entry into post-synaptic neurone. If this calcium elevation 
reaches the first threshold then LTD is induced; if it reaches the second threshold 
then LTP is induced. As was shown previously, TBSx5-induced LTP is 
NMDAR-dependent (Figure 3.6). This suggests that during TBSx5-induced LTP, 
opening of NMDARs results in calcium elevation above the LTP threshold in 
post-synaptic neurones. To investigate whether the LTD induced via TBSx2 is 
also dependent on NMDARs, TBSx2 protocol was carried out in the presence of 
DL-AP5. Application of DL-AP5 (60 µM) during TBSx2 also resulted in LTD 
induction with an average fEPSP of -19.58±2.36% 40-60 minutes post TBS 
delivery (n=12, see Figure 3.17). There was no significant difference in the size 
of LTD between TBSx2 during control conditions and TBSx2 during DL-AP5 
application (p<0.05, two sample independent t-test; see Figure 3.17B). This 
result suggests that the LTD induced with the sub-threshold TBSx2 protocol does 
not dependent on NMDA receptors.  
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Figure 3.17. TBSx2-induced LTD is not NMDAR dependent. These recordings were 
performed in WT mice. A shows the average time-courses for fEPSP recordings. Purple 
bar shows the time-span of DL-AP5 application. DL-AP5 was applied 5 minute prior to 
TBS and washed out 5 minutes post TBS. Orange arrow shows position of TBS 
application. B represents the average % change in fEPSP 40-60 minutes post TBS 
delivery. For the DL-AP5 (60 µM) recordings, the average % decrease in fEPSP was -
19.58±2.36%. For control recordings (without DL-AP5), the average % decrease in fEPSP 
was -15±6.56%. Two sample independent t-test was performed between TBSx2 and 
TBSx2+DL-AP5 data. Paired t-test was performed for average % change in fEPSP from 
baseline. p<0.05, *; p<0.01, **; p<0.001, ***.  C shows example fEPSPs before and after 
TBSx5 delivery. 
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As was shown above, application of TFLLR could reverse the direction of 
TBSx2 plasticity from LTD to LTP. This suggested that increase in vesicular 
release from astrocytes can increase depolarisaion of post-synaptic neurones 
above the second threshold of ABS rule, thereby leading to LTP induction. If 
increase in astrocytic vesicular release can increase post-synaptic depolarisation, 
then it suggests that the size of LTP in an above threshold protocol like TBSx3 
should also increase with TFLLR application. As can be seen from Figure 3.14, 
the size of LTP with TBSx3 is lower in comparison to the size of LTP with 
TBSx5. Application of TFLLR during TBSx3 should theoretically increase 
release from astrocytes further, thereby leading to increase in depolarisation of 
post-synaptic neurones and larger LTP size. To investigate whether this is the 
case, TBSx3 was delivered during TFLLR application. Application of TFLLR 
during TBSx3 resulted in an LTP of 35.14±8.39% (n=7; see Figure 3.18). This 
was larger than the 19.83±8.84% LTP size induced with TBSx3 delivered in the 
absence of TFLLR. However, there was no statistically significant difference 
between the two data (p<0.05, two sample t-test; see Figure 3.18). These results 
show that application of PAR1 agonist during TBSx3 can increase LTP size. 
This again suggests that activation of vesicular release from astrocytes can 
contribute to induction of LTP.        
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Figure 3.18. Application of PAR-1 agonist during TBSx3 increases the extent of LTP. 
These recordings were performed in WT mice. A shows the average time-courses for 
fEPSP recordings. Orange arrow shows position of TBSx3 delivery. 10 minutes of baseline 
fEPSP recordings were made before TBSx3 delivery. Purple bar shows the time-span of 
PAR1 agonist (10 µM TFLLR) application. B represents the average % increase in fEPSP 
40-60 minutes post TBSx3 delivery. The average % increase in fEPSP was 19.83±8.84% 
for TBSx3 protocol under control application. The average % increase in fEPSP was 
35.14±8.39% for TBSx3 protocol under TFLLR application. Two sample independent t-
test was performed between the two sets of data. Paired t-test was performed for 
average % change in fEPSP from baseline. p<0.05, *; p<0.01, **. C shows example fEPSPs 
before and after TBSx3 delivery. 
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As was shown in section 3.10, application of TFLLR results in the appearance of 
an NMDAR component in the fEPSP. It was suggested that the TFLLR-mediated 
activation of astrocytic vesicular release of ATP results in the activation of 
P2XRs on post-synaptic neurones. This then leads to inhibition of GABAergic 
transmission, which leads to activation of post-synaptic NMDARs. This increase 
in NMDAR opening results in a larger fEPSP. In the current section it was 
shown that TFLLR application could change the direction of TBSx2 induced 
synaptic plasticity from LTD to LTP (Figure 3.15). Furthermore, TFLLR 
application increased the extent of TBSx3 induced LTP (Figure 3.18). These 
results suggested that TFLLR activation of astrocytes can contribute to TBS-
induced LTP. As mentioned above, fEPSP size increases during the application 
of TFLLR (see Figures 3.12, 3.15A and 3.18A) and this increase is as a result of 
increase in NMDAR component. This suggests that the LTP induced via TFLLR 
application during TBSx2 protocol might be solely as a result of TFLLR i.e. that 
TFLLR by itself (without TBS delivery) induces LTP because of an increase in 
NMDAR component of fEPSP. Indeed, a study performed in the CA1 region of 
the hippocampus showed that in the absence of TBS or HFS protocol, application 
of thrombin, which is an agonist for PAR1, PAR3 and PAR4 receptors, for only 
10 minutes was enough to induce a long-lasting LTP (Maggio et al., 2008). To 
investigate whether this is the case in the somatosensory cortex, TFLLR was 
applied for ten minutes in the absence of TBS delivery. The fEPSP recording 
was continued for 50 minutes after TFLLR washout. Similar to Figure 3.12, 
application of TFLLR resulted in a significant increase in fEPSP (p<0.05, paired 
t-test; Figure 3.19A-B). The average increase was 16±11.81% following 5-10 
minutes of TFLLR application (n=6; see Figure 3.19B). However, washout of 
 161 
TFLLR resulted in a gradual decline in fEPSP. Thirty to forty minutes after 
TFLLR application, the average size of fEPSP was now only 6.75±3.60% with 
respect to baseline recording (n=6; see Figure 3.19B). These results show that in 
the somatosensory cortex, TFLLR application increases the fEPSP but that this 
increase in fEPSP is not an LTP because washout of TFLLR decreases fEPSP 
back to baseline value. This in turn suggests that the change of LTD to LTP with 
TFLLR application during TBSx2 is as a result of a long-term change in synaptic 
transmission.  
    
The above results showed that application of TFLLR can lead to an increase in 
fEPSP (Figure 3.12 and 3.19). This increase was due to an increase in NMDAR 
activity. Is this increase due to pre or post-synaptic changes? It was shown that 
application of TFLLR results in inhibition of post-synaptic GABAergic currents. 
Please refer back to section 3.9 and the paper published by my laboratory (Lalo, 
U. Palygin O. et al. 2014). It was also shown that inhibition of GABAA receptors 
could lead to increase in NMDAR activity (Figure 3.12). This suggested that 
application of TFLLR could increase NMDAR activity by inhibiting post-
synaptic GABAergic transmission. This in turn suggests that the increase in 
NMDAR activity should be as a result of effect on post-synaptic sites. To 
provide further evidence that the increase in NMDAR activity via TFLLR occurs 
at post-synaptic sites, paired pulse protocol was carried out before and after 
TFLLR application. Delivery of the second pulse 50 ms after the first pulse 
resulted in the facilitation of the second fEPSP (Figure 3.19C). The average 
paired pulse ratio (PPR) of this facilitation was 1.51±0.12 (n=6; see Figure 
3.19C-D). Application of TFLLR increases the size of fEPSP (Figure 3.19A and 
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C). If paired pulse ratio changes following this increase, then it would indicate 
that the increase in NMDAR component following TFLLR application is as a 
result of pre-synaptic changes. However, if paired pulse ratio does not change, 
then it would suggest that the increase in fEPSP is as a result of post-synaptic 
changes. As expected, delivery of paired pulse protocol during TFLLR protocol 
failed to significantly change the PPR (p<0.05, paired t-test; see Figure 3.19C-
D). Paired pulse ratio during TFLLR application was 1.40±0.11 (n=6). Washout 
of TFLLR also did not have a significant effect on PPR. These results provide 
further support that the increase in NMDAR component of fEPSP following 
TFLLR application is as a result of post-synaptic increase in NMDAR activity. 
 
Taken together, the results in this section show that in the somatosensory cortex, 
the increase in fEPSP mediated by TFLLR application is not an LTP. However, 
if TFLLR is applied to sub-threshold TBS protocols, then LTP can be induced or 
its size increased. This suggests that activation of astrocytic vesicular release 
with TFLLR application can contribute to TBS-induced LTP.    
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Figure 3.19. Application of PAR-1 agonist neither leads to LTP nor does it change 
the PPR. These recordings were performed in WT mice. A shows the time-course for 
fEPSP recordings before and after TFLLR application. Purple bar shows the time-span of 
TFLLR (10 µM) application. The time-course is from a single experiment. Each dot shows 
the average fEPSP slope of fEPSPs recorded in a 1 minute time window. B shows the 
average % change in fEPSP across several experiments following TFLLR application. The 
average % change in fEPSP 5-10 minutes post PAR-1 application was +16±11.81%. The 
average % change in fEPSP 30-40 minutes post PAR-1 application was 6.75±3.60%. The 
average % change in fEPSP 40-60 minutes post PAR-1 agonist application was 2±2.83%. 
Paired t-test was performed for average % change in fEPSP from baseline. p<0.05, *. C 
shows example fEPSP traces. Increase in slope and amplitude of fEPSP can be seen 
following TFLLR application. This example also shows the fEPSP as a result of second 
pulse. There was a 50 ms time interval between the two pulses. D shows the average PPR 
across the six recordings from B. Paired pulse protocol was carried out under control 
conditions, 5 minutes after TFLLR application, and 20 minutes after TFLLR washout. Two 
sample independent t-tests were performed between each two sets of data. There was no 
significant difference between any two sets of data (p<0.05).  
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Box 3.4. 
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3.12. Application of PAR-1 agonist results in the astrocytic 
vesicular release of glutamatergic gliotransmitters onto extra-
synaptic NMDARs  
 
For summary of results thus far please refer to Box 3.4. Sections 3.7 to 3.12 
show that in the somatosensory cortex, application of PAR-1 agonist can result in 
the vesicular release of ATP from astrocytes. This ATP release can activate 
P2XRs on neurones. Activation of P2XRs on neurones leads to the inhibition of 
post-synaptic GABAergic transmission (Lalo et al., 2014). This in turn leads to 
an increase in post-synaptic NMDAR activity. If this PAR-1 agonist mediated 
increase in NMDAR activity occurs during the delivery of TBS protocols, then it 
can contribute to LTP induction. What these results suggest is that vesicular 
release of ATP from astrocytes can contribute to LTP induction. However, 
astrocytes can also release D-serine and glutamate. Therefore it would be 
interesting to know what roles these gliotransmitters play in synaptic 
transmission and plasticity. For this purpose, in this section and the following 
section of this chapter, the role of glutamatergic transmission in the context of 
tripartite synapse will be investigated. 
 
Studies from other labs have provided evidence for vesicular exocytosis of 
glutamate from astrocytes in culture preparations (Araque et al., 2000, Bezzi et 
al., 2004). In hippocampal brain slice preparations, evidence for glutamate 
release has also been shown (Fellin et al., 2004). However, whether in brain slice 
preparations release of glutamate occurs via vesicular exocytosis remains to be 
determined. Evidence for astrocytic release of D-serine via vesicular exocytosis 
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has been provided in both culture preparations (Bezzi et al., 2004, Mothet et al., 
2005) and hippocampal slice preparations (Kang et al., 2013). Therefore, in this 
project, the aim was to provide evidence for vesicular exocytosis of glutamate 
and D-serine from astrocytes in the somatosensory cortex.       
 
To investigate whether D-serine and glutamate are released via vesicular 
exocytosis from astrocytes, my colleagues used microelectrode biosensors to 
measure the concentration of glutamate and D-serine in cortical slices 
(unpublished data). They showed that application of TFLLR (10 µM) to WT 
mice resulted in a robust increase in the extracellular concentrations of both D-
serine and glutamate. In contrast, application of TFLLR to dnSNARE cortical 
slices did not result in increase in either D-serine or glutamate concentrations. 
These results suggested that TFLLR application can result in vesicular release of 
glutamate and D-serine specifically from astrocytes, thereby providing evidence 
that cortical astrocytes are capable of releasing D-serine and glutamate via 
vesicular exocytosis.    
 
The biosensor data indicate that glutamate and D-serine can be released from 
astrocytes by vesicular exocytosis. If this were the case then one would expect an 
increase in glutamatergic transmission following the astrocytic release of 
glutamate and D-serine. To investigate this notion, neurones in layer 2/3 of the 
cortex were voltage clamped at membrane potential of -40mV. NMDAR-
mediated spontaneous EPSCs were recorded under antagonists of GABAA 
receptors (100 µM Picrotoxin), AMPA receptors (30 µM DNQX) and P2X 
receptors (10 µM PPADS and 5 µM 5-BDBD). To specifically activate vesicular 
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release from astrocytes, TFLLR (10 µM) was applied to cortical slices following 
10 minutes of baseline NMDAR-mediated spontaneous EPSC recordings 
(NMDAR sEPSCs). Application of TFLLR significantly increased the frequency 
of NMDAR sEPSCs (p<0.01, paired t-test; see Figures 3.20A and 3.20E). The 
frequency of NMDAR sEPSCs was 0.32±0.36 Hz during baseline recordings 
(n=13). This frequency increased to 0.87±0.39 Hz during TFLLR application 
(n=13). In contrast, TFLLR application did not significantly alter the average 
amplitude of NMDAR sEPSCs (p<0.05, paired t-test; see Figure 3.20E). The 
average NMDAR sEPSC was 5.58±0.32 pA during baseline conditions (n=13). 
TFLLR application decreased the average amplitude of NMDAR sEPSCs to 
4.78±0.48 pA (n=13). To investigate whether the increase in frequency of 
NMDAR sEPSCs were as a result of vesicular release from astrcoytes, TFLLR 
was applied to cortical slices from dnSNARE mice. Application of TFLLR to 
dnSNARE mice had no significant effect on the frequency and amplitude of 
NMDAR sEPSCs (p<0.05, paired t-test; see Figures 3.20B and 3.20E). During 
baseline recordings in dnSNARE mice, the average amplitude of NMDAR 
sEPSCs was 6.09±0.42 pA and the average frequency was 0.29±0.22 Hz (n=6). 
With TFLLR application the average amplitude was 5.98±0.39 pA and the 
average frequency was 0.32±0.25 Hz. Taken together, these results suggest that 
application of TFLLR results in vesicular release of glutamatergic 
gliotransmitters from astrocytes. This vesicular release results in increase in 
frequency of NMDAR sEPSCs on neurones.     
    
Further analysis of NMDAR sEPSCs revealed that in WT mice, sEPSCs showed 
a bimodal amplitude and decay distributions (Figure 3.20C). The sEPSCs with 
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slower amplitudes had longer decay times whilst the sEPSCs with larger 
amplitudes had faster decay times. Application of TFLLR selectively increased 
the probability of the detection of smaller and slower sEPSCs (Figures 3.20C and 
3.20E). Application of TFLLR to dnSNARE mice did not increase the number of 
these slow sEPSCs (Figures 3.20B and 3.20D). This suggests that vesicular 
release from astrocytes results in increase in frequency of these “slow” NMDAR-
mediated sEPSCs. This TFLLR-mediated increase in frequency of “slow” 
NMDAR sEPSCs is similar to the increase in frequency of “slow” P2XR-
mediated sEPSCs following TFLLR application (Figure 3.2). Together, these 
results suggest that astrocytes, in addition to releasing purinergic gliotransmitters 
via vesicular exocytosis, are also capable of releasing glutamatergic 
gliotransmitters via vesicular exocytosis.  
 
It has been shown that GluN2B-containing NMDARs have lower peak currents 
and slower decay times compared to GluN2A-containing NMDARs (Monyer et 
al., 1994, Erreger et al., 2005). Furthermore, it has been shown that release of 
glutamate from hippocampal astrocytes can activate GluN2B containing 
NMDARs (Fellin et al., 2004). These reports suggest that the slow sEPSCs that 
appear following TFLLR application in my recordings could be due to activation 
of GluN2B containing NMDARs. To investigate this, Ifenprodil (10µM), which 
is an antagonist of GluN2B containing NMDARs, was applied to cortical slices 
subsequent to TFLLR application. Application of Ifenprodil resulted in a 
significant decrease in the average frequency of NMDAR sEPSCs (p<0.01, 
paired t-test) by inhibiting the slow sEPSCs (Figures 3.20A, 3.20C and 3.20F). In 
contrast, Ifenprodil application resulted in a significant increase in the average 
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amplitude of sEPSCs (p<0.05, paired t-test; Figure 3.20F). As ifenprodil inhibits 
GluN2B-containing NMDARs, the ratio of large NMDAR sEPSCs to GluN2B-
mediated slow sEPSCs will increase; hence resulting in an increase in the 
average amplitude of NMDAR sEPSCs. Application of Ifenprodil during control 
conditions (without TFLLR) did not significantly alter the average amplitude and 
average frequency of sEPSCs (Figure 3.20F), suggesting that GluN2B-
containing NMDA receptors are not activated under baseline spontaneous 
recordings where astrocytic release is not activated.   
 
Taken together, these results show that the slow sEPSCs were due to GluN2B 
containing NMDARs. It is believed that in adult mice, synaptic NMDARs 
mainly consist of GluN2A subunits whilst extra-synaptic NMDARs mainly 
consist of GluN2B subunits (Tovar and Westbrook, 1999, Papouin et al., 2012). 
Based on this, one can suggest that the results in this section show that activation 
of astrocytes can lead to vesicular release of glutamatergic gliotransmitters from 
these cells. These glutamatergic gliotransmitters can then activate extra-synaptic 
GluN2B containing NMDARs. 
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Figure 3.20.  Activation of vesicular release from astrocytes via PAR-1 agonist leads to 
the appearance of small amplitude GluN2B-dependent NMDAR sEPSCs. A and B show 
example NMDAR sEPSC recordings from one WT mouse and one dnSNARE mouse. NMDA 
sEPSCs were recorded at -40 mV holding voltage under Picrotoxin (100 M), DNQX (30 M), 
5-BDBD (10 M) and PPADS (10 M). The effect on sEPSCs following PAR-1 agonist (10 µM 
TFLLR) and Ifenprodil (10 µM) application are shown. C and D show the probability density 
functions for the examples shown in A and B. Bar-charts shown in E represent the average % 
change in the frequency, amplitude and decay time of control NMDAR sEPSCs following 
application of PAR-1 agonist. Bar-charts shown in F represent the average % change in 
amplitude and frequency of NMDAR sEPSCs following application of Ifenprodil in WT cortical 
slices. Ifenprodil was applied either on control conditions or on TFLLR treated slices. Paired 
t-test was performed for average % change in sEPSCs from baseline. p<0.05, *; p<0.01, **.      
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The above results show that TFLLR can lead to vesicular exocytosis of 
glutamatergic gliotransmitters specifically from astrocytes. This release was 
indicated by the increase in frequency of NMDAR sEPSCs. TFLLR-mediated 
release of glutamatergic gliotransmitters involves the release of both glutamate 
and D-serine, as was suggested by the above-mentioned biosensor experiments 
carried out by my colleagues. Are both D-serine and glutamate release from 
astrocytes contributing to increase in frequency of NMDAR sEPSCs? To 
investigate the effect of D-serine on NMDAR sEPSCs, exogenous D-serine was 
applied to cortical slices from WT mice. The effect of exogenous D-serine on 
NMDAR sEPSCs can then be compared to effect of TFLLR on NMDAR 
sEPSCs, thereby enabling one to suggest what effect, if any, does TFLLR-
mediated release of D-serine from astrocytes has on NMDAR activity. Same as 
in Figure 3.20, sEPSCs were recorded at -40mV in the presence of PPADS (5 
µM), 5-BDBD (5 µM), DNQX (30 µM) and picrotoxin (100 µM). Application of 
exogenous D-serine significantly increased both the average amplitude and 
average frequency of NMDAR sEPSCs with respect to control (p<0.05, paired t-
test; see Figure 3.21A-C). This result is in contrast to TFLLR application (Figure 
3.20), where there was only an increase in the average frequency of sEPSCs and 
not in the average amplitude. Furthermore, the increase in frequency with 
TFLLR was much larger than the increase in frequency with D-serine. With 
TFLLR the increase in the average frequency was 172% whilst the increase in 
the average frequency with D-serine was only 20% (see Figures 3.20E and 
3.21B).     
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Further analysis of NMDAR sEPSCs revealed that unlike TFLLR application, 
application of D-serine showed no increase in the “slow” NMDAR sEPSCs. As 
can be seen from Figure 3.21D, there were two peaks on the amplitude 
probability distribution functions, labeled (a) and (b). These peaks were similar 
in sEPSC amplitude to the two peaks in the bimodal distribution shown on 
Figure 3.20C. However, in the example shown on Figure 3.21D, the second peak 
(b) is split in to two more peaks. Application of D-serine did not increase the 
probability of the first peak (a) (Figure 3.21D) but shifted the probability density 
function to the right. Furthermore, there was no appearance of a second “slower” 
peak in the decay time probability distribution function following D-serine 
application. These results show that application of exogenous D-serine increases 
the amplitude of NMDAR sEPSCs and does not lead to the appearance of the 
“slow” NMDAR sEPSCs. This is in contrast to TFLLR application, where there 
was no increase in amplitude but a large increase in frequency of “slow” 
NMDAR sEPSCs. This suggests that the TFLLR-mediated increase in “slow” 
extra-synaptic NMDAR sEPSCs is not mediated via astrocytic D-serine release 
and it might be mediated via astrocytic release of glutamate. Support for this 
notion comes from the report that in the hippocampus, D-serine only activates 
synaptic NMDARs and not the extra-synaptic GluN2B-containing NMDARs 
(Papouin, Ladepeche et al. 2012). It is possible that the D-serine released via 
TFLLR activation of astrocytes does not increase the average amplitude of 
NMDAR sEPSCs because the large increase in frequency of small GluN2B-
mediated sEPSCs occludes the effect of D-serine on synaptic NMDARs. Indeed, 
when exogenous D-serine was applied to TFLLR treated slices, there was no 
change in either the average amplitude or the average frequency of NMDAR 
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sEPSCs (Figure 3.21B-C). Application of D-AP5 removed all the NMDAR 
sEPSCs, thereby showing that the sEPSCs were indeed mediated by activity of 
NMDARs (Figure 3.21A). 
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Figure 3.21. see next page for Figure legend. 
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Figure 3.21.  Exogenous D-serine can increase the amplitude and frequency of 
NMDAR sEPSCs in control/baseline conditions but not in PAR-1 agonist treated 
slices. These recordings were performed in WT mice. A shows example traces for 
NMDAR sEPSC recordings under control, D-serine (10 µM) and D-AP5 (30 µM). The 
blue lines show the curves that were fitted on the sEPSCs. NMDAR sEPSCs were 
recorded at -40 mV holding voltage under Picrotoxin (100 M), DNQX (30 M), 5-
BDBD (10 M) and PPADS (10 M). B shows bar-charts representing the average % 
change in the amplitude and frequency of NMDAR sEPSCs under control and PAR-1 
(10 µM TFLLR) treated slices. In control conditions, the average amplitude of NMDAR 
sEPSC was 5.70±1.23 pA and the average frequency was 0.33±0.13 Hz. Under PAR-1 
agonist, the average amplitude was 4.78±0.48 pA and the average frequency was 
0.87±0.39 Hz. Paired t-test was performed for each data in comparison to control 
(p<0.05,*). C shows NMDAR sEPSC examples before and after D-serine application. 
Each of these examples are the average of twenty sEPSCs. D shows probability 
distribution functions for before and after D-serine application for one example 
recording.   
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Other labs have reported that D-serine application on hippocampal slices does 
not lead to change in the amplitude of evoked NMDAR EPSC (NMDAR eEPSC) 
(Fellin et al., 2009, Deng et al., 2011). In these reports, NMDAR eEPSCs were 
evoked using afferent stimulation. These results are in contrast to my 
spontaneous NMDAR mediated EPSC recordings in the somatosensory cortex, 
where D-serine application increases both the amplitude and frequency of 
NMDAR sEPSCs. One possibility that can explain the difference between my 
results and those from other labs is that it is possible that during evoked 
recordings, D-serine/glycine levels are saturated. To investigate this, D-serine 
and TFLLR were applied to slices from somatosensory cortex during recording 
of NMDAR eEPSCs. This experiment also allows one to investigate what are the 
effects of D-serine and TFLLR application on NMDARs when afferent neurons 
are persistently activated.  
 
NMDAR eEPSCs were recorded under PPADS (10 µM), 5-BDBD (5 µM) 
picrotoxin (10 µM) and DNQX (30 µM). Baseline eESPCs were set at 20-30% 
of maximal response. Application of exogenous D-serine, subsequent to 5-10 
minutes of baseline evoked EPSC recordings, significantly increased the evoked 
current by an average size of +106.75±5.74% (p<0.001, paired t-test, n=4; see 
Figure 3.22A). This showed that NMDA receptors are not saturated with respect 
to D-serine/glycine levels. Application of TFLLR also significantly increased the 
eEPSC amplitude by +27.94±25.33% (p<0.05, paired t-test, n=7; see Figure 
3.22A). However, the increase in eEPSC amplitude with TFLLR was 
significantly smaller than the increase with D-serine application (p<0.001, two 
sample independent t-test; see Figure 3.22A). 
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Similar to spontaneous NMDAR EPSC recordings shown on Figure 3.21B-C, 
exogenous D-serine was applied subsequent to 10 minutes of TFLLR application 
to see whether D-serine could further increase the NMDAR EPSC after the 
initial rise due to TFLLR application. In contrast to spontaneous NMDAR 
EPSCs, application of D-serine resulted in a significant further increase of 
+47.15±30.65% in the amplitude of evoked NMDAR EPSCs. This increase was 
statistically significant (p<0.05, paired t-test, n=7; see Figure 3.22A). The overall 
change in eEPSC amplitude following application of TFLLR and D-serine with 
respect to baseline was +86.83±40.40%. There was no statistically significant 
difference between the increase in eEPSC amplitude when both TFLLR and D-
serine where applied and when only D-serine was applied (p<0.05, two sample 
independent t-test). Application of D-AP5 completely abolished the NMDAR 
EPSC, thereby showing that the evoked EPSC was indeed mediated by NMDAR 
activity (Figure 3.22A).  
 
Increase in eEPSC amplitude could be either due to pre-synaptic or post-synaptic 
changes. Further analysis of NMDAR eEPSC were carried out to investigate 
whether the increase in amplitude following D-serine and TFLLR application 
were due to pre-synaptic or post synaptic effects. Figure 3.22B shows the 
amplitude probability distribution functions (PDFs) for baseline (control) 
NMDAR eEPSC recordings and for eEPSCs recordings during application of 
exogenous D-serine. Binomial models of release were fitted to the data. These 
models are shown as grey lines on the pdfs on Figure 3.22B. The parameters for 
binomial models are also given on Figure 3.22B. Application of exogenous D-
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serine increased the quantal amplitude from 2.01 pA to 5.07 pA, suggesting 
increase in post-synaptic NMDAR activity. The pre-synaptic parameters of the 
model, which are probability of release (p), number of release sites (n) and the 
average number of quanta (m), showed slight decrease.  
 
Figure 3.22C shows amplitude PDFs for baseline NMDAR eEPSC recordings 
and for eEPSC recordings following application of TFLLR. Binomial model of 
release could be fitted for baseline recordings as shown on Figure 3.22C. 
However, binomial model could not be fitted for NMDAR eEPSCs recorded 
under TFLLR application (unimodal model could not be rejected). This was the 
case for all 7 NMDAR eEPSC recordings under TFLLR. Therefore, it is not 
possible to determine from these evoked EPSC recordings whether TFLLR 
application results in increase in eEPSC amplitude as a result of increase in 
release probability or as a result of an effect on post-synaptic receptors. 
However, as was shown on Figure 3.20, TFLLR application resulted in a 
significant increase in frequency of spontaneous NMDAR EPSCs, suggesting 
that the effect of TFLLR on NMDAR activity is due to increase in release 
probability and not as a result of a post-synaptic effect.   
 
Figure 3.22C also shows the amplitude pdf for eEPSC recordings during D-
serine application on top of TFLLR-treated cortical slices. Binomial model of 
release could be fitted to this data. The quantal amplitude of this model was 5.41 
pA, which is larger than the 1.85 pA quantal amplitude of baseline recording. In 
contrast, there was no change in probability of release (p) and in number of 
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release sites (n). These results again suggest that D-serine increases NMDAR 
EPSCs by increasing the opening of post-synaptic NMDARs. 
 
Taken together, the results in this section show that TFLLR can result in the 
release of glutamate and D-serine specifically from astrocytes. This release of 
glutamatergic gliotransmitters from astrocytes activates extra-synaptic GluN2B 
containing NMDA receptors on neurons. It was also suggested that application of 
exogenous D-serine can increase the amplitude of NMDAR eEPSCs by acting on 
post-synaptic NMDARs. As exogenous D-serine results in an increase in the 
amplitude of post-synaptic NMDARs whilst TFLLR does not increase the 
amplitude of NMDAR EPSCs but increases the frequency, one can suggest that 
the astrocytic release of D-serine following TFLLR application does not have a 
similar effect to exogenous D-serine application. 
 
 
 
 
 
 
 
 
 
 
 
 
 180 
10 20 30 40 50 60
0.00
0.02
0.04
0.06
0.08
0.10
0.12
0.14
P
ro
b
a
b
ilt
t 
D
e
n
s
it
y
 (
1
/p
A
)
NMDAR eEPSC amplitude (pA)
 Control, p=0.65, q=1.85 pA, n=7, m=4.55, mean=8.63±3.14 pA
 TFLLR, mean=12.3±5.22 pA, Unimodel model could not be rejected
 +D-serine, p=0.69, q=5.41 pA, n=7, m=4.83, mean=26.1±8.24 pA
10 pA
100 msec
 Control
 TFLLR
 +D-serine
 +D-AP5
10 pA
100 msec
80
120
160
200
240
*** *
n=7
**
N
M
D
A
R
 E
P
S
C
 a
m
p
li
tu
d
e
  
  
  
(%
 o
f 
c
o
n
tr
o
l)
D-serine TFLLR TFLLR 
+D-serine
***
*
n=4 n=7
A
B
C
 Control, p=0.67, n=11, q=2.01 pA, m=7.37, mean=14.6±4.43 pA 
 D-serine,p=0.6,  n=10, q=5.07 pA, m=6,    mean=29.82±16.07 pA
10 pA
200 msec
10 20 30 40 50
0.00
0.02
0.04
0.06
0.08
0.10
0.12
0.14
0.16
NMDAR eEPSC amplitude (pA)
P
ro
b
a
b
ili
ty
 D
e
n
s
it
y
 (
1
/p
A
)
 
 
 
 
 
Figure 3.22. For Figure legend please see next page. 
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Figure 3.22.  Exogenous D-serine and PAR-1 agonist can increase the amplitude of 
evoked NMDAR EPSCs. These recording were performed in WT mice. NMDAR eEPSCs 
were recorded at -40 mV holding voltage under Picrotoxin (100 M), DNQX (30 M), 5-
BDBD (5 M) and PPADS (10 M). Examples of NMDAR eEPSCs are shown to the right 
hand side of the figure. A shows bar-charts representing the average % increase in eEPSC 
amplitude following D-serine (10 µM) and TFLLR (10 µM) application. Paired t-test was 
performed for each data in comparison to control. Paired t-test was also performed 
between TFLLR data and D-serine+TFLLR agonist data. Two sample t-test was performed 
between control and TFLLR agonist data. Two sample t-test was also carried out between 
control and D-serine+TFLLR agonist data. p<0.05 (*), p<0.01 (**), p<0.001 (***). B shows 
Probability distribution functions before and after D-serine application for one example 
recording. C shows probability distribution functions for control recordings, subsequent 
to TFLLR application, and after D-serine application on top of TFLLR. Model parameters 
are quantal amplitude (q), number of release sites (n), probability of release (p) and 
average number of quanta released (m).   
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Box 3.5. 
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3.13. GluN2B-containing NMDA receptors contribute to LTP 
induction in the somatosensory cortex  
 
Please refer to Box 3.5 for summary of results thus far. It was suggested in the 
previous sections that vesicular release of ATP from astrocytes could contribute 
to LTP induction. However, it was also shown that astrocytes can release 
glutamatergic gliotransmitters onto extra-synaptic GluN2B containing 
NMDARs. Do these GluN2B containing NMDARs also contribute to LTP 
induction? Reports from the literature show contrasting results. Two studies have 
shown that application of GluN2B antagonist to hippocampal slices does not 
have an effect on LTP induction (Liu et al., 2004, Papouin et al., 2012). In 
contrast to these two reports, another study in the hippocampus showed that 
application of Ifenprodil significantly reduced the extent of HFS-induced LTP 
(Maggio et al., 2008). Another study in the prefrontal cortex showed that 
GluN2B-containing receptors are required for TBS-induced LTP (Zhao et al., 
2005). 
  
To investigate whether GluN2B-containing NMDARs contribute to LTP 
induction in the somatosensory cortex, TBSx5 protocol was repeated in 
Ifenprodil-treated WT cortical slices. Application of Ifenprodil (10 µM) resulted 
in a significant reduction in the extent of LTP (Figure 3.23). In Ifenprodil treated 
slices the average size of fEPSP 40-60 minutes post TBSx5 application was 
+21±7.83% (n=8), whilst in control slices the average size of fEPSP was 
+58±7.54% (n=15). There was a significant difference between these two sets of 
data (p<0.05, two sample independent t-test; see Figure 3.23B). These results 
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suggest that GluN2B containing NMDARs contribute to LTP induction in the 
somatosensory cortex.  
  
TBSx2 induced LTD is changed into LTP induction via application of TFLLR 
(Figure 3.15). This LTP induction was attributed to TFLLR-mediated ATP 
release from astrocytes. However, TFLLR also results in the astrocytic release of 
glutamatergic gliotransmitters, which activate GluN2B-containing NMDARs on 
neurons. Does this TFLLR-mediated astrocytic release of glutamatergic 
gliotransmitters contribute to change of LTD to LTP during TBSx2? To 
investigate this, TBSx2 protocol was carried out in Ifenprodil and TFLLR treated 
slices. Delivery of TBSx2 protocol under ifenprodil and TFLLR did not result in 
a significant LTP (p<0.05, paired t-test; see Figure 3.24). However, there was no 
significant difference in the average fEPSP attained 40-50 minutes post TBS 
between TBSx2 delivery under both ifenprodil and TFLLR and TBSx2 delivery 
under TFLLR only (p<0.05, two sample t-test; see Figure 3.24B). There was 
however a significant difference in the average fEPSP attained 40-50 minutes 
post TBS between the TBSx2 delivery under TFLLR and Ifenprodil and TBSx2 
induced LTD in control conditions (p<0.05, two sample independent t-test; see 
Figure 3.24B). This implies that GluN2B-containing NMDARs do not contribute 
to TFLLR-mediated reversal of TBSx2 induced LTD to LTP. In contrast, 
inhibition of P2XRs completely reversed the TFLLR-mediated TBSx2 induced 
LTP to LTD (Figure 3.15). Therefore, one can suggest that P2XRs play a more 
important role in this TFLLR-mediated LTP induction than GluN2B-containing 
NMDARs.    
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Figure 3.23. Inhibition of GluN2B-containing NMDARs decreases the size of TBSx5 
induced LTP. These recordings were performed in WT mice. A shows the average time-
courses for TBSx5 delivery under control and under Ifenprodil. Orange arrow shows 
position of TBSx5 delivery. Red bar shows the time-span of Ifenprodil (10 µM) 
application. B shows bar-charts representing the average % increase in fEPSP 40-60 
minutes post TBSx5 delivery. Two sample independent t-test was performed between 
control and ifenprodil data. Paired t-test was performed for average % change in fEPSP 
from baseline. p<0.05, *; p<0.01, **; p<0.001, ***.  C shows example fEPSPs before and 
after TBSx5 delivery. 
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Figure 3.24. Inhibition of GluN2B-containing NMDARs decrease the size of TFLLR-
mediated TBSx2 induced LTP.  These recordings were performed in WT mice. A shows 
the average time-courses for TBSx2 protocol under different conditions. Orange arrow 
shows position of TBSx2 delivery. Dark yellow bar shows the time-span of Ifenprodil (10 
µM) application. Red bar shows the time-span of TFLLR (10µM) application. TFLLR was 
applied 5 minutes prior to and washed out 5 minutes post TBSx2. B shows bar-charts 
representing the average % change in fEPSP 40-50 minutes post TBSx2 delivery. The 
average % decrease in fEPSP was -15±6.56% for TBSx2 protocol under control 
conditions. The average % increase in fEPSP was +7.45±7.13% for TBSx2 protocol under 
Ifenprodil and TFLLR. The average % increase in fEPSP was +18.07±7.30% for TBSx2 
protocol under TFLLR application. Two sample independent t-test was performed 
between each two pairs of data. Paired t-test was performed for average % change in 
fEPSP from baseline. p<0.05, *; p<0.01, **. C shows example fEPSPs before and after 
TBSx2 delivery. 
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3.14. Summary of chapter 
 
In this chapter evidence for release of glutamatergic and purinergic 
gliotransmitters via vesicular exocytosis from astrocytes in the somatosensory 
cortex has been provided. It was also shown that release of ATP from astrocytes 
could activate P2XRs on neurones. This lead to inhibition of GABAergic 
transmission, which in turn resulted in increase in NMDAR activity on post-
synaptic neurones. It was suggested that astrocytic release of ATP contributes to 
LTP induction by this inhibition of GABAergic activity. It was also shown that 
release of glutamatergic transmission could result in the activation of extra-
synaptic GluN2B-containing NMDARs on neurones. These NMDARs could 
contribute to LTP induction. However, it was shown that in the somatosensory 
cortex, astrocytic release of D-serine does not contribute to LTP induction. 
Please refer to Box 6 for a summary of the results of this chapter. 
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Box  3.6. 
TBSx5 induced NMDAR-dependent LTP in somatosensory cortical slices from WT mice (Figure 3.6)
TBSx5 induced LTP is impaired in somatosensory cortical slices from dnSNARE mice (Figure 3.4). This 
suggested that vesicular exocytosis of gliotransmitters from astrocytes is required for LTP induction.
Gliotransmitters can be divided into two groups: Glutamatergic (Glutamate and D-serine) and 
Purinergic. How do these gliotransmitters contributes to synaptic transmission and LTP induction in the 
somatosensory cortex?
Investigation of role for Purinergic
gliotransmitters 
Investigation of role for glutamatergic
gliotransmitters 
Exogenous ATPγS rescued the impaired LTP in 
dnSNARE mice. This suggested that vesicular 
release of ATP from astrocytes is required for LTP  
induction (Figure 3.8). This required further 
investigation.
To investigate this, evidence for release of ATP by 
astrocytes via vesicular exocytosis was required
This project provides first ever direct evidence 
for vesicular exocytosis of ATP from astrocytes in 
cortical slices (Figure 3.9). What is the role of this 
astrocytic vesicular release of ATP in synaptic 
transmission and plasticity?
The results on sections 3.1 and 3.11 suggested 
that TFLLR application results in release of ATP 
from astrocytes onto P2XRs on neurones. 
Activation of neuronal P2XRs results in 
inhibition of GABAergic transmission. This in 
turn leads to increase in NMDAR activity. This 
TFLLR-mediated increase in NMDAR activity 
can then result in LTP induction during TBSx2 
protocol. This suggests that astrocytes 
contribute to LTP induction by releasing ATP 
via vesicular exocytosis.
Application of TFLLR results in the astrocytic 
release of D-serine and glutamate. 
GluN2B containing NMDARs contribute to LTP 
induction in the somatosensory cortex (Section 
3.13)
Exogenous D-serine 
fails to rescue the 
impaired LTP in 
dnSNARE mice. This 
suggests that 
vesicular release of 
D-serine from 
astrocytes is not 
required for LTP 
induction (Figure 
3.7). 
Do astrocytes release glutamatergic 
gliotransmitters via vesicular exocytosis? 
And what is the function of this release?
TFLLR-mediated 
release of 
glutamatergic 
gliotransmitters from 
astrocytes results in 
the activation of 
extra-synaptic Glun2B 
containing NMDARs. 
What is the role of 
these GluN2B 
containing NMDARs 
in synaptic plasticity?
Box 3.6.
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Chapter 4 
 Role for Cannabinoid Signalling during Synaptic 
Transmission and Plasticity in the Context of Tripartite 
Synapse  
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4.1 Motivation for studying cannabinoid signalling 
 
Endogenous cannabinoid, or endocannabinoid (eCB), signalling in the nervous 
system is involved in many different functions including memory, cognition, 
pain perception and movement. Endocannabinoids are as widespread as other 
neurotransmitters such as glutamate and GABA. The density of endocannabinoid 
receptors (eCB-Rs) in the brain is comparable to glutamatergic and GABAergic 
receptors (Herkenham et al., 1990). Endocannabinoid receptors can also be 
activated by exogenous cannabinoids. Intake of 9-Tetrahydrocannabinol (9-
THC), the major psychoactive component of cannabis, causes memory 
impairment by acting on CB1 receptors in the CNS (Kano et al., 2009). 
Therefore, there is great interest in investigating the role of exogenous and 
endogenous cannabinoids in synaptic transmission and plasticity. Furthermore, 
CB1 receptors are present on astrocytes in addition to their neuronal localisation. 
Therefore, in the investigation of synaptic plasticity in the context of tripartite 
synapse, the role of eCBs must also be considered.   
 
4.2 Production and release of eCBs 
 
Neurotransmitters like glutamate and GABA are anterograde messengers. They 
are released from pre-synaptic neurones and diffuse to post-synaptic sites where 
they bind to post-synaptic receptors. eCBs act as retrograde messengers, meaning 
that they are synthesised and released from post-synaptic neurones and bind to 
receptors on pre-synaptic neurones. Endocannabinoid mediated retrograde 
transmission is a form of feedback mechanism to control pre-synaptic release.   
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Endocannabinoids are lipids and cannot be stored in vesicles. N-
arachidonoylethanolamide (also called anandamide, which means inner bliss 
amide) was the first eCB that was identified (Devane et al., 1992). The second 
eCB identified was 2-arachidonoylglycerol (2-AG) (Sugiura et al., 1995). 
Anandamide (AEA) is a partial agonist of CB1 receptors. It is found at low 
concentrations (pmol per gram of tissue) in the brain (Pertwee et al., 2010). In 
contrast, 2-AG is a full agonist of CB1 receptors and is present at higher 
concentrations (nmol per gram tissue) than anandamide in the brain (Stella et al., 
1997).   
 
Endocannabinoids are produced and released from post-synaptic sites. This event 
is triggered either as a result of calcium elevations in post-synaptic neurones or 
as a result of activation of post-synaptic mGluRs (Varma et al., 2001, Kim and 
Alger, 2010). Glutamate binding to post-synaptic mGluRs activates Gq/11, which 
results in Phospholipase C- (PLC-) activation. Alternatively, PLC- is 
activated by intracellular calcium. PLC- then hydrolyses Phosphatidylinositol 
4,5-bisphosphate (PIP2) to IP3 and Diacylglycerol (DAG). Subsequently, 
Diacylglycerol lipase-α (DGL-α) uses DAG to synthesise 2-AG (Bisogno et al., 
2003). In mice brain, 50% of AEA production also depends on DGL- (Gao et 
al., 2010). However, the mechanism of this pathway is not known. Other 
pathways of AEA synthesis also exist. 
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4.3 Endocannabinoid receptors 
 
The main eCB receptor in the CNS is called the CB1 receptor, which is a class A 
G-protein coupled receptor (Matsuda et al., 1990). CB1 receptors are mainly 
localised pre-synaptically. In the hippocampus, majority of CB1 receptors are 
localised to pre-synaptic GABAergic interneurones (Katona et al., 1999) with 
lower CB1 receptor localisation in glutamatergic neurones. In the cortex, CB1 
receptors are also largely localised to interneurones (Hill et al., 2007). However, 
49% of pyramidal neurones in rat neocortex were also shown to express CB1 
receptors. 
 
4.4 Role for cannabinoids in synaptic transmission and plasticity 
 
Activation of pre-synaptic CB1 receptors by endogenous or exogenous 
cannabinoids results in decrease of neurotransmitter release. This leads to 
depression of synaptic transmission. Some experimentally induced forms of 
synaptic plasticity are mediated by eCBs. These forms of synaptic plasticity are 
depressive and are induced pre-synaptically. Depending on the experimental 
protocol, they can be short term or long term. 
 
eCB-mediated short-term depression (eCB-STD): It is believed that 
experimental depolarisation of post-synaptic neurones can release eCBs from 
these cells. These eCBs then diffuse as retrograde messengers and bind to CB1 
receptors on pre-synaptic neurones. This binding results in decrease in 
neurotransmitter release by inhibiting voltage-gated calcium channels. During 
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STD, CB1 receptors are activated for only tens of seconds (Chevaleyre et al., 
2006). If the synapse is GABAergic, this short-term plasticity is called 
depolarisation–induced suppression of inhibition (DSI). If it is excitatory it is 
called depolarisation-induced suppression of excitation (DSE) (Pitler and Alger, 
1992, Alger, 2002, Navarrete and Araque, 2010).  
 
eCB mediated long-term depression  (eCB-LTD): In the cortex and CA1 
region of hippocampus, eCB LTD is induced by the same HFS/TBS protocols 
that induce NMDAR-dependent LTP (Chevaleyre and Castillo, 2003, Huang et 
al., 2008). The difference is that HFS/TBS-induced eCB-LTD is induced 
heterosynaptically whilst NMDAR-LTP is homosynaptic. Furthermore, 
NMDAR-LTP depends on NMDARs and calcium elevation in post-synaptic 
neurones. In contrast, eCB-LTD can be induced in the absence of post-synaptic 
NMDAR activity and calcium elevations. The Induction of eCB-LTD depends 
on post-synaptic class I mGluRs and pre-synaptic CB1 receptors. Repetitive 
activation of pre-synaptic excitatory afferents (via HFS or TBS) can result in 
excess release of glutamate (Figure 4.1: parts 1-2). This glutamate release can 
activate post-synaptic mGluRs in addition to post-synaptic NMDARs (Figure 4.1 
parts 3-4), thus leading to eCB synthesis via PLC activation (Figure 4.1: parts 5-
6). eCBs can then diffuse to pre-synaptic neurones and activate pre-synaptic CB1 
receptors, which are coupled to Gi/o (Figure 4.1: part 7). This activation leads to 
reduction in adenylyl cyclase and protein kinase A activity. This leads to 
reduction in pre-synaptic transmitter release (Figure 4.1: part 8), which is the 
expression of eCB LTD (Chevaleyre et al., 2006).  
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Figure 4.1. Endocannabinoid signalling in the context of tripartite synapse. Repetitive 
activation of pre-synaptic neurones (1) results in excess release of glutamate (2). Glutamate 
can bind to NMDARs (3) and result into homosynaptic LTP induction. Glutamate also 
activates class I mGluRs (4), which leads to PLC-mediated synthesis of eCBs (5-6). eCBS can 
then diffuse to pre-synaptic neurones at heterosynaptic sites where they activate pre-
synaptic CB1 receptors (7). The heterosynapse can be either GABAergic or glutamatergic. In 
this figure, the heterosynapse has been represented as a GABAergic synapse. Pre-synaptic 
CB1 receptors are coupled to Gi/o, therefore their activation leads to inhibition of 
transmitter (in this case GABA) release (8). This leads to heterosynaptic eCB-mediated LTD. 
Released eCBs can also bind to CB1 receptors on astrocytes (9). In contrast to neuronal CB1 
receptors, astrocytic CB1 receptors are coupled to Gq/11. Activation of astrocytic CB1 
receptors leads to calcium elevation from these cells (10). This in turn leads to glutamate 
release from astrocytes (11), which can bind to extra-synaptic GluN2B containing NMDARs 
(12).  
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Modulation of NMDAR-dependent LTP by cannabinoid signalling: In 
contrast to synaptic depression, induction of NMDAR-dependent LTP does not 
require CB1 receptors but this does not necessarily mean that eCB signalling 
does not have modulatory role during NMDAR-dependent LTP induction. 
Studies have attempted to investigate the role of endogenous and exogenous 
cannabinoids during induction of NMDAR-dependent LTP. These studies will be 
reviewed in the following section. 
 
As mentioned above, CB1 receptors are present on inhibitory neurones. This 
suggests that CB1 receptor-mediated depression of GABA release can 
theoretically enhance excitability and LTP induction. It has been shown that in 
the CA1 region of hippocampus, induction of DSI or eCB LTD at inhibitory 
synapses can enhance the subsequent induction of HFS-induced LTP of 
pyramidal neurones (Carlson et al., 2002, Chevaleyre and Castillo, 2004).  
 
The role of exogenous cannabinoid application on LTP induction has also been 
investigated. Different studies show different outcomes depending on the type 
and concentration of cannabinoid used. In CA1 region of hippocampus of 2-3 
weeks old mice and rats, pre-incubation of brain slices with exogenous synthetic 
CB1 receptor agonists HU-210 (100 nM) or WIN55,212-2 (3-10 M), blocked 
HFS induced LTP (Collins et al., 1995, Misner and Sullivan, 1999). Application 
of 20 M of 2-AG to slices for 20 minutes prior to HFS delivery, can also block 
LTP induction in the CA1 region of the hippocampus (Stella et al., 1997).  
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In contrast to the above results, application of AEA for 30 minutes prior to 
delivery of HFS, does not completely block LTP (Terranova et al., 1995). At 
AEA concentrations of 1 M and 3 M, LTP extent is reduced slightly but it is 
not blocked. At concentration of 10 M, LTP extent is reduced further, but not 
completely blocked. Similarly, application of WIN55,212-2 at low concentration 
of 1 M does not block LTP (Terranova et al., 1995).   
 
Application of 9-THC (10-1000 pM) to CA1 region of hippocampus did not 
decrease the extent of LTP (Nowicky et al., 1987). Interestingly, application of 
10 pM of 9-THC increased the duration of LTP whilst application of 1000 pM 
of 9-THC decreased the duration of LTP. 
  
Effect of endogenous CB1 receptor activity during LTP induction has also been 
investigated. These investigations have been done by either pharmacologically 
blocking CB1 receptors or use of CB1 receptor knockout animals. All these 
investigations have been carried out in CA1 region of hippocampus. Different 
reports have shown outcomes that are contradictory with respect to each other. 
Some studies have shown that application of CB1 receptor antagonist does not 
have any effect on LTP induction (Carlson et al., 2002, Slanina et al., 2005). 
Another study showed enhancement of in vivo LTP in CB1 knockout mice in 
comparison to WT mice (Jacob et al., 2012). In contrast, there are studies that 
have shown complete abolishment of LTP in slices perfused with CB1 receptor 
antagonists (Chevaleyre and Castillo, 2003, de Oliveira Alvares et al., 2006, Lin 
et al., 2011). The reason for these contradictory results could be due to presence 
of CB1 receptors on both excitatory and inhibitory synapses.  
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All of the above-mentioned investigations of cannabinoid role during LTP 
induction have been performed in the hippocampus. I have only found two 
reports that attempted to investigate endocannabinoid role during LTP induction 
in the cortex. It has been shown that in the prefrontal cortex, application of 
WIN55,212-2 (1 M), decreased evoked AMPAR-mediated EPSCs by acting on 
pre-synaptic CB1 receptors (Auclair et al., 2000). Furthermore, WIN55,2212-2 
application decreased the chances of LTP induction in the prefrontal cortex. In 
contrast, in a study in the visual cortex of young (2-3 weeks old) mice, 
application of WIN55,212-2 (2 M) and AM251 (5 M), which is a CB1 
receptor antagonist, did not effect LTP induction (Huang et al., 2008).   
 
To my knowledge, there has been no study of cannabinoid role during NMDAR-
dependent LTP in somatosensory cortex. Therefore, one of the objectives of my 
project was to investigate the role of cannabinoids in the somatosensory cortex.   
     
4.5 Role for astrocytic CB1 receptors in synaptic transmission 
and plasticity 
 
Recent reports have implicated the role of astrocytic CB1 receptors in eCB-
mediated short and long-term depression. It was shown that in the CA1 region of 
hippocampus of 12-17 days old mice, astrocytic calcium levels were elevated by 
either application of various exogenous CB1 receptor agonists (AEA, 
WIN55,212-2 and 2-AG) or depolarisation of post-synaptic neurones (Navarrete 
and Araque, 2008). As CB1 receptor antagonists prevented these calcium 
elevations, it was suggested that CB1 receptors are localised on astrocytes. These 
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CB1 receptor-mediated calcium events in astrocytes were dependent on PLC 
activity, thereby suggesting that astrocytic CB1 receptors are coupled to Gq/11. 
This is in contrast to neuronal CB1 receptors, which are coupled to Gi/o. 
Furthermore, it was shown that calcium elevation in astrocytes, due to activation 
of their CB1 receptors, could result in generation of SICs in post-synaptic 
neurones. This suggests that CB1-receptor activation of astrocytes can result in 
glutamate release from these cells (Figure 4.1: parts 9-12).   
 
The same group also showed that post-synaptic depolarisation, which usually 
leads to eCB mediated DSE at some excitatory synapses, also lead to short-term 
potentiation of some other excitatory synapses. They showed that DSE occurs at 
homosynaptic excitatory synapses whilst potentiation is induced at 
heterosynaptic synapses. They showed that these potentiation events depend on 
astrocytic CB1 receptors and astrocytic calcium elevations. This was in contrast 
to DSE induction, which depends on pre-synaptic CB1 receptors and not on 
calcium elevations in astrocytes. Taken together, these results suggest that eCB 
activation of CB1 receptors on astrocytes can result in calcium elevation in these 
cells. These calcium elevations can then result in glutamate release from 
astrocytes, leading to enhancement of glutamatergic transmission. Therefore, one 
can suggest that astrocytic CB1 receptors seem to act analogously to astrocytic 
PAR1 and mGluRs (Figure 4.1: part 9). 
 
Can CB1-mediated activation of astrocytic glutamate release have an effect on 
long-term plasticity? A recent study showed that CB1 receptors on astrocytes can 
contribute to one form of eCB LTD in the somatosensory cortex (Min and 
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Nevian, 2012). As mentioned previously, delivery of HFS or TBS can induce 
eCB LTD at heterosynaptic synapses. However, another form of eCB dependent 
LTD can be induced at homosynaptic excitatory synapses in the neocortex via a 
Spike-timing dependent protocol (STDP). This protocol involves pairing post-
synaptically evoked action potentials with pre-synaptic firing. With the correct 
temporal interval between pre- and post-synaptic firing, STDP can result in long-
term depression of synaptic transmission. As mentioned previously, eCB LTD 
depends on eCB release from post-synaptic neurone, which through retrograde 
transport binds to pre-synaptic CB1 receptors resulting in depression of 
glutamate release. However, this study showed that during induction of eCB 
LTD, there was an increase in frequency of calcium elevations in astrocytes that 
were in close proximity of the LTD site (Min and Nevian, 2012). It was shown 
that eCB release from post-synaptic neurones could activate CB1 receptors on 
astrocytes, which lead to calcium elevation in these cells. This in turn resulted in 
release of glutamate from astrocytes. The authors showed that this astrocytic 
glutamate release could activate pre-synaptic NMDARs. It was suggested that 
activation of pre-synaptic NMDARs could decrease pre-synaptic release, 
presumably through calcium entry through these receptors and phosphotase 
activation, hence contributing to induction of LTD. To summarise, this study 
shows that CB1 receptors on astrocytes can result in vesicular release of 
glutamate in the somatosensory cortex. It also suggests that this glutamate 
release can contribute to induction of eCB-LTD.  
 
The above mentioned study shows that glutamate release as a result of CB1 
receptor activation of astrocytes can contribute to induction of eCB-LTD in the 
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somatosensory cortex. Can glutamate release as a result of CB1 receptor 
activation of astrocytes also contribute to induction of NMDAR-dependent LTP? 
As mentioned above, one study in the hippocampus showed that astrocytic 
glutamate release following CB1 receptor activation lead to enhancement of 
glutamatergic transmission and generation of SICs. Therefore, it is possible that 
CB1 receptor activation of astrocytes can also contribute to LTP induction. 
 
4.6 Project Objectives and hypothesis 
 
As mentioned above, studies have investigated the role played by cannabinoids 
during LTP induction. Most of these studies have been carried out in the 
hippocampus with only two reports in the cortex. In my project, the role of 
cannabinoids during synaptic transmission and LTP induction in the 
somatosensory cortex was investigated. The hypothesis was that cannabinoids 
can result in calcium elevation in astrocytes by acting on CB1 receptors on these 
cells. This cannabinoid-mediated calcium elevation in astrocytes can in turn 
result in gliotransmitter release from these cells, thereby contributing to synaptic 
transmission and LTP induction. 
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Chapter 5: Results 2 
 
Cannabinoid receptors contribute to astroglial Ca2+-
signalling and synaptic plasticity in neocortex 
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5.1. Introduction 
 
The objective in this part of the project was to investigate the role of 
endocannabinoid signalling in synaptic transmission and plasticity in the 
somatosensory cortex. Previous studies have shown that activation of CB1 
receptors on astrocytes can result in calcium elevation in these cells (Navarrete 
and Araque, 2008, Min and Nevian, 2012). It was also shown that this calcium 
elevation results in glutamate release from astrocytes. Therefore, one can suggest 
that astrocytic CB1 receptors act analogously to astrocytic PAR-1 and mGluRs. 
It was shown in chapter 3 that application of TFLLR results in vesicular release 
of ATP specifically from astrocytes. If astrocytic CB1 receptors act analogously 
to astrocytic PAR-1, then one can suggest that application of CB1 receptor 
agonist should result in calcium dependent vesicular release of ATP specifically 
from astrocytes. Therefore, the first objective of this project was to investigate 
whether application of AEA can result in vesicular release of ATP from 
astrocytes. 
 
The second objective of this project was to investigate the role played by 
endocannabinoid signalling in synaptic plasticity in the somatosensory cortex. 
More specifically, the aim was to investigate the role for AEA application and 
CB1 receptors on TBS-induced LTP. Majority of previous studies investigating 
role for cannabinoid signalling in LTP induction have been carried out in the 
hippocampus (Nowicky et al., 1987, Collins et al., 1995, Terranova et al., 1995, 
Stella et al., 1997, Misner and Sullivan, 1999, Chevaleyre and Castillo, 2003, de 
Oliveira Alvares et al., 2006, Lin et al., 2011) with only one report in the 
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prefrontal cortex (Auclair et al., 2000) and one report in the visual cortex (Huang 
et al., 2008). There is yet to be an investigation in role for cannabinoid signalling 
during LTP induction in the somatosensory cortex. This project will be the first 
ever attempt to investigate such a role for cannabinoid signalling in the 
somatosensory cortex. 
 
Previous studies have shown that activation of astrocytic CB1 receptors by either 
application of CB1 receptor agonists or by depolarisation of post-synaptic 
neurones, results in calcium elevation in astrocytes (Navarrete and Araque, 2008, 
Min and Nevian, 2012). This CB1 receptor dependent calcium elevation in 
astrocytes resulted in release of glutamate from these cells. However, as was 
shown on chapter 3, in addition to glutamate, astrocytes can also release ATP via 
vesicular exocytosis. Therefore, activation of CB1 receptors on astrocytes should 
theoretically result in vesicular release of ATP from these cells. My objective 
was to investigate this notion.  
 
Previously, my colleagues showed that activation of CB1 receptors on astrocytes 
in the somatosensory cortex can induce significant elevation of intracellular 
calcium levels in astrocytes (Rasooli-Nejad et al., 2014), thereby verifying the 
findings of the above-mentioned reports. For this purpose, they used to two 
transgenic mice lines. One was the dnSNARE mice and the other was the GFAP-
EGFP (GFEC) mice. GFEC mice express EGFP under the control of GFAP 
promoter. This means that their astrocytes express EGFP fluorescence, which 
helps in identifying these cells. 2-photon fluorescent microscopy was used to 
monitor astrocytic Ca2+ signalling. Calcium levels in astrocytes of dnSNARE 
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mice were also compared with calcium levels in astrocytes of dnSNARE wild-
type littermates. They loaded astrocytes with fluorescent dyes Rhod-2AM 
(GFEC and dnSNARE mice) or Oregon Green BAPTA-2AM. 
 
In baseline conditions (before application of AEA), astrocytes of all mice strains 
exhibited spontaneous Ca2+-transients, which were more prominent in the 
branches (Figure 5.1a-b). The average frequency of transients per astrocyte 
varied in the range of 0.5-2.1 min-1 for all mice strains. Bath application of 500 
nM AEA induced robust Ca2+ elevation both in the soma and branches and 
increased the amplitude and frequency of spontaneous Ca2+ transients (n=6; see 
Figure 5.1a-c). There was no significant difference in the action of AEA between 
astrocytes of different strains (p<0.05, two sample independent t-test; see Figure 
5.1c). It has to be emphasised that, in the concentrations used, AEA selectively 
activates CB1 receptors. The specificity of AEA action was confirmed by 
inhibition with AM251, a selective antagonist of CB1 receptors. Application of 
AM251 (1 µM) significantly decreased the response to AEA in 5 WT and 5 
dnSNARE astrocytes (p<0.01, paired t-test; see Figure 5.1c). These results 
showed that CB1 receptors can bring substantial contribution to Ca2+-signalling 
in the neocortical astrocytes. Importantly, these data showed that expression of 
dnSNARE protein in astrocytes did not affect eCB-mediated calcium signalling. 
 
Activation of CB1 receptors on astrocytes should theoretically result in vesicular 
release of gliotransmitters such as ATP and D-serine from these cells. To 
investigate this, my colleagues used microelectrode biosensors to monitor the 
concentration of ATP and D-serine in neocortical slices (Rasooli-Nejad et al., 
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2014). Activation of intracellular Ca2+ elevation in astrocytes by 500 nM AEA 
induced a robust increase in the levels of extra-cellular ATP and D-serine in 
cortical slices from WT mice. The eCB-induced elevation in the ambient 
concentration of extra-cellular ATP and D-serine reached correspondingly 
0.9±0.3 µM and 2.3±0.8 µM (n=6; see Figure 5.1d-e). The eCB-induced 
elevation in concentrations of ATP and D-serine was significantly decreased in 
dnSNARE-expressing mice correspondingly by 74±17% and 83±15% in 
comparison to WT mice (p<0.01, two sample t-test; see Figure 5.1d-e). These 
results suggested that activation of CB1 receptors on astrocytes results in 
calcium-dependent vesicular release of ATP and D-serine specifically from these 
cells. The objective of my project was to investigate the role played by this CB1-
mediated calcium dependent astrocytic vesicular release in synaptic transmission 
and LTP induction.  
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Figure 5.1. Cannabinoid receptors activate astrocytic Ca2+ signalling and release of 
gliotransmitters. a-c, Ca2+-signalling activated by the bath application of 500 nM of anandamide 
(AEA) to neocortical slices. a-b, representative 2-photon images of EGFP fluorescence and 
pseudo-color images of Rhod-2 fluorescence recorded in the astrocytes from GFAP-EGFP (a) and 
dnSNARE (b) mouse during AEA application at times indicated. Scale bars are 10 µm. Graphs 
below show the time course of Rhod-2 fluorescence averaged over regions indicated in 
fluorescence image. Note marked spontaneous elevations in the Ca2+ level, which were enhanced 
by application of AEA. c, The pooled data on spontaneous Ca2+-transients and net response to AEA 
recorded in astrocytes of different mice strains in control and in presence of CB1 receptor 
antagonist AM251 (1 µM). Data shown as mean±SD for 6 cells in control (for each strain) and 5 
cells under AM251 (WT and dnSNARE). Frequency of transients (middle graph) was measured 3 
min after application of AEA and was normalised to baseline value. Net response was measured 
with 3 min after AEA application and averaged over whole cell image. Asterisks (*) indicate 
statistical significance of effect of AEA on the peak amplitude of Ca2+-transients, double asterisks 
(**) indicate significance of inhibitory effect of AM251; p<0.01 given by paired t-test in both cases. 
d-e, AEA activated release of ATP and D-serine in slice preparations from somatosensory cortex 
was detected using microelectrode biosensors. d, The representative responses of cortical slices 
of WT and dnSNARE mice to the application of 500 nM AEA were recorded using microelectrode 
sensors to ATP and D-serine placed in layer 2/3 of cortex. e, The pooled data on the peak 
magnitude of ATP and D-serine transients evoked by application of AEA; data shown as mean ±SD 
for number of experiments indicated. Two sample independent t-test was performed between 
WT and dnSNARE mice; **, p<0.01. 
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5.2. Application of AEA results in calcium-dependent vesicular 
exocytosis of ATP from astrocytes 
 
In the introduction of this chapter it was shown that activation of CB1 receptors 
on astrocytes via AEA application can result in calcium dependent vesicular 
release of ATP from astrocytes. It was shown in chapter 3 that vesicular release 
of ATP from astrocytes could activate P2XRs on neurones. To investigate 
whether AEA application can result in vesicular release of ATP from astrocytes 
on to P2XRs on neurones, a “sniffer”-cell approach was used. In this approach, 
cortical neurones were acutely isolated via vibro-dissociation technique, which 
allows functional membrane receptors to be retained at the cell surface. Another 
benefit of this technique is the ability to retain a fraction of functional synapses, 
which can be verified by staining with FM1-43 and presence of miniature 
spontaneous synaptic currents (Figure 5.2a). Furthermore, with vibro-
dissociation, not only isolated neurones are obtained but in some cases some 
astrocytes remain attached to the isolated neurone (Figure 5.2b-c). This retains a 
certain proportion of intimate contact between thin astrocytic processes and 
neuronal membrane. Such neuron-astrocyte “bundle” could work as a good 
model of glia-neuron interaction unit, enabling efficient activation of astrcoytes 
and direct monitoring of neuronal response. In comparison to bath application of 
pharamacological agents to the whole slice, the “neuron-astrocyte bundle” has an 
advantage of better control of drug application and lack of side-effects of 
massive activation of astrocyte network and poly-synaptic connections. With 
vibro-dissociation two “types” of dissociation preparations are possible: 1) 
isolated neurones with no astrocytes attached (Figure 5.2a); 2) “neuron-astrocyte 
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bundle” (Figure 5.2b-c). Neurones from these two preparation were patch 
clamped followed by application of 500 nM of AEA to investigate the vesicular 
release of astrocytic ATP onto neuronal P2XRs.    
 
P2XR-mediated sEPSCs were recorded from acutely isolated neocortical 
neurones at membrane potential of -80 mV in the presence of CNQX (50 µM), 
D-APV (30 µM) and picrotoxin (100 µM). Prior to application of AEA, TFLLR 
(5 µM) was applied to isolated preparations to show that the effect of TFLLR on 
“neurone-astrocyte bundle” is similar to the effect of TFLLR application to 
cortical slices shown on Figure 3.2 in chapter 3. Baseline P2XR-mediated 
sEPSCs had an average amplitude of 9.8±2.2 pA with an average decay time 
constant of 8.9±1.7 ms (n=7). These values were similar to the amplitude and 
decay time of P2XR-mediated sEPSCs recorded from cortical slices shown on 
Figure 3.2. Application of TFLLR to isolated neurones with no astrocytes 
attached did not result in significant change in either the average amplitude or 
frequency of P2XR-mediated sEPSCs (Figure 5.2a and 5.2d). Further analysis of 
these sEPSCs showed a unimodal probability distribution in both amplitude and 
decay time. Application of TFLLR failed to result in the appearance of the 
“slow” P2XR-mediated sEPSCs (Figure 5.2a). In contrast, amplitude and decay 
time probability distributions of sEPSCs recorded from neurones in “neurone-
astrocyte bundle” showed bimodal distributions with amplitude distributions 
showing peaks at 5.9±1.4 pA and 9.9±2.6 pA (n=6; see Figure 5.2b). The decay 
time distributions showed peaks at 8.8±1.1 ms and 15.1±2.2 ms (Figure 5.2b). 
Application of TFLLR to these “neurone-astrocyte bundle” resulted in a 
significant increase in the frequency of sEPSCs and decrease in their average 
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amplitude (Figure 5.2b and 5.2d). This increase in frequency and decrease in 
average amplitude is as a result of increase in the slower and smaller sEPSCs 
(Figure 5.2b). These results are similar to results showed on Figure 3.9, where 
application of TFLLR to cortical slices resulted in the increase in frequency of 
the “slow” P2XR-mediated sEPSCs. To verify that the appearance of these 
“slow” sEPSCs was as a result vesicular release of ATP from astrocytes, TFLLR 
was also applied to “neurone-astrocyte bundle” isolated from dnSNARE mice, 
where vesicular exocytosis is impaired selectively in astrocytes. Application of 
TFLLR to “neurone-astrocyte bundle” from dnSNARE mice failed to 
significantly change the frequency and average amplitude of P2XR-mediated 
sEPSCs, thereby showing that the “slow” sEPSCs were indeed due to vesicular 
release of ATP from astrocytes (Figure 5.2c-d). Taken together, these results 
confirm that “neurone-astrocyte bundle” can indeed be used as a model for glia-
neuron interaction unit and that these units show similar properties to their 
counterparts in cortical slices. 
 
If, as mentioned above, AEA-mediated calcium dependent vesicular release of 
ATP is analogous to TFLLR application, then one would expect to see the 
appearance of “slow” P2XR-mediated sEPSCs following AEA application. To 
investigate this, AEA was applied to isolated neurone preparations from WT and 
dnSNARE mice. Similar to TFLLR, application of AEA to isolated neurones 
with no attached astrocytes produced no change in the frequency or average 
amplitude of P2XR-mediated sEPSCs (Figure 5.2a and 5.2d). However, 
application of AEA to “neurone-astrocyte bundle” from WT mice resulted in a 
significant increase in the frequency of the “slow” sEPSCs (Figure 5.2b and 
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5.2d). Application of AEA to “neuron-astrocyte bundle” from dnSNARE mice 
did not result in change in either frequency or average amplitude of sEPSCs 
(Figure 5.2c and 5.2d). These results show that application of AEA can result in 
vesicular exocytosis of ATP from astrocytes. This ATP release from astrocytes 
can then activate P2XRs on neurones. This suggests that CB1 receptors on 
astrocytes act analogously to PAR-1 on astrocytes. This means that calcium 
elevations in astrocytes via either PAR-1 receptors or CB1 receptors can result in 
vesicular release of ATP from these cells. 
 
The data on Figure 5.2 was obtained with collaboration with Dr Yuriy Pankratov. 
 
 
 
 
 
 
 
 
 
 
 
 211 
a
b
c
d
Isolated neuron
Neuron with WT astrocytes
Neuron with dnSNARE astrocytes
a
b
c
d
Isolated neuron
Neuron with WT astrocytes
Neuron with dnSNARE astrocytes
 
 
 
 
 
Figure 5.2. For Figure legend see next page.        
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Figure 5.2. Detection of ATP release from astrocytes using modified “sniffer-cell” 
method. a-c,  whole cell P2XR-mediated sEPSCs were recorded from acutely isolated 
neocortical pyramidal neurones at membrane potential of -80 mV under CNQX (50 
µM), D-APV (30 µM) and picrotoxin (100 µM). Astrocytes were activated by 1 min-long 
application of TFLLR (10 µM) and AEA (500 nM). a, Vibro-dissociation preparation of 
WT isolated neurone with no attached astrocyte. Whole-cell currents were recorded in 
the isolated neuron simultaneously with staining with synaptic vesicular marker FM1-
43. Prior to recording, the cell was pre-incubated with 3 µM FM1-43 for 15 min, then 
dye was washed out for 15 min. From left to right: representative fluorescent and 
gradient contrast image of neuron showing punctate staining with FM1-43, the trace 
showing spontaneous synaptic currents and distributions of sEPSCs amplitude and 
decay time. b, Similar recordings were made from vibro-dissociation preparation of 
“neurone-astrocyte bundle” from WT mice. c, Recordings from vibro-dissociation 
preparation of “neurone-astrocyte bundle” from dnSNARE mice. Green fluorescence 
confirms the dnSNARE expression in astrocytes attached to the neuron. d, Time course 
of changes in the average amplitude and frequency of P2XR-mediated sEPSCs during 
TFLLR and AEA application. Dots represent values averaged over 30 seconds time 
window. Data shown as mean±SD for number of neurons as indicated. Difference 
between WT and dnSNARE mice in the effects of TFLLR and AEA on sEPSC frequency 
was significant at p<0.005 (two sample independent t-test).        
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The above results show that activation of CB1 receptors on astrocytes can result 
in calcium-dependent vesicular release of ATP from these cells. These CB1 
receptors were activated by exogenous application of AEA. It would be 
reasonable to ask weather endogenous CBs can also activate exocytosis from 
cortical astrocytes. As was shown in chapter 3, HFS stimulation of neuronal 
afferents resulted in vesicular release of ATP from astrocytes (Figure 3.9). This 
ATP release resulted in the increase in frequency of “slow” P2XR-mediated 
sEPSCs on neurones. This effect was similar to application of TFLLR to cortical 
slices. If CB1 receptors on astrocytes are activated by endogenous cannabinoids 
during delivery of HFS to neuronal afferents, then one would expect that these 
receptors to contribute to calcium-dependent vesicular exocytosis of ATP from 
astrocytes during HFS delivery.  
 
To investigate this, P2XR-mediated sEPSCs were recorded from neurones of 
layer 2/3 of cortical slices under CNQX (50 µM) and picrotoxin (100 µM) at 
holding voltage of -80 mV. Similar to Figure 3.10, delivery of the short HFS 
train caused a significant elevation in frequency of the “slow” P2XR-mediated 
sEPSCs (Figure 5.3b-d). However, delivery of HFS during application of AM251 
(1 µM), which is an antagonist of CB1 receptors, significantly reduced the 
increase in frequency of “slow” P2XR-mediated sEPSCs (Figure 5.3b-d). 
Furthermore, delivery of HFS during application of AM251 resulted in a smaller 
increase in astrocytic calcium elevation (Figure 5.3a), thereby suggesting that 
some of the HFS-mediated calcium elevations in astrocytes are due to CB1 
receptors on these cells. Other sources of calcium elevation could be due to 
P2XRs and NMDARs on astrocytes (Palygin et al., 2010). It was shown 
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previously by my colleagues that application of UBP141 could selectively inhibit 
NMDARs on astrocytes but not NMDARs on neurones (Palygin et al., 2011). As 
UBP141 specifically blocks GluN2C/D-containing NMDARs, it was suggested 
that astrocytic NMDARs consist of GluN2C/D. Therefore, UBP141 can be used 
as a specific antagonist of astrocytic NMDARs.  To confirm the results from the 
previous report that other source of HFS-induced calcium elevation is due to 
NMDARs on astrocytes, HFS was delivered during the application of UBP141. 
The increase in astrocytic calcium elevation and P2XR-mediated sEPSCs were 
significantly less when HFS was delivered under UBP141 than when HFS was 
delivered in control conditions (Figure 5.4e).  
      
Taken together, these results show that activation of neuronal afferents can result 
in elevation of intracellular calcium levels in astrocytes, which in turn leads to 
vesicular exocytosis of ATP from astrocytes. These intra-cellular calcium 
elevations in astrocytes are due to CB1 receptors, P2XRs and NMDARs on these 
cells. Therefore, these receptors allow astrocytes to “sense” neurotransmitter 
release from neurones, thereby allowing astrocytes to be activated in response to 
neuronal activity. Following activation, astrocytes can then release 
gliotransmitters such as ATP onto neurones. These results confirm that 
bidirectional communication between astrocytes and neurones is present in the 
somatosensory cortex.  
 
In addition to CB1 receptors, NMDARs and P2XRs on astrocytes, it has been 
shown that astrocytic mGluR5 are also involved in elevation of calcium levels in 
astrocytes following electrical stimulation of afferent fibres (Panatier et al., 
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2011). Therefore inhibition of mGluRs should also decrease the extent of HFS-
induced astrocytic calcium elevation and P2XR-mediated sEPSCs. To investigate 
this, HFS was delivered during application of 10 µM of MPEP, which is a 
selective antagonist of mGluR5. As expected, HFS delivery during MPEP 
application resulted in a significantly lower increase in astrocytic calcium 
elevation and sEPSCs (Figure 5.4e). These results suggest that mGluR5 on 
astrocytes can also contribute to calcium dependent vesicular release of ATP 
from these cells. However, a recent study has shown that mGluR5 expression is 
significantly reduced in hippocampal and cortical astrocytes from mice above 2 
weeks of age (Sun et al., 2013). In this report it was shown that most mGluR5 
were located at post-synaptic spines and dendrites of neurones. If this is the case, 
then how does the inihibtion of mGluRs decrease astrocytic calcium elevation 
and vesicular release of ATP? It has been shown that eCBs are produced and 
released from post-synaptic sites following activation of mGluRs on these sites 
(Varma et al., 2001, Kim and Alger, 2010). Therefore, delivery of HFS to pre-
synaptic afferents can result in release of glutamate from these neurones. 
Anterograde transport of glutamate can result in the activation of mGluR5 on 
post-synaptic neurones, thereby leading to release of eCBs from post-synaptic 
sites. Retrograde transport of eCBs can then activate CB1 receptors on 
astrocytes, thereby leading to calcium-dependent vesicular exocytosis of ATP 
from astrocytes. If this mechanism is true, it would explain why mGluR5 are 
involved in calcium elevation in astrocytes, even though these receptors are 
present on post-synaptic neurones. This needs to be investigated further in the 
future.  
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The results on Figure 5.3 were obtained in collaboration with Dr Yuriy 
Pankrotov. The results on Figures 5.2 and 5.3 have been published (Rasooli-
Nejad et al., 2014). 
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Figure 5.3. For Figure legend see next page.        
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Figure 5.3. Attenuation of Ca2+-signalling in cortical astrocytes via inhibition of 
CB1 receptors inhibits the release of ATP from these cells. a, Ca2+ signalling was 
monitored in cortical astrocytes loaded with Rhod-2AM using 2-photon fluorescent 
microscopy. HFS was delivered at zero time to trigger Ca2+ elevation in the astrocyte. 
Graphs show the time course of Rhod-2 fluorescence averaged over a single astrocyte 
process indicated in the GFAP-EGFP fluorescent imgae of astrocyte (scale bar is 5 µM). 
The representative pseudo-colour 2-photon images, recorded at time indicated, are 
shown below. b, example P2XR-mediated sEPSC recordings from cortical neuron 
before and after HFS delivery under control and under application of AM251 (1 µM). 
P2XR-mediated sEPSCs were recorded from neurones of layer 2/3 of somatosensory 
cortex of WT mice. These sEPSCs were recorded at holding potential of -80 mV in the 
presence of picrotoxin (100 µM) and CNQX (50 µM). c, The average time course of HFS 
delivery during P2XR-mediated sEPSC recordings under control and AM251 
application. Each dot shows the average amplitude and frequency of spontaneous 
currents recorded in 1 min time window in the pyramidal neurones; data are 
presented as mean±SD for 7 neurons. The asterisks (*) indicate the significant 
difference from the control values (p<0.05, paired t-test). d, The amplitude and decay 
time probability distributions of P2XR-mediated sEPSCs recorded before and during 1-
3 minutes after HFS for one example recording. e, bar-charts show the peak magnitude 
of HFS-induced Ca2+ transients in the astrocyte and frequency of slow P2XR-mediated 
sEPSCs averaged within 3 min time window before (baseline) and after HFS train. Data 
are shown as mean±SD for following number of experiments: 7 for AM251, 6 for 
UBP141 and 4 for MPEP. The statistical significance of difference from the control 
values was as indicated. P<0.05, *; p<0.01, **.      
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5.3. Activation of astrocytic vesicular release with AEA 
contributes to TBS-induced LTP 
 
In the previous section it was shown that application of AEA could result in 
calcium dependent vesicular release of ATP from astrocytes. This suggested that 
AEA and CB1 receptors act analogously to TFLLR and PAR-1. It was shown in 
chapter 3 that application of TFLLR could change the direction of TBSx2-
induced synaptic plasticity from LTD to LTP. It was shown that this change from 
LTD to LTP was as a result of ATP release from astrocytes following application 
of TFLLR. If AEA acts in a similar manner to TFLLR application, then one 
would expect that application of AEA during TBSx2 delivery to also result in 
LTP induction. To investigate this, TBSx2 was delivered after 15 minutes of 
AEA (500 nM) application. AEA was washed out 10 minutes after delivery of 
TBSx2. 
   
Delivery of TBSx2 during AEA reversed the direction of synaptic plasticity from 
LTD to LTP (Figures 5.4A and 5.4C). The size of this LTP, 40-50 minutes post 
TBSx2, was +41.3±14.4% (n=10). There was a significant difference between 
TBSx2 under control and TBSx2 under AEA (p<0.01, two sample independent t-
test; see Figure 5.4D). These results suggest that application of AEA can 
contribute to LTP induction in a similar manner to application of TFLLR. 
 
In chapter 3 it was shown that TFLLR could rescue LTP via vesicular exocytosis 
of ATP from astrocytes. It was shown that inhibition of P2XRs prevented the 
rescue of TBSx2-induced LTP with TFLLR, suggesting that P2XRs and hence 
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ATP release are involved in the rescue of LTP. In section 5.2, it was shown that 
application of AEA could result in release of ATP from astrocytes, thereby 
leading to activation of P2XRs on neurones. It was also shown that inhibition of 
CB1 receptors could decrease the degree of HFS-induced increase in P2XR-
mediated sEPSCs. These results suggested that AEA can result in vesicular 
release of ATP from astrocytes and onto P2XRs on neurones. Therefore, the 
mechanism of rescue of LTP during TBSx2 under AEA could be similar to 
TFLLR i.e. depend on ATP release and activation of P2XRs. To investigate this, 
TBSx2 was delivered again under AEA but this time P2X receptor antagonists 
PPADS (10 µM) and 5-BDBD (5 µM) were perfused alongside AEA. As 
expected, inhibition of P2X receptors prevented rescue of LTP with AEA 
(Figures 5.4A and 5.4C). Delivery of TBSx2 under AEA, PPADS, 5-BDBD, 
resulted in a significant LTD of -23.77±9.08% (n=13, p<0.05, paired t-test; see 
Figure 5.4D). The size of this LTD was similar to LTD induced when TBSx2 
was delivered under control (no drugs applied) conditions (Figure 5.4D). These 
results suggest that the LTP induced with TBSx2 under AEA application is 
dependent on the activity of P2XRs. 
  
The above results show that AEA application during TBSx2 can result in LTP 
induction. It was suggested that this rescue of LTP is dependent on vesicular 
release from astrocytes. To provide evidence that this LTP rescue is indeed due 
to vesicular release from astrocytes, the above recordings were repeated in 
cortical slices in dnSNARE mice. Delivery of TBSx2 to dnSNARE cortical 
slices in the absence of any pharmacological agents resulted in an LTD of -
25.38±15.37% (n=8; see Figure 5.4B-D). This TBSx2-induced LTD in 
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dnSNARE mice was similar in size to TBSx2 induced LTD in WT mice (Figure 
5.4D). Application of AEA to dnSNARE cortical slices failed to change the 
direction of TBSx2-induced synaptic plasticity from LTD to LTP i.e. AEA 
application also resulted in an LTD (Figure 5.4B-C). The size of this LTD was -
10.82±8.76% (n=11). This is in contrast to AEA application to WT mice, where 
a significant LTP was induced (Figures 5.4A and 5.4D).  
 
Taken together, the results in this section suggest that AEA can contribute to 
TBS-induced LTP by resulting in vesicular exocytosis from astrocytes. As 
inhibition of P2XRs prevented this rescue of LTP, one can suggest that this 
rescue of LTP is due to AEA-mediated vesicular release of ATP from astrocytes.  
 
The results on Figure 5.4 have been published (Rasooli-Nejad et al., 2014). 
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Figure 5.4. AEA application can result in TBSx2-induced LTP via vesicular 
exocytosis. A, These recordings were performed in WT mice. The average time-courses 
for fEPSP recordings with TBSx2 protocol are shown. Orange arrow shows position of 
TBSx2 delivery. All drugs were applied 15 minutes prior to TBSx2 delivery and were 
washed out 10 minutes after TBSx2. B, shows the average time-courses for fEPSP 
recordings with TBSx2 in cortical slices from dnSNARE mice. C, shows example fEPSPs 
before and after TBSx2 delivery. D, shows bar-charts representing the average % change 
in fEPSP 40-50 minutes post TBSx2 delivery. For TBSx2 delivery in WT mice under AEA, 
PPADS, and 5-BDBD, the average % change in fEPSP was -23.77±9.08%. For TBSx2 
delivery in WT mice under control conditions, the average % change in fEPSP was -
15±6.56%. For TBSx2 delivery to WT mice under AEA, the average % change in fEPSP 
was +41.3±14.36%. For TBSx2 delivery in dnSNARE mice under AEA, the average % 
change in fEPSP was -10.82±8.76%. For TBSx2 delivery in dnSNARE mice under control 
conditions the average % increase in fEPSP was -25.38±15.37%. Two sample 
independent t-test was performed between each pair of data. Paired t-test was 
performed for average % change in fEPSP from baseline. p<0.05, *; P<0.01, **; p<0.001, 
***.    
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5.4. CB1 receptors are required for induction of TBSx5-induced 
LTP  
 
The results in the previous two sections showed that application of AEA could 
result in calcium elevation in astrocytes by binding to the CB1 receptors on these 
cells. It was also shown that AEA application could result in release of ATP from 
astrocytes. It was suggested that this release of ATP could contribute to TBS-
induced LTP in the somatosensory cortex. It was also shown that inhibition of 
CB1 receptors with AM251 resulted in a decrease in astrocytic calcium elevation 
and astrocytic ATP release. As vesicular release from astrocytes is required for 
LTP induction, then it is possible that inhibition of CB1 receptors on astrocytes 
can lead to impairment of LTP induction. Previous studies, which all have been 
carried out in the hippocampus, have shown contradictory results. Two studies 
have shown that application of CB1 receptor antagonist does not have any effect 
on LTP induction (Carlson et al., 2002, Slanina et al., 2005).  Another study 
showed enhancement of in vivo LTP in CB1 receptor knockout mice in 
comparison to WT mice (Jacob et al., 2012). In contrast, three other studies have 
shown complete abolishment of LTP in slices perfused with CB1 receptor 
antagonists (Chevaleyre and Castillo, 2003, de Oliveira Alvares et al., 2006, Lin 
et al., 2011).       
 
To investigate the role of endogenous cannabinoids on LTP induction in the 
somatosensory cortex, TBSx5 protocol was delivered during application of 
AM251. Delivery of TBSx5 during application of AM251 completely abolished 
LTP and actually induced a significant LTD of -26.69±5.02% (n=13, p<0.001, 
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paired t-test; see Figure 5.5). These results suggest that CB1 receptors and hence 
eCBs are required for LTP induction in the somatosensory cortex. 
 
The above results suggest that CB1 receptors are required for LTP induction in 
the somatosensory cortex. If this is the case, then it would be interesting to see 
what effect application of exogenous cannabinoids has on TBSx5-induced LTP 
induction. As shown in the previous section, application of AEA contributed to 
induction of LTP with TBSx2. Therefore, one would expect an enhancement of 
LTP if AEA were applied during the delivery of TBSx5. However, CB1 
receptors are also present on pre-synaptic sites, where they can inhibit transmitter 
release. Previous studies that have attempted to investigate the role of application 
of exogenous cannabinoids have shown contrasting results. In CA1 region of 
hippocampus of 2-3 weeks old mice and rats, pre-incubation of brain slices with 
exogenous synthetic CB1 receptor agonists HU-210 (100 nM) or WIN55,212-2 
(3-10 M), blocked HFS induced LTP (Collins et al., 1995, Misner and Sullivan, 
1999). Application of 20 M of 2-AG to slices for 20 minutes prior to HFS 
delivery also blocked LTP induction in the CA1 region of the hippocampus 
(Stella et al., 1997). A study in the prefrontal cortex showed that application of 
high concentration of WIN55,212-2 (1 mM), decreased the chances of LTP 
induction in the prefrontal cortex (Auclair et al., 2000). In contrast, another study 
showed that application of AEA, for 30 minutes prior to delivery of HFS, did not 
completely block LTP (Terranova et al., 1995). An earlier study showed that 
application of 9-THC (10-1000 pM) to CA1 region of hippocampus did not 
decrease the extent of LTP (Nowicky et al., 1987). In a study in the visual cortex 
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of young (2-3 weeks old) mice, application of WIN55,212-2 (2 M) did not 
effect LTP induction (Huang et al., 2008).   
 
None of the above studies were carried out in the somatosensory cortex. To 
investigate the effect AEA application has on LTP induction in the 
somatosensory cortex, TBSx5 was delivered during application of 500 nM of 
AEA. Application of AEA resulted in a significant LTP of +68.78±22.11% (n=8, 
paired t-test, p<0.05; see Figure 5.5). There was no statistically significant 
difference between LTP with AEA and LTP in control conditions (p<0.05, two 
sample t-test; see Figure 5.5B). These results show that application of 500 nM of 
AEA does not have an effect on TBSx5 induced LTP in the somatosensory 
cortex. 
 
The results on Figure 5.5 have been published (Rasooli-Nejad et al., 2014). 
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Figure 5.5. CB1 receptors are required for induction of TBSx5-induced LTP. A, 
These recordings were performed in WT mice. The average time-courses for fEPSP 
recordings during TBSx5 protocol are shown. Orange arrow shows position of TBSx5 
delivery. All drugs were applied 15 minutes prior to TBSx5 delivery and were 
washed out 10 minutes after TBSx5. B, shows bar-charts representing the average % 
change in fEPSP 40-60 minutes post TBSx5 delivery. For TBSx5 delivery in control 
conditions, the average % change in fEPSP was +58±7.54%. For TBSx5 delivery 
under AM251 (1 µM), the average % change in fEPSP was -26.69±5.02%. For TBSx5 
delivery under AEA (500 nM), the average % change in fEPSP was +68.78±22.11%. 
Two sample independent t-test was performed between control and AM251 data. 
Paired t-test was performed for average % change in fEPSP from baseline. p<0.05, *; 
P<0.01 **; p<0.001. C, shows example fEPSPs before and after TBSx5 delivery.     
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5.5. Application of AEA can increase fEPSPs by increasing 
vesicular release of gliotransmitters from astrocytes 
 
As shown in the previous sections, AEA application during TBSx2 resulted in 
the induction of LTP. It was suggested that this rescue of LTP is due to AEA-
mediated vesicular release of ATP from astrocytes onto neuronal P2XRs. It was 
suggested that this action of AEA is similar to TFLLR application. TFLLR 
application could increase the fEPSP size without delivery of TBS protocol. 
However, it was shown that this TFLLR mediated increase in fEPSP was not an 
LTP because washout of TFLLR reduced the fEPSP back to baseline value (see 
Figure 3.19 in chapter 3). If AEA action is similar to TFLLR, then one would 
expect that AEA, by binding to CB1 receptors on astrocytes and thus inducing 
calcium dependent release of gliotrasnmitters from these cells, to result in 
increase in fEPSP. However, AEA can also bind CB1 receptors on pre-synaptic 
sites, which results in inhibition of neurotransmitter release. This latter action 
could either decrease neurotransmitter release at excitatory synapses, thereby 
decreasing fEPSP, or decrease neurotransmitter release at inhibitory synapses, 
thereby increasing fEPSP. To investigate the effect of AEA on synaptic 
transmission in somatosensory cortex, 500 nM of AEA was applied to cortical 
slices during recordings of fEPSPs. Anandamide was applied subsequent to 10 
minutes of baseline fEPSP recordings (Figure 5.6A). Within 2-10 minutes of 
AEA application, there was a significant increase of 17.18±3.78% in fEPSP 
(n=10, p<0.01, paired t-test; see Figures 5.6A and 5.6C). Following 10 minutes 
of application, AEA was washed out from the slice. Washout of AEA resulted in 
decrease of fEPSP back to baseline value. The average size of fEPSP following 
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10-20 minutes of AEA washout was 6.72±4.03% in comparison to baseline 
fEPSP (before AEA application) (Figures 5.6A and 5.6C). There was no 
significant difference between baseline fEPSP and fEPSP following AEA 
washout (p<0.05, paired t-test; see Figure 5.6C). These results suggest that 
similar to TFLLR application, AEA application can increase the fEPSP but that 
this increase is not an LTP because washout of AEA reduces the fEPSP back to 
baseline value.       
 
The increase in fEPSP following AEA application can be due to two reasons: 1) 
fEPSP increases as a result of activation of CB1 receptors on astrcoytes, which 
leads to increase in vesicular release of gliotransmitters from these cells; 2) 
activation of CB1 receptors on pre-synaptic inhibitory neurones leads to decrease 
of neurotransmitter release, hence leading to increase in fEPSP. To investigate 
whether AEA increase in fEPSP was due to vesicular release from astrocytes, 
AEA (500 nM) was applied to cortical slices from dnSNARE mice. In contrast to 
WT mice, application of AEA to cortical slices from dnSNARE mice did not 
increase the fEPSP. In fact it resulted in a significant decrease of -11.97±3.77% 
in fEPSP (n=7, p<0.05, paired t-test; see Figure 5.6A). Washout of AEA did not 
bring the fEPSP back to baseline value (Figures 5.6A and 5.6C). These results 
suggest that AEA application to dnSNARE cortical slices results in a decrease in 
synaptic transmission. This decrease is an LTD because washout of AEA does 
not bring the fEPSP back to baseline level. These results imply that when 
vesicular release from astrocytes is impaired, AEA application results in decrease 
in synaptic transmission, presumably through decrease of transmitter release 
from excitatory neurons. These results also suggest that the increase in fEPSP in 
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WT mice following the application of AEA is as a result of AEA-mediated 
activation of astrocytic vesicular release. 
 
The above data suggested that in WT mice, AEA application could increase 
vesicular release from gliotranmitters from astrocytes, thereby increasing fEPSP. 
It was also suggested that in dnSNARE mice, AEA decreases fEPSP by 
decreasing release of neurotransmitters from pre-synaptic sites. To investigate 
whether these effects are due to changes in release probability or due to post-
synaptic effects, paired pulse protocol was carried out during the fEPSP 
recordings shown on Figure 5.6A. If PPR does not change following AEA 
application, then one can suggest that the change in fEPSP is due to post-
synaptic changes. However, if PPR changes in response to AEA application, then 
one can suggest that the change in fEPSP is as a result of changes in release 
probability. The results of paired pulse protocol are shown on Figure 5.6D. 
Paired pulse protocol was carried out during control (C), following 5-10 minutes 
of AEA application (A), and following 10-20 minutes after AEA washout (W). 
Two inter-stimulus intervals were used: 50 ms and 200 ms. Example fEPSPs 
during paired pulse protocol with inter-stimulus interval of 50 ms are shown on 
Figure 5.6E. Example fEPSPs during paired pulse protocol with inter-stimulus 
interval of 200 ms are shown on Figure 5.6F.  
 
Delivery of paired pulse protocol with 50 ms interval under control conditions in 
WT mice resulted in the second fEPSP being larger than the first fEPSP (Figure 
5.6E). The average PPR across 8 experiments was 1.61±0.18 (Figure 5.6D). 
When AEA was applied to cortical slices from WT mice, the fEPSP increased 
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(Figure 5.6E). Delivery of Paired pulse protocol resulted in a significant increase 
in paired pulse ratio (p<0.05, paired t-test; see Figure 5.6D-E). The PPR under 
AEA was 2.21±0.25 (n=8). Washout of AEA decreased the PPR to 1.80±0.18 
(n=8; see Figure 5.6D). These results suggest that the increase in fEPSP as a 
result of application of AEA is due to increase in release probability and not due 
to an increase in post-synaptic component. This is in contrast to TFLLR 
application, where PPR did not change, thereby suggesting that the increase in 
fEPSP was due to a post-synaptic component (Figure 3.19). 
 
Delivery of paired pulse protocol with 200 ms interval under control conditions 
in WT mice resulted in a PPR of 1.13±0.12 (n=7; see Figures 5.6D and 5.6F). 
This PPR is smaller in comparison to PPR with 50 ms interval. This is as 
expected because increasing the interval between the two pulses (200 ms) 
theoretically results in a lower intra-cellular calcium levels in pre-synaptic 
terminals in comparison to when inter-stimulus interval is shorter at 50 ms. This 
means that during paired pulse protocol with 50 ms interval, there is large rise in 
calcium levels in pre-synaptic terminal when the second pulse is going to be 
delivered; this results in a larger pre-synaptic release during the second pulse, 
hence leading to a large PPR. However, during paired pulse protocol with 200 
ms interval, the calcium rise in pre-synaptic terminals drops due to the longer 
interval between the two pulses; this results in a lower neurotransmitter release 
form pre-synaptic terminals during the delivery of the second pulse, thereby 
resulting in a lower PPR. Therefore the PPR with 200 ms is smaller than PPR 
with 50 ms interval. Application of AEA did not significantly alter the PPR with 
200 ms interval (Figures 5.6D and 5.6F).   
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The above paired pulse protocols were repeated in cortical slices from dnSNARE 
mice. Under control conditions, the PPRs with 50 ms interval and 200 ms 
interval were significantly less in dnSNARE mice in comparison to WT mice 
(two sample independent t-test, p<0.05; see Figures 5.6D-F). This suggests that 
the release probability in dnSNARE mice is less than in WT mice. This drop in 
release probability could be due to the impairment of vesicular release of 
gliotrasnmitters from astrocytes. 
 
Application of AEA to dnSNARE mice results in decrease in fEPSP (Figure 
5.6E). Delivery of paired pulse protocol with 50 ms interval during AEA 
application in dnSNARE mice results in a significant increase in PPR (p<0.001, 
paired t-test; see Figure 5.6D). The PPR for 50 ms interval during control 
conditions was 1.26±0.07, whilst PPR under AEA application was 1.39±0.08 
(n=7; see Figures 5.6D-E). Change in PPR with AEA application to dnSNARE 
cortical slices suggests that the decrease in fEPSP as a result of AEA is due to 
decrease in release probability.  
 
It was shown that in WT mice application of 500 nM of AEA could increase 
fEPSP by increasing vesicular exocytosis from astrocytes. In contrast to this, a 
recent report in the CA1 region of hippocampus has shown that application of 
exogenous cannabinoids can result in decrease of fEPSP and can induce LTD 
(Han et al., 2012). One possible explanation for this contradiction between my 
results and this report is that in my experiments a low concentration of AEA was 
used. To see what effect does a higher concentration of AEA has on synaptic 
transmission, 5 µM of AEA was applied to cortical slices from WT mice during 
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recording of fEPSPs. Application of 5 µM of AEA resulted in a significant drop 
in fEPSP of -23.18±6.74% (n=6, p<0.05, paired t-test; see Figure 5.6B-C). 
Washout of AEA did not increase the fEPSP back to baseline (Figure 5.6B-C), 
suggesting that the decrease in synaptic transmission was an LTD. This suggests 
that, in WT cortical slices, application of higher concentration (5 µM) of AEA 
results in decrease in synaptic transmission and LTD, whilst application of lower 
concentration (500 nM) of AEA results in increase in synaptic transmission.     
 
Taken together, the results in this section show that application of 500 nM of 
AEA can increase fEPSP by increasing vesicular release of gliotransmitters from 
astrocytes.  
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Figure 5.6. For Figure legend see next page. 
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Figure 5.6. Application of AEA can increase fEPSPs by increasing vesicular release of 
gliotransmitters from astrocytes. A, shows average time-courses for fEPSP recordings 
before and after application of 500 nM AEA in WT and dnSNARE mice. Blue bar shows 
the time-span of AEA application. B, shows average time-course for fEPSP recordings 
before and after application of 5 µM of AEA in WT mice. C, shows the data from A and B 
in form of bar-charts. Paired t-test was performed for fEPSP change from baseline. Two 
sample independent t-test was performed between WT and dnSNARE data. Two 
sample t-test was also performed between data for application of 500 nM of AEA to WT 
mice and data for application of 5 µM of AEA to WT mice. The statistical significant 
levels were as follows p<0.05, *; p<0.01, **; p<0.001, ***. D, paired pulse protocol was 
carried out during the fEPSP recordings shown in A. Paired pulse protocol was carried 
out under control conditions (C), 5 minutes after AEA application (A), and 15 minutes 
after washout of AEA (W). Two inter-stimulus intervals were used for paired pulse: 50 
ms and 200 ms. For each time interval (50 and 200 ms), paired t-test was performed 
between control and AEA data. Furthermore, for each time interval, paired t-test was 
also performed between control and washout data. These t-tests were performed for 
both WT and dnSNARE recordings. The statistical significant levels were as follows 
p<0.05, *; p<0.01, **; p<0.001, ***. E, shows example fEPSP traces for 50 ms inter-
stimulus interval for paired pulse protocol under control and AEA in WT and dnSNARE 
mice. Downward arrow indicates increase in paired pulse ratio. F, shows example 
fEPSP traces for 200 ms inter-stimulus interval for paired pulse protocol under control 
and AEA in WT and dnSNARE mice. Upward arrow indicated decrease in paired pulse 
ratio.   
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5.6. Application of AEA may increase NMDAR activity 
 
In the previous sections it was shown that application of AEA could result in 
vesicular release of ATP from astrocytes. It was suggested that in this action, 
AEA acts similarly to TFLLR. However, it was shown in chapter 3 that TFLLR 
application could also result in release of glutamatergic gliotransmitter release 
from astrocytes in addition to release of ATP (see sections 3.13 and 3.14). This 
suggests that AEA application might also result in release of glutamatergic 
transmitters. One previous study in the CA1 region of the hippocampus showed 
that activation CB1 receptors on astrocytes results in rise in intracellular calcium 
levels in these cells. This in turn leads to glutamate release from astrocytes 
(Navarrete and Araque, 2008). To investigate whether in the somatosensory 
cortex, AEA application can result in enhancement of NMDAR activity, 500 nM 
of AEA was applied to cortical slices from WT mice during recording of evoked 
NMDAR EPSCs. Similar to Figure 3.24, NMDAR eEPSCs were recorded at -40 
mV holding voltage under PPADS (10 µM), 5-BDBD (5 µM), picrotoxin (10 
µM) and DNQX (30 µM).  
 
Application of AEA resulted in a percentage increase of 55.14±34.61% in the 
average amplitude of NMDAR eEPSC (n=3). Increase in eEPSC amplitude could 
be either due to changes in release probability or due to post-synaptic changes. 
Quantal analysis was carried out to investigate whether the increase in amplitude 
following AEA application were due to release probability or due post-synaptic 
changes. Figure 5.7A shows the amplitude probability distributions for baseline 
NMDAR eEPSC recordings and for eEPSC recordings during application of 
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AEA. Binomial models of release were fitted to the data and are shown. These 
models are shown as grey lines on the PDFs. The parameters of the models are 
also given. Application of AEA resulted in an increase in probability of release 
(p) and maximum number of release sites (n). In contrast, there was no increase 
in quantal amplitude (q). This suggests that the increase in the average amplitude 
of NMDAR eEPSC seen as a result of AEA application is due to increase in 
release of glutamatergic transmitters. These are preliminary results. The next step 
for investigating whether this AEA-mediated increase in release of glutamatergic 
transmitters is as a result of vesicular release from astrocytes would be to repeat 
the above protocol in dnSNARE mice.  
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Figure 5.7. Application of AEA can increase the average amplitude of evoked 
NMDAR EPSCs by increasing release probability. Example of an evoked NMDAR 
EPSC recordings prior to and post AEA (500 nM) application. Evoked NMDAR EPSCs 
were recorded at -40 mV holding voltage under Picrotoxin (100 µM), PPADS (10 µM), 
5-BDBD (5 µM) and DNQX (30 µM). A, shows the amplitude probability distribution 
functions for before and after AEA application. Both baseline and AEA PDFs were fitted 
with a binomial release model and the fit of this model to data is shown as grey lines. 
Model parameters are quantal amplitude (q), number of release sites (n), probability of 
release (p), and the average number of quanta released (m). B, shows example evoked 
NMDAR EPSCs. These example eEPSCs shown are average of 20 successive recorded 
eESPCs.  As can be seen, DL-AP5 completely abolished the current thereby indicating 
that the evoked current was due to NMDAR activity. 
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5.7. Summary of chapter 
 
The aim of this chapter was to investigate the role of endogenous and exogenous 
cannabinoids in synaptic transmission and plasticity in context of tripartite 
synapse. First, it was shown that AEA could elevate intracellular calcium 
concentrations in astrcoytes by binding to CB1 receptors on these cells. It was 
then shown that AEA-mediated activation of calcium elevation on astrocytes 
could result in release of ATP and D-serine from astrocytes via vesicular 
exocytosis. In addition, by using vibro-dissociation technique, it was shown that 
application of AEA onto isolated astrocytes resulted in vesicular release of ATP 
from these cells. The released ATP activated P2XRs on isolated neurones. It was 
also shown that delivery of HFS resulted in calcium elevation in astrocytes and 
vesicular release of ATP from these cells. This calcium elevation depended on 
CB1 receptors, thereby indicating that endogenous cannabinoids can activate 
calcium dependent vesicular release of ATP from astrocytes. This suggested that 
activation of astrocytes during TBS/HFS-induced LTP could involve endogenous 
cannabinoids. Field recordings were carried out to provide evidence for this 
notion. It was shown that CB1 receptors are required for the induction of LTP. It 
was also shown that application of AEA could induce LTP during TBSx2 
protocol. This LTP induction depended on vesicular release from astrocytes and 
P2XRs, thereby suggesting that AEA can contribute to LTP in the somatosensory 
cortex by resulting in vesicular exocytosis of ATP from astrocytes.       
 
 
 
 240 
Chapter 6: Discussion 
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6.1. Summary of results 
 
The main aim of this project was to investigate the role for gliotransmitter release 
from astrocytes during synaptic transmission and plasticity in the somatosensory 
cortex. The role of cannabinoid signalling in the context of tripartite synapse was 
also investigated. The original findings of this project were:  
 
 TBS-induced NMDAR-dependent LTP in the somatosensory cortex requires 
vesicular exocytosis of gliotransmitters from astrocytes 
 Astrocytes can release ATP by calcium dependent vesicular exocytosis 
 ATP release from astrocytes contributes to LTP induction in the 
somatosensory cortex. 
 Astrocytes can release glutamatergic gliotransmitters (D-serine and 
glutamate) via vesicular exocytosis. Release of glutamatergic gliotransmitters 
results in activation of extra-synaptic GluN2B-containing NMDARs on 
neurones. 
 GluN2B-containing NMDARs contribute to LTP induction in the 
somatosensory cortex.  
 In the somatosensory cortex, vesicular release of D-serine from astrocytes 
does not contribute to LTP induction. 
 Application of AEA results in calcium elevation in astrocytes of the 
somatosensory cortex by activating CB1 receptors on these cells. AEA-
mediated calcium elevation in astrocytes leads to release of ATP and D-
serine from astrocytes. This release of ATP can contribute to LTP induction  
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 In the somatosensory cortex, stimulation of neuronal afferent fibres leads to 
calcium elevation in astrocytes. This calcium elevation depends on CB1 
receptors and NMDARs on astrocytes. CB1 receptor-mediated calcium 
elevation in astrocytes leads to release of ATP from these cells. 
 In the somatosensory cortex, CB1 receptors are required for LTP induction. 
 
6.2. Role for purinergic gliotransmitters  
 
Previous reports had already shown that in the hippocampus and hypothalamus, 
vesicular release of gliotransmitters from astrocytes is required for LTP 
induction (Pascual et al., 2005, Panatier et al., 2006, Henneberger et al., 2010). 
However, there had been no study showing the importance of vesicular 
exocytosis from astrocytes during LTP induction in the somatosensory cortex. 
The first original finding of this project was that, similar to hippocampus and 
hypothalamus, vesicular exocytosis from astrocytes is required for induction of 
NMDAR-dependent LTP in the somatosensory cortex. Those previous studies 
from hippocampus and hypothalamus had shown that ATP and D-serine are the 
gliotransmitters that contribute to LTP induction. For this reason, in this project, 
the role of these gliotransmitters in LTP induction was investigated in the 
somatosensory cortex. It was shown that in the somatosensory cortex, the 
modulation of NMDAR activity that contributes to LTP induction is not due to 
D-serine release from astrocytes, but due to ATP release from astrocytes.  
 
One of the objectives of this project was to investigate the role played by 
vesicular release of ATP from astrocytes on synaptic transmission and plasticity. 
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The group of researchers who engineered the dnSNARE mice had already shown 
that in the CA1 region of hippocampus, vesicular release of ATP from astrocytes 
is required for LTP induction (Pascual et al., 2005). They suggested that ATP, 
following release from astrocytes, is broken down into adenosine in the synapse 
(see Figure 6.1, steps 2-10). Increase in extracellular levels of adenosine results 
in increase in tonic inhibition of glutamatergic transmission during baseline 
activity. This means that as a result of ATP release from astrocytes, baseline 
glutamatergic transmission is lowered. Therefore, during delivery of HFS, there 
is a larger range for glutamatergic transmission to increase by. Hence, a large 
LTP can be induced in WT mice. However, in dnSNARE mice, vesicular release 
of ATP is impaired, and so less adenosine is available. This leads to a greater 
baseline glutamatergic transmission, which leads to a smaller range for LTP to 
increase by. Hence, LTP size is reduced. Basically, the idea is that astrocytes by 
releasing ATP can lower baseline glutamatergic activity, and therefore modulate 
the size of LTP. However, in contrast to this report, my results showed that in the 
somatosensory cortex, baseline activity is actually higher in WT mice than in 
dnSNARE mice (Figure 3.4). This means that the impairment of vesicular release 
from astrocytes results in decrease in baseline transmission in the somatosensory 
cortex. This suggests that, in contrast to hippocampus, in the somatosensory 
cortex, the impairment of LTP induction seen in dnSNARE mice is not due to 
increase in baseline transmission. This suggests that, in the somatosensory 
cortex, the impairment of LTP induction is not due to adenosine-mediated 
increase in glutamatergic tonic inhibition. Therefore, the mechanism of this LTP 
impairment must be different in the somatosensory cortex.   
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It was shown that application of ATPS, which is a non-hydrolysable form of 
ATP, could rescue the impaired TBS-induced LTP in cortical slices from 
dnSNARE mice. This suggested that vesicular release of ATP from astrocytes is 
required for LTP induction in the somatosensory cortex. It also suggests that 
ATP can contribute to LTP induction without being broken down to adenosine.  
 
To investigate how astrocytic ATP contributes to LTP induction, first evidence 
for calcium dependent exocytosis of ATP from astrocytes was provided (Figure 
3.9). This was one the main original findings of this project. This project 
provided the first ever direct evidence for ATP release from astrocytes via 
calcium-dependent exocytosis in any region of brain. Furthermore, it was shown 
that release of ATP from astrocytes could activate P2XRs on neurones, which in 
turn lead to inhibition of phasic and tonic GABAergic transmission. This 
inhibition of inhibition resulted in increase in NMDAR activity (see Figure 6.1, 
steps 11-15). This suggested that ATP release from astrocytes can contribute to 
increase in NMDAR activity and hence to NMDAR-dependent LTP.     
 
How does activation of neuronal P2XRs result in inhibition of GABAA 
receptors? It has been shown by my colleagues that P2XRs can inhibit 
GABAARs by acting through Ca
2+-dependent phosphorylation by protein kinase 
C (Lalo et al., 2014). Protein Kinase C can directly phosphorylate the 
intracellular loop of GABAAR  subunits (Brandon et al., 2000). This results in 
decrease in GABAA channel activity. 
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Figure 6.1. Modulation of synaptic transmission by astrocytic purinergic signalling. 
Previous studies have suggested different mechanisms for modulation of synaptic 
transmission via purinergic signalling. One mechanism suggests that ATP can enhance 
NMDAR activity by acting as a phosphate donor for phosphorylation by ecto-protein 
kinases (1). Another mechanism involves the breakdown of astrocytic ATP to adenosine: 
stimulation of pre-synaptic fibres (2) results in release of neurotransmitters from these 
fibres (3). Spillover of neurotransmitters to extra-synaptic sites results in activation of 
astrocytic ionotropic receptors (4). This leads to calcium elevation in astrocytes (5). 
Activation of CB1 receptors can also result in calcium elevation in astrocytes (6). Calcium 
elevation in astrocytes leads to vesicular exocytosis of ATP from these cells (7). ATP is 
then broken down to adenosine in the extra-cellular space (8). Adenosine can then bind 
to A1 receptors on pre-synaptic neurones (9) leading to a persistent tonic suppression of 
calcium dependent neurotransmitter release (10). In this PhD project, a different 
mechanism has been suggested. It was shown that following activation neuronal 
afferents (2) or activation of PAR-1 via TFLLR (11), vesicular release of ATP from 
astrocytes could lead to activation of P2XR on neurones (12). This triggers activation of 
protein kinase C, which results in inhibition of neuronal GABAARs (13). This leads to 
increase in excitation and depolarisation (14), leading to increase in activation of post-
synaptic NMDARs (15).     
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6.3. Role of glutamatergic transmission 
 
In addition to vesicular exocytosis of ATP from astrocytes, this project also 
provides the first ever evidence for release of glutamatergic gliotransmitters 
(Glutamate and D-serine) from cortical astrocytes via vesicular exocytosis. It 
was shown that application of TFLLR could result in increase in frequency of 
GluN2B-dependent NMDARs sEPSCs. This increase in frequency was 
dependent on vesicular exocytosis of glutamate from astrocytes. The next step in 
this investigation would be to show that this astrocytic vesicular exocytosis of 
glutamatergic gliotransmitters could be induced, not only via TFLLR application, 
but also following stimulation of neuronal afferents of layer IV/V of cortex. 
Basically, the experiments on Figure 3.10 should be repeated, with the exception 
that that NMDAR-mediated sEPSCs should be recorded instead of P2XR-
mediated sEPSCs. 
 
It was suggested that application of TFLLR could result in vesicular release of 
glutamatergic gliotransmitters onto extra-synaptic GluN2B-containing NMDARs 
on neurons. Are both glutamate and D-serine release from astrocytes involved in 
this effect? Application of TFLLR resulted in increase in only the frequency of 
NMDAR sEPSCs but not the average amplitude. In contrast, application of 
exogenous D-serine resulted in an increase in both the average amplitude and 
frequency of NMDAR-mediated sEPSCs. Therefore, If D-serine were also 
released from astrocytes following TFLLR application, then one would expect an 
increase in the average amplitude of NMDAR sEPSCs. However, there was no 
increase in average amplitude following TFLLR application. This could suggest 
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that D-serine is not released by astrocytes. However, the preliminary data 
obtained by my colleagues by using microelectrode biosensors suggest that D-
serine is indeed released by astrocytes via vesicular exocytosis following 
application of TFLLR. Therefore, it seems that D-serine is released by astrocytes 
but its release does not increase the average amplitude of NMDAR sEPSCs. 
There could be two possible scenarios.  
 
(i) In the first scenario, application of TFLLR could result in the release of 
endogenous D-serine from astrocytes onto extra-synaptic GluN2B-containing 
NMDARs, leading to the full opening of these NMDARs. This would in turn 
lead to increase in detection of these NMDAR-mediated sEPSCs and so increase 
in frequency of these sEPSCs. As these GluN2B-containing extra-synaptic 
NMDARs have lower amplitude than GluN2A-containing synaptic NMDARs, 
their activation results in a decrease in the average amplitude of sEPSCs. It is 
possible that when D-serine is released from astrocytes, it only binds to extra-
synaptic NMDARs. In contrast, it is possible that when exogenous D-serine is 
applied, it results in global activation of NMDARs, leading to opening of both 
synaptic and extra-synaptic NMDARs, thereby leading to an increase in both the 
average amplitude and frequency of sEPSCs.  
 
(ii) The idea of the second scenario comes from a study from the CA1 region of 
hippocampus, where it was shown that D-serine acts on synaptic and not extra-
synaptic NMDARs (Papouin et al., 2012). Therefore, it is possible that the D-
serine released from astrocytes following application of TFLLR, acts only on 
synaptic NMDARs and not extra-synaptic GluN2B-containing NMDARs. In this 
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scenario, it is possible that activation of extra-synaptic GluN2B-containing 
NMDARs depends solely on glutamate release from astrocytes and not D-serine 
release. Again, as these extra-synaptic NMDARs have lower amplitude than 
synaptic GluN2A-containing NMDARs, their activation results in decrease in 
average amplitude of NMDAR sEPSCs. Activation of extra-synaptic NMDARs 
could occlude the effect of endogenous D-serine on synaptic NMDARs, thereby 
preventing increase in the average amplitude of sEPSCs. To investigate whether 
D-serine released by cortical astrocytic acts on extra-synaptic NMDARs would 
be an area for future investigation. 
 
It has been shown that in the CA1 region of hippocampus, calcium elevation in 
astrocytes, either spontaneously or as a result of application of agonists of PAR-1 
or mGluR5, can result in generation of neuronal GluN2B-dependent SICs (Fellin 
et al., 2004, Shigetomi et al., 2008). However, in my recordings of sEPSCs from 
cortical slices, no SICs were seen. The GluN2B-dependent SICs have average 
amplitude of 100 pA (Fellin et al., 2004). In contrast, the GluNB-dependent 
NMDARs from my recordings have average amplitude of 4 pA (see Figure 
3.20). Due to the large amplitude of SICs, it has been suggested that SICs cannot 
be generated as a result of release from SLMVs (SLMVs are the same size as 
synaptic vesicles; approximately 30-40 nm in diametre). Therefore, it has been 
suggested that SICs are probably due to astrocytic release from full fusion of 
vesicles that are 300 nm or larger (Fellin et al., 2004, Kang et al., 2013). The 
presence of these large vesicles has been shown in the hippocampus (Kang, Peng 
et al. 2013). However, to my knowledge, there is yet no evidence for presence of 
such large vesicles in the cortex. The absence of SICs in my recordings from the 
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somatosensory cortex suggests that these large vesicles are perhaps absent in the 
somatosensory cortex. Therefore, the small GluN2B-dependent sEPSCs observed 
following application of TFLLR are probably due to release from astrocytic 
SLMVs. However, it is also possible that such large vesicles are also present in 
the cortex; the generation of the small GluN2B-dependent sEPSCs could be due 
a kiss and run release mechanism from the larger vesicles where only a fraction 
of the vesicular content is release into extra-synaptic space. The nature of 
astrocytic vesicles in the cortex is another area for future investigation.   
 
It was shown that in the somatosensory cortex, GluN2B-containing NMDARs 
contribute to LTP induction (Figure 3.23). As was mentioned above, release of 
glutamate from astrocytes can activate extra-synaptic GluN2B-containing 
NMDARs. However, release of glutamate from astrocytes is not the only 
glutamate source for activation GluN2B-containing NMDARs. During 
recordings of spontaneous NMDAR sEPSCs shown on Figure 3.20, prior to 
application of TFLLR, there is no or very few GluN2B-dependent NMDARs 
sEPSCs. This is because during spontaneous activity (i.e. when afferent fibres 
are not stimulated) neuronal release of glutamate mainly activates synaptic 
NMDARs (Dalby and Mody, 2003). This means that during spontaneous 
activity, there is no spillover of glutamate onto extra-synaptic sites. However, 
during stimulation of afferent fibres (e.g. during recordings of fEPSPs and TBS 
delivery), glutamate released from neurones can theoretically spillover from 
synapse onto extra-synaptic sites, where it can activate GluN2B-containing 
NMDARs. This means that the source of glutamate that activates extra-synaptic 
GluN2B-containing NMDARs need necessarily not be astrocytic; it could also be 
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due to neuronal glutamate spillover from synapses. Are the GluN2B-containing 
NMDARs that contribute to LTP induction activated by spillover of neuronal 
glutamate or does astrocytic release of glutamate on these NMDARs also 
contribute to LTP induction? The results on Figure 3.24, where TFLLR was 
delivered during TBSx2 delivery, suggested that the release of glutamate from 
astrocytes onto GluN2B-containing NMDARs does not contribute to LTP 
induction. This suggests that, similar to D-serine, glutamate release from 
astrocytes does not make a major contribution to LTP induction.  
 
If the numbers of GluN2B subunits decrease during development, then how do 
GluN2B containing NMDARs contribute to LTP induction? Studies have 
attributed this to interaction of GluN2B with CaMK-II. Following activation, 
CaMK-II can remain locked in active conformation by interacting with the C-
terminal of GluN2B subunits (Strack and Colbran, 1998, Bayer et al., 2001). 
This interaction seems to be important, as one study showed that over-expression 
of the C-terminal of GluN2B, which blocked the interaction of this subunit with 
CamK-II, resulted in decrease in size of HFS-induced LTP in the CA1 region of 
hippocampus of 3-4 months old mice (Zhou et al., 2007). This showed that 
GluN2B subunits contribute to LTP induction via their interaction with CaMK-
II. 
 
It has been suggested that rapid uptake of glycine by GlyT-1 prevents saturation 
of NMDARs, enabling D-serine to act as the primary co-agonist for modulating 
NMDAR activity (Fossat et al., 2011, Henneberger et al., 2013). As it is the 
general consensus that astrocytes are the main source of D-serine, it is suggested 
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that astrocytic D-serine release can modulate NMDAR activity and hence LTP. 
However, in this project it was it was shown that vesicular release of D-serine 
from astrocytes is not required for LTP induction in the somatosensory cortex. 
This was in contrast to studies from the hippocampus and hypothalamus, where 
D-serine release from astrocytes contributed to the induction of LTP (Panatier et 
al., 2006, Henneberger et al., 2010). This suggests that in the somatosensory 
cortex, either the modulation of NMDAR is mainly through glycine and not D-
serine or that D-serine is indeed involved in modulation of NMDARs but the 
source of this D-serine is neuronal and not astrocytic. A group of researchers 
showed that in the cortex, D-serine was mainly localised to neurones and that 
cortical neurones can release D-serine via non-vesicular mechanism 
(Kartvelishvily et al., 2006, Rosenberg et al., 2010). Based on these results it has 
been suggested that astrocytes are the site for the production of L-serine, which 
is a precursor for D-serine. Astrocytes then release L-Serine into extra-cellular 
space, where it can be taken up by neurones. Neurons can then convert L-serine 
to D-serine (Wolosker, 2011). This means that neurones can both store and 
release D-serine. Therefore, it is possible that in the cortex, D-serine is indeed 
involved in modulation of NMDAR activity but the source of D-serine is 
neuronal and not astrocytic. This could explain the reason as to why in this 
project it was shown that vesicular release of D-serine from astrocytes is not 
involved in LTP induction. It could be that the level of D-serine released from 
neurones is sufficient in modulating NMDAR activity. Therefore the release of 
D-serine from astrocytes does not contribute further to NMDAR activity and 
LTP induction. In the future, the potential role of endogenous neuronal D-serine 
in synaptic transmission and plasticity should be investigated.  
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A recent study has shown that calcium elevations in cultured astrocytes as a 
result of TFLLR application results in glutamate release not by vesicular 
exocytosis but via bestrophin-1 channels (Woo et al., 2012). In contrast to this 
report, the results shown on Figure 3.22 clearly show that in the absence of 
vesicular exocytosis, TFLLR application does not lead to release of glutamate. 
Therefore release from bestrophin-1 channels is unlikely in slice preparations 
from somatosensory cortex. It is possible that the release of glutamate from 
bestrophin-1 channels could be due to astrocytes in cultured preparation and not 
in astrocytes from slices. 
 
A disadvantage of using TFLLR to selectively mediate astrocytic release is that 
PAR1 receptors are also present on neurons. Even though it has been shown by 
my colleagues and other research groups (Lee et al., 2007, Lalo et al., 2014) that 
TFLLR application specifically activates calcium elevation in astrocytes and not 
neurones, the other potenial effects of TFLLR as a result of activation of 
neuronal PAR1 receptors cannot be ruled out. This means that TFLLR, as a 
pharmacological agent which leads to PAR1-mediated intracellular calcium 
elevation, is selective for astrocytes, but it is not necessarilly selective for 
astroctyes over neurones as a pharmacological agent that activates PAR1 
receptors in general. Recently, a group of researchers have used a genetic 
approach to address this problem (Agulhon et al., 2013). They enginnered a 
transgenic mice line called GFAP-human M3 Muscarinic receptor (hM3Dq) that 
expresses a Gq GPCR called hM3Dq DREADD (Designer Receptors Exclusively 
Activated by Designer Drugs) selectively in GFAP positive glial cells. This 
receptor cannot be activated by endogenous GPCR ligands and can only be 
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activated via an inert pharmacological ligand called Clozapine-N-Oxide (CNO). 
These researchers showed that application of CNO selectively activates calcium 
elevation in astrocytes and not neurons. This DREADD approach is a superior 
method to TFLLR application and future investigation for selective activation of 
astrocytic calcium elevation should utiliswe this approach.  
 
6.4. Role for endocannabinoid signalling in the context of 
tripartite synapse 
 
Previous studies had shown that activation of CB1 receptors on astrocytes could 
result in calcium-dependent release of glutamate form these cells (Navarrete and 
Araque, 2010, Min and Nevian, 2012). In this PhD project it was shown that 
activation of CB1 receptors on astrocytes could also result in calcium dependent 
vesicular release of ATP from these cells. 
 
Calcium elevations in astrocytes can occur either spontaneously or as a result of 
activation of their receptors. Activation of neuronal afferents leads to release of 
neurotransmitters such as glutamate and ATP. These neurotransmitters can then 
spillover onto extra-synaptic sites, where they can activate receptors on 
astrocytes. This leads to calcium-dependent exocytosis from astrocytes. This is 
why when HFS is delivered to afferent neurones there is a large increase in 
frequency of calcium-dependent exocytosis of ATP from astrocytes (Figures 3.9 
and 5.3). Previous reports had shown that the astrocytic receptors that induce 
calcium elevations are mGluR5 (Fellin et al., 2004, Panatier et al., 2011). 
However, a recent report suggested that mGluR5 is only expressed on astrocytes 
 254 
of mice that are less than 2 weeks old (Sun et al., 2013). This report suggested 
that receptors other than mGluR5 must be involved in elevation of calcium levels 
in astrocytes. The work performed in this PhD project and the previous work 
carried out by my colleagues has shown that   P2XRs and NMDARs are involved 
in calcium elevation in astrocytes following delivery of HFS to neuronal 
afferents (Palygin et al., 2010). In addition to the involvement of NMDARs and 
P2XRs in calcium elevation in astrocytes, it was shown that CB1 receptors are 
also involved in calcium elevation in astrocytes (Figure 5.3). It was suggested 
that release of glutamate from afferent neurones could activate mGluR5 on post-
synaptic neurones. This in turn can result in production and release of 
endogenous cannabinoids from post-synaptic neurons. These cannabinoids can 
then activate CB1 receptors on astrocytes, thereby leading to calcium elevations 
in these cells.  
 
It has been shown that not all calcium elevations in astrocytes result in release of 
gliotransmitters or result in changes in synaptic plasticity (Shigetomi et al., 2008, 
Agulhon et al., 2010). However, the results in this PhD project clearly show that 
CB1 receptors, PAR-1 and NMDARs are all involved in calcium-dependent 
vesicular exocytosis of ATP and that this release results in modulation of 
synaptic plasticity. 
 
The data in this PhD project showed that inhibition of CB1 receptors with 
AM251 could result in complete abolishment of TBSx5-induced LTP. There are 
two possible mechanisms for this outcome. The first mechanism can be 
attributed to CB1 receptors on astrocytes. Inhibition of CB1 receptors on 
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astrocytes results in decrease in calcium dependent vesicular release of ATP 
from astrocytes. As vesicular release of ATP from astrocytes is required for LTP 
induction, inhibition of CB1 receptors results in impairment of LTP induction. 
This mechanism is also supported by the data showing that application of 500 
nM of AEA can result in increase in fEPSP and can contribute to induction of 
LTP (Figures 5.4 and 5.6). The other possible mechanism for the impairment of 
TBSx5-induced LTP with AM251 could be due to CB1 receptors on inhibitory 
neurons. It has been reported by a previous study that constitutive eCB release 
from post-synaptic hippocampal neurones can result in tonic inhibition of GABA 
release (Neu et al., 2007). In this study, application of AM251 to slices from 
CA1 region of hippocampus lead to an increase in GABA release. When BAPTA 
was used in the post-synaptic cell, the tonic eCB inhibition was abolished. These 
results suggested that post-synaptic cells constitutively release eCBs, which bind 
to GABAergic pre-synaptic CB1 receptors, thereby leading to tonic decrease in 
GABA release. Furthermore, another study has shown that inhibition of GABA 
release from pre-synaptic neurones via eCBs can facilitate LTP induction in 
excitatory neurones (Carlson et al., 2002). Therefore, it is possible that during 
application of AM251, CB1 receptors on GABAergic pre-synaptic neurons are 
inhibited, thereby leading to increase in GABAergic transmission, which leads to 
decrease in excitation. This decrease in excitation can theoretically result in 
impairment of LTP induction following delivery of TBS or HFS protocol.  
 
What has been discussed above suggests that inhibition of CB1 receptors results 
in impairment of LTP by increasing GABA release. However, if CB1 receptors 
on GABAergic pre-synaptic neurones were continuously inhibited, then one 
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would expect a decrease in baseline glutamatergic transmission. If baseline 
glutamatergic transmission decreases, there is a possibility that there is a larger 
extent for glutamatergic transmission to increase by during the induction of LTP. 
Therefore, a smaller stimulation is required for LTP induction i.e. the LTP 
threshold becomes smaller (ABS curve from Figure 1.2 shifts to the left). If this 
latter scenario is the case, then inhibition of CB1 receptors on pre-synaptic 
GABAergic neurones should result in enhancement of LTP during delivery of 
TBS or HFS. This suggests that inhibition of CB1 receptors on GABAergic 
neurones can result in either enhancement or impairment of LTP. This could 
explain why different studies show different outcomes when delivering 
HFS/TBS during inhibition of CB1 receptors. Three studies reported that when 
slices are incubated with CB1 receptor antagonists, LTP induction is completely 
abolished (Chevaleyre and Castillo, 2003, de Oliveira Alvares et al., 2006, Lin et 
al., 2011). These are in agreement with the results in this PhD project. In 
contrast, in another study where HFS was delivered to hippocampal slices from 
CB1 receptor KO mice, enhancement of LTP was reported (Jacob et al., 2012). It 
could be that with CB1 receptor KO mice there is a continuous increase in 
GABAergic transmission and hence a persistent decrease in baseline 
glutamatergic transmission, thereby resulting a decrease in LTP threshold. In 
contrast, with application of antagonists of CB1 receptor, GABAergic CB1 
receptors are inhibited for a short-time interval and so there is no shift in the 
LTP threshold. In this case, the inhibition of GABAergic CB1 receptors can 
yield in a “temporary” decrease in excitation that results in impairment of LTP 
induction. 
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The discussion above suggests two possible ways in which cannabinoids can 
modulate LTP induction: (1) via CB1 receptors on GABAergic pre-synaptic 
neurones. (2) via CB1 receptors on astrocytes. However, there exists a third 
possible way in which cannabinoids can contribute to LTP induction: (3) via 
CB1 receptors on glutamatergic pre-synaptic neurones. Activation of these CB1 
receptors can result in decrease in release of glutamate from pre-synaptic 
terminals. It has been shown that application of exogenous cannabinoids can 
decrease excitatory synaptic transmission. Application of 2 M of synthetic 
cannabinoid agonist WIN55,212-2 can decrease evoked AMPA EPSC amplitude 
in slices from hippocampus and cortex (Schlicker and Kathmann, 2001, 
Kawamura et al., 2006). In several studies it has been shown that application of 
exogenous cannabinoids can result in impairment of HFS-induced LTP (Collins 
et al., 1995, Stella et al., 1997, Misner and Sullivan, 1999). This has been 
attributed to the reduction in glutamate release as a result of activation of CB1 
receptors. However, as was mentioned above, activation of CB1 receptors on 
GABAergic neurons and activation of CB1 receptors on astrocytes should result 
in enhancement of LTP. In fact, it has been shown that there is a significantly 
higher expression of CB1 receptors on GABAergic neurons than glutamatergic 
neurons (Katona et al., 1999, Hill et al., 2007). Therefore, one would expect an 
enhancement in LTP induction rather than impairment of LTP. If this is the case, 
then why do most studies show impairment?  
 
The synthetic CB1 receptor agonist WIN55212-2 can inhibit IPSCs at low 
concentrations (EC50 of 0.24 M) whilst it can inhibit EPSCs at higher 
concentrations (EC50 of 2.01 M) in the CA1 region of the hippocampus (Hajos 
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et al., 2001). The latter outcome has been attributed to TRPV1 channels. It has 
been shown that exogenous cannabinoids are involved in activation of Transient 
receptor potential vanilloid type 1 (TRPV1) channels. Activation of TRPV1 
channels can lead to LTD by resulting in internalisation of posy-synaptic AMPA 
receptors (Chavez et al., 2010). Therefore, it seems that at lower concentrations 
of CB1 agonists, mainly inhibitory synapses are inhibited because there are more 
CB1 receptors on GABAergic neurones. However, with increase in concentration 
of CB1 receptor agonists, excitatory neurones also show depression, mainly 
through activation of TRPV1 channels by cannbinoids. This could explain why 
in this PhD project, application of 5 M of AEA to WT cortical slices resulted in 
depression of fEPSPs whilst application of 500 nM of AEA resulted in increase 
in fEPSP (Figure 5.6). The depression in fEPSP with 5 M of AEA is probably 
due to TRPV1 channels. The increase in fEPSP with 500 nM of AEA is either 
due to activation of CB1 receptors on astrocytes or due to activation of CB1 
receptors on GABAergic pre-synaptic neurones. However, application of 500 nM 
of AEA to cortical slices from dnSNARE mice resulted in depression of fEPSP, 
suggesting that the increase in fEPSP in WT mice is due to CB1 receptors on 
astrocytes.    
 
Another area of endocannabinoid research open for future investigations involves 
the research in different roles for the two different eCBs. It is not known why 
neurones release two types of eCBs. It has been shown that anandamide and 2-
AG induce different physiological effects in vivo (Alger and Kim, 2011) but how 
neurones utilise these two different eCBs differently to induce these effects is not 
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known. Future studies should investigate whether endogenous AEA and 2-AG 
have different effects on different LTP/LTD protocols. 
 
In a recent finding it was shown that in vivo application of exogenous 
cannabinoids resulted in LTD of excitatory transmission in CA1 region of 
hippocampus (Han et al., 2012). They showed that this LTD was due to decrease 
in AMPAR activity. As mentioned above, previous studies had suggested that 
this decrease in AMPAR activity is due to decrease in release of glutamate from 
excitatory pre-synaptic neurones as a result of activation of CB1 receptors on 
these cells. However, this study, by using specific neuronal and astrocytic CB1 
receptor knockout mice, showed that the LTD was dependent on astrocytic CB1 
receptors and not on neuronal CB1 receptors. They showed that activation of 
CB1 receptors on astrocytes could result in glutamate release from these cells. 
They showed that the glutamate released from astrocytes could activate post-
synaptic NMDARs, which in turn lead to AMPAR endocytosis and LTD. It is 
possible that the AMPAR endocytosis observed in this report is due to activity of 
TRPV1 channels and not NMDAR channels. The authors did not investigate this 
possibility. Nonetheless, the importance of this report is the finding that 
astrocytes can release glutamate on post-synaptic NMDARs. For future 
investigations, these mice can be used to distinguish between the effect of 
astrocytic CB1 receptors and neuronal CB1 receptors. 
 
In this PhD project, the effect of AEA application on NMDAR activity in the 
somatosensory cortex was also investigated. It was shown that application of 
AEA could indeed increase NMDAR activity (Figure 5.7). However, more 
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experiments are required to show that this increase in NMDAR activity is as a 
result of vesicular exocytosis from astrocytes. For this purpose, cortical slices 
from dnSNARE mice should be used. Furthermore, evidence should be provided 
showing that the release of glutamate from astrocytes is dependent on activation 
of CB1 receptors on these cells. For this purpose, AM251 can be applied during 
recordings of NMDAR eEPSCs. However, to provide stronger support that the 
release of glutamate from astrocytes are due to astrocytic CB1 receptors, the 
above-mentioned transgenic mice line where CB1 receptors are specifically 
knocked out in astrocytes should be used.   
 
To summarise the above discussion, endocannabinoids can modulate synaptic 
transmission and plasticity with the following 5 mechanisms: 
  
(1) By acting on CB1 receptors on presynaptic glutamatergic neurones, eCBs can 
decrease synaptic transmission (Figure 6.2: steps 1-4), thereby contributing to 
LTD induction or impairment of LTP induction of excitatory transmission. 
 
(2) Activation of CB1 receptors on astrocytes can result in release of glutamate 
from these cells. The released glutamate can activate NMDARs on pre-synaptic 
neurones, leading to decrease in release of glutamate from neurones via an 
unknown mechanism (Figure 6.2: steps 5-9). The decrease in glutamate release 
results in depression of synaptic transmission (Min and Nevian, 2012).  
 
(3) Activation of TRPV1 channels by cannabinoids can result in AMPAR 
endocytosis leading to LTD (Figure 6.2: steps 10-11).  
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(4) Cannabinoids can inhibit GABAergic transmission by activating CB1 
receptors on pre-synaptic neurones (Figure 6.2: steps 12-13). This leads to 
increase in excitation, which can result in modulation of LTP. 
 
(5) Cannabinoids can increase release of gliotransmitters from astrocytes by 
acting on CB1 receptors on these cells. Release of transmitters such as glutamate 
and ATP onto post-synaptic receptors can increase excitability and LTP (Figure 
6.2: steps 14-16).  
 
Results from previous studies show evidence for mechanisms (1) to (4). The 
importance of the research in this PhD project is that it shows that mechanism (5) 
should also be considered when investigating role for endocannabinoid 
signalling.  
 
It is believed that smoking cannabis impairs learning and memory by acting on 
CB1 receptors (Kano et al., 2009). How do exogenous cannabinoids impair 
memory by acting on CB1 receptors? i.e. how do mechanisms (1) to (5) result in 
impairment of memory?  
 
Depression of synaptic transmission refers to changes that lead to weakening of 
synaptic transmission, whilst potentiation refers to changes that lead to 
strengthening of synaptic transmission. It is the general consensus that LTP is 
associated with formation of memory whilst LTD is associated with impairment 
of memory. This reasoning comes from pioneering observations that 
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manipulations that block LTP also significantly impair performances in learning 
and memory related tasks (Martin et al., 2000). This suggests that when 
potentiation of synaptic transmission and plasticity is observed, it is associated 
with enhancement of memory; whilst when depression is observed, it is 
associated with impairment of memory. If this reasoning is to be accepted then it 
suggests that mechanisms (1) to (4) result in impairment of learning and memory 
because the outcome of all these mechanisms is decrease in release of 
transmitters and hence depression of synaptic transmission. This implies that 
mechanism (5), which results in increase in transmission, cannot be associated 
with cannabinoid-induced impairment of memory, thereby suggesting that 
mechanisms (1) to (4) might be the more likely mechanisms for explaining the 
reason for impairment of memory following intake of exogenous cannabinoids. 
However, just because research shows that blocking of LTP results in 
impairment of memory does not necessarily mean that potentiation can be 
linearly associated with memory formation or that depression can be linearly 
associated with memory impairment. This is actually a misunderstanding. In fact 
it is has been suggested that both potentiation and depression of synaptic 
transmission are required for formation of new memories. It has been suggested 
that “correct processing of memory-related information should be dependent on 
defining the salience of information to be encoded, a process that requires not 
only potentiation of synaptic strength but also depression” (Costenla et al., 
2010). I believe this misunderstanding is the reason as to why there has been no 
investigation of an increase in excitation following the action of endogenous or 
exogenous cannabinoids. To my knowledge this PhD project provides the first 
evidence for such an effect. This reasoning should be kept in mind not just for 
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research in role of cannabinoids in synaptic transmission and plasticity, but for 
all research that associates in vitro and in vivo synaptic plasticity with learning 
and memory tasks. 
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Figure 6.2.  Endocannabinoids can modulate synaptic transmission by different 
mechanisms.  Mechanism (1): Activation of class I mGluRs (1) leads to PLC-mediated 
synthesis of eCBs (2). eCBS can then diffuse to pre-synaptic glutamatergic neurones 
where they activate pre-synaptic CB1 receptors (3). Pre-synaptic CB1 receptors are 
coupled to Gi/o, therefore their activation leads to inhibition of glutamate release (4). 
Mechanism (2): eCBs can also activate CB1 receptors on astrocytes (5). In contrast to 
neuronal CB1 receptors, astrocytic CB1 receptors are coupled to Gq/11. Activation of 
astrocytic CB1 receptors leads to calcium elevation in these cells (6). This results in 
glutamate release from astrocytes (7), which can bind to pre-synaptic NMDARs (8). This 
leads to decrease in glutamate release via an unknown mechanism (9).  Mechanism (3): 
eCBs like AEA can also remain intracellularly where they can activate TRPV1 channels 
(10). Activation of TRPV1 channels can result in endocytosis of AMPARs via activation of 
calcineurin (11). Mechanism (4): Released eCBs can also diffuse to pre-synaptic 
GABAergic neurones where they can activate CB1 receptors on these cells (12). This 
leads to inhibition of GABA release (13). Mechanism (5): Activation of CB1 receptors on 
astrocytes (5) can result in calcium dependent vesicular release of ATP from astrocytes 
(14). The released ATP can then activate P2XRs in neurones (15). Glutamate release 
from astrocytes can activate GluN2B-containing NMDARs on post-synaptic sites (16). 
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6.5. Conclusion  
 
The primary role of astrocyte is to isolate individual synapses so that 
neurotransmitter release from one synapse does not spillover into another 
synapse i.e. glutamate spilled over from synaptic transmission is transported into 
the astrocytes. This isolation of synaptic transmission allows for precise spatial 
and temporal information processing (Nedergaard and Verkhratsky, 2012). 
However, as was shown in this PhD project, another function of astrocytes is to 
release gliotransmitters onto extra-synaptic sites. This suggests that astrocytic 
gliotransmitters modulate synaptic transmission not by directly effecting synaptic 
transmission by specific local gliotransmitter release but by exerting a less 
specific control by release onto extra-synaptic sites. This means that astrocytes 
can allow for rapid and precise synaptic transmission by isolating synapses and 
at the same time modulate synaptic transmission by releasing gliotransmitters 
onto less specific extra-synaptic sites. 
 
This project provides evidence for calcium dependent vesicular exocytosis of 
glutamate, ATP and D-serine from astrocytes. This direct evidence is in the form 
of electrophysiological recordings. However, as was mentioned in the first 
chapter, vesicular exocytosis from neurones requires the presence of certain 
proteins involved in the exocytosis mechanism. The presence of only some of the 
proteins involved in exocytosis has been shown in astrocytes. These are 
VGLUT1/2, VAMP2 and VAMP3 (Bezzi et al., 2004, Martineau et al., 2013). If, 
as the results in this project show, astrocytes are capable of calcium-dependent 
vesicular exocytosis, then the presence of all the proteins involved in exocytosis 
 266 
must be shown in astrocytes. Therefore, in future investigations, attempts should 
be made to provide evidence for other proteins involved in exocytosis in 
astrocytes. If future investigations fail to provide such evidence, then it is 
possible that in dnSNARE mice, the expression of cytosolic portion of VAMP2 
specifically in astrocytes is affecting other release mechanisms that are non-
exocytotic. If this were the case, then it is possible that vesicular exocytosis does 
not occur in astrocytes. However, even if this possibility was the case, it is clear 
that the results in this project show that gliotransmitters are released from slice 
preparation via calcium-dependent mechanism.  
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